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Abstract 
Synthesis and Fluorination of Iodonium Salt Precursors for the Formation of 
[18F]F-DOPA (CH2) 
[
18
F]F-DOPA is a widely used radiotracer most commonly employed in the diagnosis of 
Parkinson’s disease[1] and neuroendocrine tumours (NETs).[2] 
In this thesis, the syntheses of suitable diaryliodonium salt precursors for [
18
F]F-DOPA 
production via fluorination with nucleophilic, no carrier added (n.c.a.) [
18
F]fluoride are 
described. The complex iodonium salt precursors are prepared by a simple and robust 
procedure in good yields and are bench stable compounds. Incorporation of both ‘cold’ 
[
19F]fluoride and ‘hot’ [18F]fluoride using the prepared precursors has been 
investigated.
[3]
 
 
 
 
Fluorinations occur with complete regioselectivity for fluorination at the DOPA moiety 
when using a range of precursors with varying protecting group strategies. Optimisation 
of the radiofluorination and subsequent isolation method allowed for isolation of a 
protected [
18
F]F-DOPA species in 2% radiochemical yield (RCY). 
 
Solid-Supported Iodonium Salts for Fluorinations (CH3) 
Secondly, solid-supported iodonium salt precursors have been prepared and used for the 
production of fluoroarenes. The importance of the resin functionality for the attachment 
of the iodonium salt moieties has been demonstrated. Use of a tris(aminoethyl) 
funtionalised resin rather than aminomethyl resin as starting material gives improved 
reproducibility and yields for precursor formation. 
The successful radiofluorination of a simple solid-supported precursor with no carrier 
added (n.c.a) [
18
F]fluoride is also reported, producing [
18
F]fluorobenzene with 3% 
radiochemical conversion (RCC).
[4]
 
 
viii 
 
 
 
Extension of the solid-supported methodology to the production of synthetically useful 
fluoroarenes was investigated. Preparation of benzyl protected 4-fluorophenol was 
accomplished using this strategy. Optimisation of the fluorination conditions gave 24% 
yield of the aryl fluoride from the resin bound iodonium salt precursor. 
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1 
Introduction 
1.1 Positron Emission Tomography (PET) 
1.1.1 Overview 
Positron emission tomography (PET) is a highly sensitive and versatile molecular 
imaging technique that can be used to non-invasively study the pharmacokinetics and 
biodistribution of positron emitting radiotracers in vivo. It has become crucial for the 
diagnosis and evaluation of diseases, including cancers
[1–3]
 and neurodegenerative 
diseases such as Parkinson’s disease.[4,5] 
Molecular imaging may be defined as ‘the visualisation of in vivo biological processes 
at the molecular level using specific imaging probes’, covering methods such as 
magnetic resonance imaging (MRI), radiotracer imaging, optical imaging and 
ultrasound.
[5]
 The basic requirements for PET tracers include those necessitated by any 
of the ‘imaging probes’ alluded to above. These comprise of the following:[6] 
1. Be useable in concentrations small enough to not alter the system under 
investigation 
2. Interact with the system in a predictable, informative and reproducible manner 
3. The concentration should be measurable quantitatively 
The use of such positron emitting radiotracers relies on the incorporation of positron 
emitting nuclides into molecules of biological interest. This is what enables the 
‘molecular visualisation’. However, it is not the emitted positron that is detected: 
PET relies on the three dimensional detection of gamma rays arising from the 
annihilation of a positron emitted from the radionuclide. The gamma rays are emitted in 
almost exactly opposite directions allowing for the origin of annihilation to be 
calculated upon detection of the gamma rays. The positron travels a short distance 
before decelerating enough to interact with an electron (approx. 2 mm in water for 
18
F)
[7]
 which means that high resolution images of the tracers’ distribution can be 
constructed subsequent to computational analysis (Figure 1). 
 Introduction Ch1 
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PET is often used in conjunction with X-ray computed tomography (CT) to form a 
superimposed image incorporating both the anatomical information provided by CT and 
the functional data for tracer distribution provided by the PET image.
[8]
 
 
Figure 1 – Imaging with PET. Image courtesy of Metrohm AG, taken with permission from 
Separation Science [http://www.sepscience.com/Sectors/Pharma/Articles/429-/Radio-IC-for-
Quality-Control-in-PET-Diagnostic].
[9]
 
1.1.2 Production of radiotracers for PET 
A number of radionuclides are available to be inserted or added to the compound of 
interest. The most commonly used of these are 
18
F, 
11
C, 
13
N and 
15
O. These isotopes can 
be substituted into a biomolecule without significantly altering its behaviour, allowing 
in vivo application.
[10]
 In fact the use of carbon, nitrogen and oxygen isotopes allows for 
the direct replacement of the stable isotope with the radionuclide, producing a tracer 
without any alteration to its biological activity.
[11]
 
The use of more unusual radiolabels such as 
123
I and 
125
I, has also been evaluated.
[12,13]
 
Furthermore, the coordination chemistry of radionuclides such as 
64
Cu and 
89
Zr has led 
to their application with a number of chelator systems for PET imaging and targeted 
radiotherapy of cancer.
[14,15]
 Properties of some more commonly used radionuclides can 
be seen in Table 1.  
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Table 1 – Common radioisotopes and their properties.[5,6] 
Isotope β+ decay (%) Half-life (min) Decay Product 
18
F 97 110 
18
O 
11
C 100 20.4 
11
B 
13
N 100 9.96 
13
C 
15
O 100 2.03 
15
N 
76
Br 57 966 
76
Se 
124
I 23 6048 
124
Te 
68
Ga 89 68.1 
68
Zn 
64
Cu
 
18 762 
64
Ni 
 
The use of radiotracers for PET imaging requires the formation and purification of the 
labelled compounds. This challenge necessitates the employment of multiple disciplines 
and can be broken down into 3 major steps: Production of the radioisotope, 
incorporation of the radioisotope and isolation of the radiotracer. The details of these 
steps are outlined below. 
Step 1: Production of the radioisotope 
Emission of a positron from proton rich radioisotopes is the key to detecting the 
radiolabelled tracer of interest. The production of such proton rich isotopes therefore 
provides an important start to the production of any PET tracer and is achieved by 
bombardment of a ‘target’ with a proton source at high velocity. 
The proton source is most commonly a proton or deuteron and is accelerated to high 
velocities using a particle accelerator called a cyclotron (Figure 2). 
 
Figure 2 – Principals of a cyclotron. Image courtesy of Metrohm AG, taken with permission from 
‘Radio IC for Quality Control in PET Diagnostics’, Separation Science, 4(2), 2012. [16] 
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The cyclotron achieves acceleration by utilising a combination of magnetic and electric 
fields. The two dees (Figure 2) are separated by an electric field, which accelerates the 
proton (or deuteron) into one of the dees as it enters the gap between them. A magnetic 
field perpendicular to the dee then influences the positively charged particle causing it 
to move in a semi-circle, and back towards the gap. Reversal of the electric field then 
accelerates the particle across the gap into the other dee, where it follows a slightly 
wider semi-circle back to the gap. The electric field is switched to accelerate the particle 
back to the original dee, and the process is repeated, accelerating the particle with every 
transition through the accelerating electric field. Eventually the particle exits the 
cyclotron at high velocity for bombardment of the target.
[6]
 
A number of different targets are used for the production of desired radionuclides. 
These transformations involve a nuclear reaction in which the charged particle 
accelerated by the cyclotron hits the target isotope, prompting the emission of another 
particle from the nucleus and producing the radioisotope product. 
As a quick manner of communicating the details of the nuclear reaction, a short hand 
has been developed (Figure 3). Target isotope (A), particle bombarding the target (b), 
particle emitted by the target isotope (c) and the produced radioisotope (D) are all 
shown.  
 
 
Figure 3 – Nuclear reaction short hand 
Some common targets and their corresponding nuclear reactions are shown in Table 2. 
  
(Z = atomic mass) 
Isotope Produced 
Bombarding Particle Emitted Particle 
Target Isotope 
zA(b,c)zD 
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Table 2 – Targets for production of radioisotopes.[6,17] 
Target Nuclear Reaction Product 
N2+0.1% O2 
14
N(p,α)11C [11C]CO2 
N2+5% H2 
14
N(p,α)11C [11C]CH4 
N2+0.2% O2 
14
N(d,n)
15
O [
15
O]O2 
H2
18
O 
18
O(p,n)
18
F [
18
F]F
-
(H2O)n 
18
O2 + 0.6% F2 
18
O(p,n)
18
F [
18
F]F2 
H2O/ethanol 
16
O(p,α)13N [13N]NH3 
CO2 (trace N2) 
12
C(d,n)
13
N [
13
N]N2 
 
In some instances the product of the nuclear reaction is the sought after labelled 
molecule. An example is [
15
O]O2 which is produced by the 
14
N(d,n)
15
O reaction and 
subsequently used for the study of oxygen utilisation. In the majority of cases, once the 
desired radioisotope has been produced, its delivery to a destination for manipulation 
and chemical transformation is required. This is generally a suitably equipped, heavily 
shielded compartment known as a ‘hot cell’.  
Step 2: Incorporation of the radioisotope 
The short half-lives of the most commonly used radioisotopes (
11
C, 
18
F, 
13
N and 
15
O) 
present radiochemists with a significant challenge for the synthesis and purification of 
the radiotracer before unacceptable loss of activity (typically < 2 half-lives). Such a 
problem must be addressed by a combination of rapid, selective reactions and a quick 
purification. Reactivity of the radioactive moiety, reaction stoichiometry and precursor 
design are key factors in achieving this. 
Reactivity of the Radioactive Moiety 
This necessitates the use of the radioisotope in a ‘reactive form’. Some radioisotopes are 
produced as reactive species directly from the bombardment of the appropriate target. 
For example the production of [
18
F]F2 gas. This allows for direct reaction with an 
appropriate substrate after delivery to the hot cell.
[18]
 
In target formation of the radioisotope as a moiety with desirable reactivity isn’t always 
possible. However, a chemical transformation after delivery can be performed in order 
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to attain the radioisotope in a more reactive or suitable reagent. A common example is 
the formation of [
11
C]MeI from [
11
C]CO2 or [
11
C]CH4.
[19–21]
  
In other cases it is necessary to adjust the environment of the radioactive species in 
order to improve reactivity, for example in the azeotropic drying of [
18
F]fluoride to 
improve its nucleophilicity. This is required for the majority of reactions it is used 
for.
[22]
  
Reaction Stoichiometry 
The super-stoichiometric amounts of precursor used relative to the radioisotope can also 
help to speed up the reaction by giving pseudo first order kinetics.
[5]
 
Precursor Design 
To further reduce the time from estimated time of bombardment (EOB) to obtaining a 
product suitable for application, it is desirable to introduce the isotope at as late a stage 
as possible. This often requires highly functionalised ‘activated’ precursors which 
typically undergo a labelling step followed by a deprotection. It should be mentioned, 
however, that the use of quite lengthy multistep syntheses, subsequent to labelling, have 
proved successful for certain isotopes by optimisation of the subsequent 
transformations.
[23]
 
A quick reaction for the incorporation of the short-lived radioisotope is a very important 
consideration when designing the synthesis of a tracer. However, there are many other 
factors that are required for an ideal radiochemical synthesis. A list of essential 
requirements and further desirable properties is given below. 
Essential 
1. The reaction must cope with the unusual stoichiometry of these reactions: Large 
differences in the concentration of non-radioactive (or ‘cold’) precursor and 
radioactive (or ‘hot’) radionuclide can make translation from ‘cold’ to ‘hot’ 
chemistry challenging.
[7]
 
2. Short reaction and purification time (< 2 half-lives): Subsequent to purification 
and isolation of the tracer (in a form suitable to administer to the patient -
commonly as an isotonic and sterile solution), the tracer must undergo rigorous 
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quality control (QC).
[24]
 Short reaction and purification times are crucial if the 
tracer is to be available for patient administration with suitable radioactivity. 
3. High enantiomeric excess (> 98% ee): When applicable, enantiomerically pure 
tracers should be produced, as different enantiomers can exhibit very different 
biological behaviour. Chiral integrity is tested using the appropriate QC 
procedures (HPLC on chiral stationary phases). 
4. Operationally simple procedure suitable for automation: The nature of the 
tracers and their positron emitting nuclides necessitate manipulation within 
heavily shielded compartments called ‘hot cells’. In order to perform chemistry 
within the hot cell, an automated system must be programmed to perform the 
necessary manipulation of reagents. If a tracer synthesis is to be successful, an 
automated synthesis is compulsory. As improvements in such automated 
systems evolve, the term ‘operationally simple’ covers an ever growing number 
of operations, allowing success for previously daunting multistep syntheses.
[23]
  
5. Reproducible: Due to the time restrictions involved in tracer production, tracers 
are often produced in close vicinity to the patient and just minutes before 
administration. Tracer synthesis failure severely inconveniences patients, and 
reliability is of upmost importance. 
Desirable 
1. Starting from a bench stable and accessible precursor: For a tracer synthesis to 
be implicated it is necessary for the precursor synthesis to be viable financially 
(both in terms of the expense of the reagents and the time needed to synthesise 
it). Furthermore, bench stable/ storable compounds greatly improve convenience 
for PET centres. 
2. High radiochemical yield (RCY): High radiochemical yield is clearly desirable. 
While not essential, a high radiochemical yield has important implications, 
including the number of patients that can be scanned with the isolated tracer. 
Additionally, transportation of the radiotracer is possible for certain 
radioisotopes if the RCY is suitably high. 
3. Ambient conditions: Ambient conditions are desirable for simplification of 
procedure. This allows facile reproducibility of the synthesis in PET centres that 
may not have specialist radiochemists. 
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4. High specific activity (SA): Specific activity is a measure of the radioactivity per 
unit mass of tracer. A tracer with a greater SA will be administered with a lower 
concentration of ‘cold’ compound. This means a lower dose of potentially 
harmful compound for the patient. High SA is essential in some cases where 
dilution with the unlabelled analogue must be low to achieve acceptable 
resolution.
[22]
 
 
The methods available for the incorporation of different desirable radioisotopes are vast 
and a number of labelled reagents are available depending on the chemistry required. A 
brief description into some of the more important techniques and strategies used for 
radioisotope introduction is given bellow. 
Carbon – 11 
The most common method used to produce the 
11
C isotope is the 
14
N(p,α)11C 
reaction.
[11]
 As shown in Table 2, when performed in the presence of oxygen the 
product is [
11
C]CO2, whilst in the presence of hydrogen [
11
C]CH4 is obtained. From 
these two labelled compounds a variety of reagents can be produced for further 
chemical reactions. Those regularly used are shown in Scheme 1.
[5]
 
 
Scheme 1 – [11C]Reagents produced from [11C]CO2.
[5]
 
The most important reagent for 
11
C labelling is [
11
C]CH3I. Its successful utility for the 
[
11
C]methylation of a number of heteroatoms (generally S, O and N methylation) has 
produced a large number of [
11
C]tracers.
[11]
 Its production traditionally follows what is 
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called the ‘wet’ method: Reduction of [11C]CO2 with LiAlH4, followed by iodination 
with HI yields the [
11
C]CH3I.
[19]
 A second method for the generation of [
11
C]CH3I, 
termed the ‘dry’ or ‘gas-phase’ method, employs high temperatures for the iodination of 
[
11
C]CH4 with I2 (Scheme 2).
[20,21]
 The ‘dry’ method has become the method of choice 
due to improved specific activity (SA) of the produced reagent.
[5]
 
 
Scheme 2 – ‘Wet’ and ‘Dry’ methods for the production of [11C]CH3I 
Whilst most commonly used for heteroatom [
11
C]methylation, other strategies for 
incorporation such as C-
11
C bond formation via Stille- and Suzuki-couplings, have also 
been reported.
[25,26]
 Some reported syntheses of [
11
C]tracers are shown in Scheme 3.  
 
Scheme 3 – Application of [11C]CH3I for the production of [
11
C]radiotracers. a) Suzuki coupling for 
the formation of M-MTEB 2 reported by Burns et al.
[26]
 b) [
11
C]methylation reaction for the 
formation of [
11
C]flumazenil 4 using a ‘microreactor’ column reported by Aigbirhio et al.[27] 
The use of [
11
C]CH3OTf provides a more reactive alternative to [
11
C]CH3I.
[28]
 Other 
incorporation strategies include the use of carbonyl chemistry with [
11
C]phosgene and 
introduction of [
11
C]CN and [
11
C]CO functionality with various cyanation and 
carbonylation reactions.
[11]
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Nitrogen – 13 
The short half-life of 
13
N (9.96 min), along with the lower resolution of [
13
N]tracers, has 
limited the isotopes widespread application in tracer synthesis. However, the presence 
of nitrogen in a large number of biologically interesting compounds offers an incentive 
to overcome these short falls and a number of attractive applications have been reported. 
The process most commonly used for the formation of 
13
N is the 
16
O(p,α)13N reaction. 
When performed with water as the target a mixture of [
13
N]NO3
-
, [
13
N]NO2
-
 and 
[
13
N]NH3 is produced. Subsequent treatment of the mixture with DeVarda’s alloy 
reduces the nitrate and nitrite products to the [
13
N]ammonia product. Conveniently, 
when performed with the addition of ethanol or acetic acid to water target (5 mM), a 
higher percentage of initially produced [
13
N]NH3 is obtained (95%).
[17]
 
The [
13
N]NH3 produced by these reactions is the most common reagent used for 
incorporation of the 
13
N isotope. Along with its uses as a nucleophile (for example in 
the attack of acyl chloride derivatives)
[29]
 another useful reaction is its employment in 
enzymatic [
13
N]amino acid synthesis.
[30–32]
 Also notable is the use of [
13
N]NH3 for the 
synthesis of [
13
N]cis-platin using a solid phase methodology.
[33]
 Examples of 
radiochemistry performed with [
13
N]NH3 are shown in Scheme 4. 
 
Scheme 4 - Application of [
13
N]NH3 for the production of [
13
N]radiotracers. a) A one-pot synthesis 
of the tracer [
13
N]NCP 6 reported by Zhang et al.
[34]
 b) Enzymatic incorporation of 
13
N for the 
production of ʟ-[13N]glutamate 8 reported by Lathrop et al.[32] 
Additionally, in target incorporation is possible for more simple tracers. [
13
N]N2 is 
produced by the 
12
C(d,n)
13
N nuclear reaction and has found utility in nitrogen fixation 
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and ventilation studies,
[35]
 while [
13
N]NH3 has been applied to study blood flow and 
perfusion in the brain and myocardium.
[36–38]
 
Oxygen – 15 
The time constraints present for manipulation of the 
15
O isotope are severe due to its 2 
minute half-life. Tracers with 
15
O incorporation are generally simple, for example 
[
15
O]H2O and [
15
O]O2 for the study of blood flow and oxygen utilisation 
respectively.
[39]
 Nonetheless, very rapid synthesis of a labelled glucose analogue 
[
15
O]ODG has been made possible by the use of a mild, radical reaction not requiring 
the use of protecting groups.
[40]
 Scheme 5 shows conditions for the production of some 
simple [
15
O]tracers from [
15
O]O2.
[11]
 
 
Scheme 5 – Incorporation of 15O into simple tracer molecules.[11] 
Positron emitting metals 
Some positron emitting metals such as 
89
Zr, 
68
Ga and 
64
Cu, have shown utility for PET 
imaging as well.
[14,15,41]
 Rather than being incorporated directly into the molecule of 
interest, coordination chemistry is used to tag the positron emitting isotope to the 
molecule of interest. The coordinating ligand is coupled to the biomolecule of interest 
by various linkage strategies. Substitution reactions with reactive amines and thiols 
found on the biomolecule are a common approach.
[15]
 Click chemistry has also been 
implemented successfully.
[15]
 
Fluorine – 18 
Incorporation of the 
18
F isotope is not ubiquitous for the majority of tracers and yet it 
has become the radioisotope of choice for production of a huge variety of PET tracers. 
This is due to a number of desirable properties. As late stage introduction of 
18
F is a 
focus of this thesis, a discussion on these ‘desirable properties’ and the methods used 
for the isotopes incorporation will be presented in the following pages (‘PET and 
Radiochemistry with the 
18
F Isotope’, Pg. 14). 
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Step 3: Isolation of the radiotracer 
Finally, suitable purification and quality control needs to be conducted before the tracer 
can be used for imaging.  
Purification 
Successful purification is crucial after synthesis of the tracer has been completed. 
Likewise to the synthesis of the tracer, fast procedures suitable for automation are 
required of the purification process. HPLC is commonly used for more complex 
purifications; however, if possible the use of cartridges is preferable as these provide a 
simplified and faster purification. Once the tracer has been isolated in a form suitable 
for injection (generally as an isotonic solution), it is finally passed through a sterile 
filter. A portion is dispensed for performing quality control. 
Quality Control (QC) 
Quality control (QC) is required to make sure the standard of the tracer meets the 
established criteria before its use in the clinic. Some typical QC procedures include:
[24]
 
 Visual Inspection. 
 Analytical HPLC – determining radiochemical purity and identity. 
 Radio TLC – determining radiochemical purity and identity. 
 Radioisotope dose calibrator – validating the half-life. 
 GC – determining the quantity of any residual solvent in the sample. 
 pH reading. 
 Residual Kryptofix analysis by a spot test is required if the reagent has been 
used. 
 Testing the integrity of the sterile filter used for purification. 
 Endotoxin analysis using an appropriate testing system. 
1.1.3 Conclusion 
Obtaining a radiotracer for PET is far from trivial, but can be achieved using multiple 
disciplines and innovative techniques to perform rapid transformations. A list of some 
PET tracers that have been produced using such methodologies is shown in Table 3. 
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Table 3 - Common PET Tracers
[42]
 
Tracer Use/ Biological Target 
Carbon 11 
[
11
C]methionine Amino-acid transport 
[
11
C]leucine Protein synthesis 
[
11
C]methyl-spiperone Dopamine and serotonin receptors 
[
11
C]PK-11195 Peripheral benzodiazepine receptors 
[
11
C]diprenorphine Nonselective opiate receptors 
[
11
C]carfentanil µ-Opioid receptor 
[
11
C]flumazenil (FMZ) Central benzodiazepine receptors 
[
11
C]raclopride Dopamine type 2 (D2) receptor 
[
11
C]Schering-23390 Dopamine type 1 (D1) receptor 
[
11
C]nomifensine Dopamine transporter (DAT) 
[
11
C]deprenyl Monoamine oxidase type-B (MAO-B) 
[
11
C]McNiel 5652 Serotonin transporter (SERT/5-HTT) 
[
11
C]WAY 100635 Serotonin 5-HT1A receptor 
[
11
C]FBL 457 Dopamine (D2/3) receptors 
L-1-[
11
C]tyrosine Brain tumor protein synthesis  
[
11
C]MDL 100907 Serotonin 5-HT2A receptor 
[
11
C]b-CIT-FE Dopamine transporter (DAT) 
[
11
C]PMP Acetylcholinesterase (ACE) 
[
11
C]verapamil P-glycoprotein (P-gp) substrate 
[
11
C]MP4A Acetylcholinesterase (ACE) 
[
11
C]NNC112 Dopamine (D1) receptor 
[
11
C]a-methyl-l-tryptophan Tryptophan activity 
[
11
C]DASB Serotonin transporter (SERT/5-HTT) 
[
11
C]Rol5-4513 GABA-benzodiazepine receptors 
[
11
C]temozolomide Temozolomide pharmacokinetics 
[
11
C]PIB β-Amyloid 
[
11
C]harmine Monoamine oxidase type-A (MAO-A) 
[
11
C]methylreboxetine (MRB) Norepinephrine transporter (NET) 
[
11
C]ABP688 Glutamate receptor 5 (mGluR5) 
Fluorine 18 
[
18
F]FDG Glucose utilisation 
[
18
F]F-DOPA Dopamine synthesis 
[
18
F]A-85380 Nicotine acetylcholine receptors 
[
18
F]fallypride Dopamine (D2) receptor 
[
18
F]SPA-RQ Neurokinin-1 receptor 
[
18
F]fluoroethyl-L-tyrosine Brain tumor protein synthesis 
[
18
F]fluorothymidine Brain tumor proliferation 
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[
18
F]MK-9470 Cannabinoid receptor type 1 (CBR-1) 
[
18
F]fluoromisonidazole Brain tumor hypoxia 
Oxygen 15 
[
15
O]oxygen Oxygen utilisation 
[
15
O]water Blood flow 
 
1.2 PET and Radiochemistry with the 18F Isotope 
As mentioned earlier, the 
18
F isotope has become the radioisotope of choice for the 
production of a huge variety of PET tracers despite not being ubiquitous for 
incorporation into the majority of tracers. This is due to a number of desirable 
characteristics the radioisotope possesses. Primarily, a half-life of 110 min provides 
considerably more time for target synthesis and purification than 
11
C, 
13
N and 
15
O, and 
can even allow for transportation of tracers. This longer half-life is also an important 
consideration for investigation of systems with slower biological kinetics.
[22]
 Some 
properties of the 
18
F isotope are shown in Table 4. 
Table 4 – Properties of the 18F nuclide[22] 
Property Value 
half-life 110 min 
maximum energy of e
+
 0.64 MeV 
mode of decay β+(97%) 
decay product 
18
O 
 
PET imaging with [
18
F]tracers also provide high resolution images with respect to 
positron emitters such as 
13
N and 
11
C.
[11]
 This is due to the emission of lower energy 
positrons (maximal 0.64 MeV).
[22]
 Once emitted, the positron only travels a short 
distance (≈ 2 mm) before annihilation with an electron producing the detectable 511 
KeV gamma rays.
[7,11]
 Furthermore, its production via the 
18
O(p,n)
18
F nuclear reaction 
is high yielding with low energy protons (< 16 MeV), producing enough activity for 
multiple patient doses on the scale of several curies.
[22]
 This reaction also produces 
18
F 
with high specific activity in the absence of ‘cold’ [19F]F2 (used for the production of 
[
18
F]F2). Radiochemistry using [
18
F]fluoride produces high specific activity tracers 
suitable for imaging with very low concentrations of the tracer.  
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There are of course possible drawbacks of using 
18
F. Due to its high electronegativity, 
incorporation of fluorine into a molecule can alter its biological behaviour. In the cases 
where radiolabelling with the 
18
F isotope changes the structure of the molecule of 
interest (i.e. when it is not directly replacing 
19
F), investigation into the effects of this 
structural modification are required. If incorporation of 
18
F is in a position that will 
affect the distribution or metabolism of the compound then the tracer will generally not 
serve its purpose. Another consideration is the in vivo stability of the C-F bond. Whilst 
C-F bonds are generally stable under in vivo conditions, some aliphatic C-F bonds 
undergo enzymatic cleavage. Aromatic C-F bonds show greater stability.
[22]
 
Fluorine commonly replaces hydrogen or hydroxyl functionalities. It is isoelectronic to 
a hydroxyl substituent and possesses similar steric bulk to an oxygen atom.
[22]
 This 
allows for its widespread use for labelling a number of compounds without adverse 
effects regarding influence on the system under investigation. The subject of this thesis, 
[
18
F]F-DOPA 9, for example has the hydrogen atom in the 6 position of ʟ-DOPA 
replaced by the 
18
F nuclide. Despite the alteration to the compound, the labelled DOPA 
tracer is biologically equivalent to its parent compound and therefore can be used to 
monitor ʟ-DOPA metabolism and more importantly the distribution of ʟ-DOPAs 
metabolite dopamine.  
There are examples where modification of the tracers’ metabolism can be beneficial. 
One such example is that of the most successful PET tracer to date – 
[
18
F]fluorodeoxyglucose ([
18
F]FDG) 10.  
 
Figure 4 – Structures of tracers [18F]F-DOPA 9 and [18F]FDG 10. 
 [
18
F]FDG 10 is used to show the biodistribution of glucose and therefore can show high 
uptake in tumours where sugar metabolism is accelerated.
[2]
 The mechanism for the 
uptake into the cell is uninhibited by the replacement of the hydroxyl group for the 
[
18
F]fluorine. Once in the cell phosphorylation occurs preventing the [
18
F]FDG 10 from 
being released. However, further metabolism (glycolysis) is no longer possible due to 
the lack of the OH functionality in the 2 position. This process is known as metabolic 
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trapping and means that the [
18
F]FDG 10 does not exit the cell but accumulates to 
provide high uptake images for cells with accelerated sugar metabolism (see Figure 5). 
Upon decay of the 
18
F to 
18
O, normal metabolism of the product ensues. 
 
Figure 5 – Mechanism for [18F]FDG accumulation in cells with high glucose metabolism. Image 
obtained from reference 43 (no permission required).
[43]
 
1.3 Fluorination chemistry for radiotracer synthesis 
Incorporation of [
18
F]fluorine into a molecule for radiotracer production generally 
involves the formation of a C-F bond. Despite the considerable amount of work done in 
this field, such transformations are far from trivial and general reaction conditions for 
the formation of C-F bonds have yet to be realised. This is predominantly due to the 
nature of the element itself. It is often mentioned that fluorine is available in only an 
extremely reactive or almost inert state. This refers to the very low reactivity of the 
fluoride anion, which is generally highly solvated in solution, and the severe reactivity 
of F2 gas, which can rarely be tamed for a selective fluorination. The challenge for 
radiochemists is increased due to difficulties in translating such methods using the 
19
F 
isotope to reactions using 
18
F.
[44]
 These difficulties have been attributed largely to the 
huge differences in reagent concentration and stoichiometry.
[7]
 However, a number of 
advances in fluorination chemistry are providing a platform for advances in 
radiofluorination chemistry. A summary of important aromatic fluorination methods 
precedes a review on radiofluorination chemistry as the field is of great importance 
within the subject of this thesis. 
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Aromatic Fluorinations 
 
The formation of aromatic C-F bonds is key for the production of 
18
F labelled 
radiotracers. Indeed, the subject of this thesis, [
18
F]F-DOPA, is labelled via aromatic 
fluorination. A summary of important fluorination methods for aryl fluoride formation 
is given below to show the ‘tool box’ currently available. Conversion of some of the 
presented methods to radiochemistry has already been accomplished (Late Stage 
Incorporation of the 
18
F Nuclide, Pg. 20), while other methods offer avenues of 
investigation to provide new radiofluorination approaches. Reactions for aryl fluoride 
formation are shown in Scheme 6 (General aromatic fluorinations) and Scheme 7 (Metal 
catalysed and mediated fluorinations). 
General aromatic fluorinations 
 
Scheme 6 – Summary of fluorination methods for the production of arylfluorides. a) 
Deoxyfluorination of phenols: Using deoxyfluorination reagents such as PhenoFluor
®[45–47]
 or an 
oxidation-fluorination-reduction protocol
[48]
. b) Nucleophilic aromatic substitution: Substrates 
include aryl chlorides, aryl bromides, aryl quaternary ammonium salts, nitro arenes and aryl 
diazonium salts. Furthermore hypervalent iodine species (iodonium ylides
[49]
, iodyl species
[50]
 and 
iodonium salts
[51–54]
) and sulfonium salts
[55,56]
 are utilised for aromatics bearing more complex 
functionality. c) Oxidative fluorination: Phenols
[57,58]
 and monoprotected aniline derivatives
[58,59]
 are 
fluorinated in the presence of a hypervalent iodine oxidant. d) Electrophilic aromatic substitution: 
Electrophilic sources of fluorine are incorporated by reaction with aryl metal compounds to give 
improved selectivity and scope over reactions using Ar-H. Aryl metal species for fluorination 
include aryl-tin
[60–62]
, -mercury
[60,61,63]
, -boron
[64,65]
, -germanium
[61,62]
, -lead
[61]
, and -silicon
[62,66]
.  
a) The use of deoxyfluorination reagents for the conversion of phenoxy substrates to 
arylfluorides has been accomplished using both deoxyfluorinating reagents
[44–47]
 and 
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oxidation-fluorination-reduction reactions.
[48]
 The current reagent of choice for this 
reaction is Phenofluor
®
 due to its impressive substrate scope and the operational 
simplicity of the reaction, as reported by Ritter et al.
[45–47]
 b) Nucleophilic aromatic 
substitution reactions with appropriate leaving groups is a common method for the 
introduction of fluorine into electron deficient aromatic moieties. While generally 
substrate scope is limited, complex aryl fluoride formation has been achieved by 
appropriate precursor design and judicious choice of leaving group.
[23]
 Furthermore, the 
use of super effective leaving groups such as iodonium salts allows access to electron 
rich aryl fluorides (Hypervalent Iodine for late stage fluoriantions, Pg. 30).
[67]
 c) 
Oxidative fluorination of phenols and protected aniline derivitives has been 
reported.
[58,59]
 Gouverneur et al. demonstrated the use of this methodology for 
radiofluorination.
[57]
 The reactions use hypervalent iodine species as the oxidant. The 
fluorine atom replaces a proton or tBu group in the para position of the phenol or 
anilide. d) Electrophilic aromatic substitution provides a traditional method to access 
electron rich arylfluorides not suitable for nucleophilic methods. Many aryl metal 
species have been employed as substrates to improve the regioselectivity of such 
reactions with respect to the corresponding C-H precursor. Aryl-tin
[60–62]
, -
mercury
[60,61,63]
, -boron
[64,65]
, -germanium
[61,62]
, -lead
[61]
, and  
-silicon
[62,66]
 have been used with varying degrees of success. One method of particular 
note is the fluorodestannylation, which is used for the production of [
18
F]F-DOPA 
([
18
F]F-DOPA, Pg. 37, Scheme 24).
[7]
 
Metal-catalysed and metal-mediated fluorinations 
The use of metals for to mediation and catalyse fluorination reactions is an area of great 
interest and a large number of reactions have been reported in recent years. A brief 
overview of aromatic fluorination reactions using metals is given below.  
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Scheme 7 - Summary of metal catalysed fluorination methods for the production of arylfluorides. a) 
Metal catalysed fluorination of halides and triflates: Pd catalysed
[68–72]
 or Cu catalysed.
[73]
 b) Metal 
catalysed fluorination of mesityl iodonium salt: Using Cu catalyst.
[74,75]
 c) Metal catalysed and 
mediated fluorination of aryl C-H bonds. Production of 2-fluoropyridines using AgF2 in process 
analogous to the Chichibabin reaction.
[76]
 Aromatic fluorination via C-H activation using Pd 
catalysts
[77–79]
 or Cu catalyst
[80]
. d) Metal catalysed fluorination of boronic acid derivatives: Pd 
catalysed
[81]
, Ag mediated
[82]
 and Cu mediated
[83,84]
. e) Metal catalysed fluorination of stannanes: Ag 
catalysed
[85]
 and Cu mediated
[86]
. 
e) Buchwald has pioneered work on aryl fluoride formation via palladium catalysed 
nucleophilic fluorination. Substrates include aryl bromide, iodides and triflates.
[68–72]
 
The difficulties associated with the reductive elimination step to form the aryl fluoride 
were overcome by use of the bulky monodentate t-BuBrettPhos ligand. The use of a 
copper catalyst for nucleophilic fluorination has been reported by Hartwig et al. using 
aryl iodide substrates.
[73]
 f) The use of mesityl iodonium salts for fluorination in the 
presence of a copper catalyst has been reported by Sandford et al. with excellent 
selectivity and substrates scope.
[75]
 This work was adapted for radiofluorination with 
[
18
F]fluoride (Pg. 24 Scheme 21).
[74]
 g) C-H fluorination has been accomplished by the 
use of activating groups, as was first reported by Sandford et al.
[77]
 Work using this 
methodology has been accomplished using both palladium
[77–79]
 and copper
[80]
 catalysts. 
Hartwig also published an important paper on the fluorination of pyridines using 
silver(II) fluoride in a reaction analogous to the Chichibabin reaction.
[76]
 h) The use of 
aryl boronic acid derivatives for metal catalysed and mediated reactions has been 
accomplished using palladium catalysis
[81]
, copper mediation
[83,84,86]
 and silver 
mediation.
[82]
 The radiofluorination of boronic esters in the presence of copper(II) 
triflate was reported by Gouverneur et al. (Pg. 27, Scheme 17).
[87]
 i) Aryl stannanes 
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have also been used as substrates for metal catalysed and mediated fluorinations. The 
use of copper to mediate the fluorination of aryl stannanes was described by  
Sanford et al. 
[86]
 Late stage fluorination of aryl stannanes using a silver catalyst was 
published by Ritter et al.
[85]
 Fluorination of a range of small complex molecules was 
accomplished using this method. 
The number of methods available for the production of aryl fluorides has expanded 
rapidly over the past decade. While substrate scope and applicability to 
18
F reactions 
may hinder the use of some protocols for radiotracer production, this ever expanding 
tool box for aryl C-F bond formation provides a platform for radiochemistry to build on.  
1.4 Late Stage Incorporation of the 18F Nuclide 
Incorporation of the 
18
F nuclide can proceed by either electrophilic or nucleophilic 
fluorination. The most common and preferred synthetic route is with nucleophilic 
fluoride. This is because of the higher specific activity (higher radioactivity per unit 
mass) of the reagent and its availability to a wider number of PET centres. However, 
synthesis is highly dependent on the target compound and both strategies must be 
considered important tools to allow for the formation of a wide variety of different 
labelled compounds. 
1.4.1 Electrophilic Synthesis 
The disadvantages found when using electrophilic sources of fluorine stem from the fact 
that most reagents are derived from carrier added [
18
F]fluorine gas.
[5,10,11]
 This 
compound is dangerous and difficult to handle, leading to its unavailability at many 
PET centres. Also, due to its carrier added nature, it is only available with poor specific 
activity (approx. 1 GBq µmol
-1
).
[7]
 The contamination of the 
18F nuclide with its ‘cold’ 
19
F isotope means that the reagent and any subsequent radiochemistry performed with it 
will have lower radioactivity per mol. The result is a greater mass of ‘cold’ compound 
being administered to the patient. This can give lower resolution images and is 
especially problematic for compounds that do not benefit from accumulative uptake or 
‘metabolic trapping’ as seen by that of [18F]FDG. It should be mentioned that improved 
specific activity can be attained with the “Solin method” which uses a smaller quantity 
of carrier [
19
F]F2 gas (55 GBq µmol
-1
).
[88,89]
 
1.4.1.1 Reagents 
Scheme 8 shows some electrophilic reagents which can be derived from [
18
F]F2 gas.
[5]
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Scheme 8 – Electrophilic reagents derived from [18F]F2 for the incorporation of 
18
F. 
There are a number of electrophilic fluorination reagents available for the introduction 
of 
18
F. The most commonly used is [
18
F]F2 gas which advantageously can be delivered 
directly from the cyclotron. Reagents for electrophilic incorporation include O-F 
reagents such as [
18
F]perchloryl fluoride ([
18
F]FClO3) and [
18
F]acetyl hypofluorite 
([
18
F]AcOF).
[90–92]
 The high reactivity of [
18
F]F2 gas and these O-F reagents derived 
from it creates problems with selectivity for more complex precursors. This provided a 
strong incentive to produce milder more selective electrophilic 
18
F sources and the 
production of a number of N-F reagents accomplished this. Such reagents include [
18
F]-
N-fluoropyridinium salts and [
18
F]-N-fluorosulfonimides.
[93,94]
 One N-F reagent of 
particular note is [
18
F]Selectfluor bis(triflate) 12 which was developed and used by 
Gouverneur et al.
[88]
 The reagent has also been used for the production of [
18
F]F-DOPA 
9 from various precursors including the appropriate stannane and a novel boronic ester 
precursor 13 (Scheme 9).  
 
Scheme 9 – Gouverneur’s synthesis of [18F]selectfluor bis(triflate) and its utility in the production of 
[
18
F]F-DOPA
[88,95]
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Another notable electrophilic reagent is xenon difluoride [
18
F]XeF2 [
18
F]14, due to its 
possible production from nucleophilic fluoride.
[96,97]
 This route means it should be an 
accessible reagent at any PET facility able to produce [
18
F]fluoride. However, due to its 
production from [
19
F]XeF2 14, the [
18
F]XeF2 [
18
F]14 reagent is still of lower specific 
activity and its widespread utility in radiotracer synthesis has yet to be realised.  
Scheme 10 shows the production of [
18
F]XeF2 [
18
F]14 from nucleophilic [
18
F]fluoride. 
 
Scheme 10 – Formation of [18F]XeF2 by exchange with [
18
F]fluoride 
1.4.2 Nucleophilic Synthesis 
The use of nucleophilic [
18
F]fluoride as the source of the radioisotope is preferred due to 
its high specific activity and wide availability. However, as alluded to in ‘Reactivity of 
the Radioactive Moiety’ (Pg. 5), [18F]fluoride is delivered in an aqueous medium in 
which the [
18
F]fluoride anion is unreactive (in most cases) due to its high energy of 
solvation. To improve its reactivity the water must be removed by azeotropic distillation 
to give the more reactive ‘naked fluoride’. Figure 6 shows the general process used to 
provide the anion in its ‘naked’ form. It should be mentioned that full dehydration of the 
anion does not occur.
[22]
 
 
Figure 6 - General procedure for the drying of [18F]fluoride 
Once isolated in its ‘reactive form’, the [18F]fluoride can be used in a wide range of 
reactions. Historically, aliphatic incorporation has had greater success for the production 
of radiotracers. [
18
F]FDG 10 for example is produced via an SN2 reaction of the 
mannose triflate precursor 15 with the nucleophilic [
18
F]fluoride (Scheme 11).
[24]
 
Production of [
18
F]fluoride via proton bombardment of [
18
O]water to give aqueous [
18
F]fluoride. 
↓ 
Trapped on a QMA cartridge (anion exchange cartridge). 
↓ 
Eluted to the Reactor with a Kryptofix K2CO3 solution 
↓ 
Dried by azeotropic distillation with acetonitrile. 
↓ 
Precursor then added to the dried [
18
F]KF/K222 salt. 
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Scheme 11 – Synthesis of [18F]FDG from mannose triflate 
1.4.2.1 Aliphatic Incorporation of [18F]Fluoride 
Substitution reactions for the incorporation of 
18
F into aliphatic moieties are common 
and a number of leaving groups have been employed along with the triflate leaving 
group shown above. Commonly used as leaving groups are halides (Cl, Br or I) and 
other sulfonates such as mesylates, tosylates and nosylates.
[22]
 
Metal-Mediated Incorporation 
The metal-mediated incorporation of 
18
F into aliphatic compounds has seen a number of 
recent advances. For example, multiple procedures have been developed for allylic 
fluorination with nucleophilic fluoride using various metal catalysts.
[98–100]
 Iridium 
complexes have proved to be very successful in this area. 
The chiral introduction of [
18
F]fluoride has also been reported. Doyle et al. were able to 
access [
18
F]fluorohydrins 18 using a cobalt salen ligand complex 16OTs(a) and epoxide 
precursors 17 (Scheme 12a).
[101]
 The chiral ring opening of the epoxide proceeded with 
good stereocontrol and showed its utility in the production of [
18
F]FMISO.  
Further developments include a late stage benzylic fluorination reported by Groves et 
al. (Scheme 12b).
[102]
 Here a Mn(salen) complex 16OTs(b) was used for the 
introduction of [
18
F]fluoride, providing the labelled targets 20 without the need for ‘pre-
activated’ precursors. Both Doyle and Groves’ work advantageously avoid the need for 
azeotropic drying of the [
18
F]fluoride by direct elution of the [
18
F]fluoride from the 
QMA with the respective Mt(salen)OTs complexes. 
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Scheme 12 – Mt(salen) based fluorinations. a) Stereoselective formation of [18F]fluorohydrins 
utilising a monomeric or dimeric Co(salen)OTs reported by Doyle et al.
[101]
 b) Late stage benzylic 
[
18
F]fluorinations with a Mn(salen)OTs complex reported by Groves et al.
[102]
 
Another area of fruitful developments has been the synthesis of [
18
F]CF3 functionalities. 
As trifluoromethyl groups are prevalent in a number of pharmaceuticals, such reactions 
can be valuable tools for any required 
18
F incorporation. Methods for the generation of 
high specific activity [
18
F]CF3 functionality have been reported for both alkyl and aryl 
functionalization. 
A promising strategy for aliphatic targets is the [
18
F]fluorination of gem-difluoro vinyl 
precursors by nucleophilic addition of [
18
F]HF.
[103]
 A common strategy for aromatic 
substrates is to perform a cross-coupling reaction with [
18
F]CuCF3 which can be 
produced in situ.
[104–107]
 The strategy was first reported by Gouverneur et al. who 
showed in situ produced [
18
F]CuCF3 could be coupled to a wide range of both aryl and 
heteroaryl iodides 21 (Scheme 13).
[104]
  Boronic acids have also been used for this type 
of cross-coupling reaction.
[105,107]
 
 
Scheme 13 – In situ generation and cross-coupling of [18F]CuCF3 with aryl and heteroaryl iodides 
21 reported by Gouverneur et al.
[104]
 
Enzymatic Fluorination 
Radiochemists have also exploited nature’s solution to forming carbon fluorine bonds. 
The fluorinase enzyme is used to catalyse the formation of 5’-fluoro-5’-deoxyadenosine 
from S-adenosyl-ʟ-methionine.[108] Mild radiofluorination conditions have been 
developed using the fluorinase enzyme for the labelling of peptides and other 
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biomolecules.
[109–111]
 Advantageously such reactions are carried out under aqueous 
conditions. Disadvantages include the high substrate specificity of the enzyme, which 
limits the scope of such reactions. However improved understanding of these reactions 
has led to an enhanced scope of peptide substrates.
[109]
 
 
Scheme 14 – Enzymatic [18F]fluorination of a peptide 23 with fluorinase. O’Hagan et al. utilised an 
acetylene functionality to exploit an “Achillies heel” in the enzyme substrate specificity.[109] 
1.4.2.2 Aromatic Incorporation of [18F]Fluoride 
The synthesis of [
18
F]fluoroarene tracers with [
18
F]fluoride is very desirable due to the 
reasons already discussed (‘PET and Radiochemistry with the 18F Isotope’, Pg. 14). 
However, the wide spread utility of such reactions for tracer synthesis has been 
hampered by the lack of a reliable, robust methodology for [
18
F]fluoride incorporation. 
This is especially true for the synthesis of electron rich [
18
F]fluoroarenes. 
Traditional nucleophilic routes for labelling aromatic compounds include aromatic 
substitution of halides and other leaving groups such as nitro groups and ammonium 
salts. Unfortunately, these reactions are generally limited to aromatic compounds 
bearing electron-withdrawing groups and regioselectivity remains an issue. Introduction 
of [
18
F]fluoride using Balz-Schiemann and Wallach reactions is also possible but these 
methods generally suffer from poor radiochemical yields (RCYs) and the harsh 
conditions used limit the substrate scope of such transformations.
[112,113]
 Extending these 
traditional methodologies to complex systems can be difficult and often requires 
multistep synthesis. 
A number of recent developments in late stage fluorination are combating these 
problems. Among these progressions are new reagents and novel ‘activating’ 
functionalization of precursors. 
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Metal Mediated Aromatic [
18
F]Fluorination 
One strategy that has generated a lot of interest is the use of transition metal catalysts/ 
precursors for fluorination with [
18
F]fluoride.  
Ritter and co-workers showed that palladium complexes could be used to generate 
electrophilic 
18
F from nucleophilic [
18
F]fluoride.
[114]
 These palladium complexes 26 
could be used for the introduction of the 
18
F isotope into a range of pre-functionalised 
targets 27 (Scheme 15). 
 Scheme 15 – Palladium-catalysed fluorination of aromatics. 
Mechanistic investigation suggests a single electron transfer (SET) mechanism for the 
oxidative transfer of the [
18
F]fluoride from 26 to 27. Subsequent reductive elimination 
affords the [
18
F]aryl fluoride products.
[115]
 
Another metal mediated [
18
F]fluorination of aryl moieties reported by Ritter et al. uses  
nickel complex precursors in the presence of an oxidant 30.
[116]
 The reaction proceeds 
using aqueous, no carrier added (n.c.a) [
18
F]fluoride to give the [
18
F]labelled product in 
under one minute with high specific activity (SA). The use of aqueous fluoride for the 
reaction negates the need for time-consuming azeotropic drying steps, creating an 
extremely rapid procedure from end of bombardment (EOB). Disadvantages include a 
complex precursor synthesis and the instability of the oxidant. Scheme 16 shows the 
methods utility for the production of protected [
18
F]F-DOPA 31. 
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Scheme 16 – Oxidative fluorination of Nickel precursors in the presence of an oxidant with aqueous 
fluoride reported by Ritter et al.
[116]
 
Gouverneur et al. have recently reported the reaction of pinacol-derived boronic esters 
with [
18
F]KF/K222 in the presence of a copper catalyst.
[87]
 The optimised protocol 
proved to be a robust methodology for the synthesis of a diverse range of 
18
F labelled 
compounds. The suitability of the method for production of known tracers was proved 
by the synthesis of [
18
F]F-DOPA 9. Reaction of the protected DOPA boronic ester 32 
gave the 
18
F labelled compound 33 in good yields (Scheme 17). Deprotection with HI 
and HPLC purification provided the isolated [
18
F]F-DOPA 9 with an impressive decay 
corrected RCY of 12%. All PET centres with the capacity to produce 2-[
18
F]fluoro-L-
deoxyglucose 10 should be able to use this very promising method. 
 
Scheme 17 – Copper mediated [18F]fluorination of arylboronic esters reported by Gouverneur et 
al.
[87] 
The recent advance in radiochemistry, especially with regard to late-stage aromatic 
fluorinations, has been considerable. A recent review by Scott et al. entitled ‘Late-stage 
[18F]fluorination: New solutions to old problems’, highlights a variety of significant 
achievements in the area that have overcome shortfalls in the previously quite limited 
methodology.
[117]
 The use of hypervalent iodine for late stage incorporation of 
[
18
F]fluorine is a very active field and is responsible for a number of important 
advances. As the subject of this thesis, a more thorough overview of hypervalent iodine 
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compounds and their use in late stage fluorination reactions is presented below 
(Hypervalent iodine for late stage fluorinations, Pg. 30). 
Radiochemistry has a rapidly expanding toolbox with many new reagents and methods 
becoming available for the incorporation of isotopes. Just as with every area of 
chemistry, it is also benefiting from new technologies and methodologies. Flow 
chemistry using microreactors for 
18
F incorporation is a substantial field.
[118–120]
 In fact 
recently the first human use of a tracer made using microfluidic radiofluorination was 
published by Liang et al.
[121]
 The use of microwaves has also found utility in the field of 
late stage 
18
F fluorinations.
[122]
 It is unsurprising that these technologies, recognised to 
accelerate many reactions, have gained considerable attention in a field where short 
reaction times are of upmost importance. Electrochemistry is also an area receiving 
attention for its application in 
18
F incorporation.
[123–125]
 
Another methodology of interest is solid-supported synthesis of labelled 
compounds.
[126]
 Such reactions can provide the advantage of a simplified purification in 
which the labelled compound can be washed directly from the resin, with other side 
products (generally a leaving group) left bound to the resin. Both electrophilic and 
nucleophilic methods for 
18
F incorporation using resin bound precursors have been 
explored (Scheme 18).
[127,128]
 Despite the potential advantages of this methodology, its 
mainstream application for the production of tracers or prosthetic groups (Prosthetic 
Groups, Pg. 29) has not yet been seen.  
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Scheme 18 – Solid supported synthesis of 18F labelled tracers. a) Solid-supported synthesis of 
[
18
F]FDG 10 reported by Brown et al.
[127]
 b) Solid-supported synthesis of a protected [
18
F]F-DOPA 
moiety 36 reported in a patent published by Wadsworth et al.
[128]
 
1.4.3 Prosthetic Groups 
Direct incorporation of 
18
F into the compound of interest is not always necessary and 
sometimes it is desirable to label the biological moiety by linkage to an already labelled 
compound. These compounds are known as prosthetic groups and are generally used to 
label larger molecules such as peptides and antibodies where direct labelling is not 
feasible.
[5,11,22]
 Some examples of prosthetic groups are shown below (Scheme 19).  
 
Scheme 19 - Examples of prosthetic goups. 4-[
18
F]fluorobenzoic acid ([
18
F]FBzA) 37.
[129]
 4-
[
18
F]fluorobenzaldehyde ([
18
F]FBA) 38.
[130]
 
18F labelled alkyne for ‘click’ conjugation 39.[131] N-
succinimidyl-4-[
18
F]fluorobenzoate ([
18
F]SFB) 40.
[132]
 
18F labelled azide for ‘click’ conjugation 
41.
[133]
 
18
F labelled thiol 42.
[134]
 High specific activity [
18F]aryltrifluoroborate for ‘click’ conjugation 
43.
[135]
 
A number of linker strategies are available to attach the prosthetic group to the bioactive 
molecule of interest. Traditionally alkylation, acylation and amidation reactions have 
been used. Modern methodologies include the use of click chemistry with copper 
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catalysed cycloaddition.
[131,133,135]
 Linkage of a particularly high specific activity 
prosthetic group; [
18
F]aryltrifluoroborate 43, utilised such ‘click’ chemistry (Scheme 
19). Prosthetic groups with [
18
F]fluoride bound to elements such as boron, aluminium 
and silicon have become an important labelling strategy.
[136]
 
It is noteworthy that indirect incorporation of 
18
F by functionalization with cross 
coupling reactions has also proved desirable for some applications.
[137–139]
 Such 
incorporation is generally used for the construction of smaller labelled compounds. 
1.5 Hypervalent Iodine for late stage fluorinations 
1.5.1 Hypervalent Iodine 
The first organic hypervalent iodine compound was discovered in 1886 by Willgerodt 
who synthesised PhICl2.
[140]
 Many years since this discovery, hypervalent iodine 
compounds have found themselves in routine use in organic laboratories, most 
commonly as mild oxidants.
[140,141]
 The attractive nickel fluorination reported by Ritter 
et al. used a hypervalent iodine compound 30 as an oxidant for the incorporation.
[116]
 
More directly impacting the field of radio fluorinations however, are hypervalent iodine 
precursors; the most widely used and investigated of which are diaryliodonium salts.
[67]
 
1.5.2 Iodonium Salts 
Iodonium salts have generated a lot of interest as precursors for the nucleophilic 
incorporation of [
18
F]fluoride into electron rich target molecules. This is because their 
properties make them ideal precursors for aromatic radiotracer synthesis using 
nucleophilic [
18
F]fluorination. A quick, selective reaction is crucial for short reaction 
and purification times to increase RCY. This is achieved by the salts high reactivity, 
attributed to the ‘hyperleaving group ability’ of the PhI group, which is approximately 
10
6
 times greater than that of a triflate.
[142]
 
The use of diaryliodonium salts for the formation of 
18
F labelled aromatic compounds 
was first reported by Pike et al. using both symmetrical and unsymmetrical 
diaryliodonium precursors.
[51]
 These compounds have a characteristic T-shaped 
geometry, which means that if the iodonium salt is unsymmetrical then two 
interconverting isomers exist (Figure 7).
[143]
 The aromatic substituent at which the 
fluorination takes place is dependent on both the electronic and steric properties of the 
two attached aryl moieties. This allows precursors to be designed for selective 
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fluorination at the desired aromatic ring by employing a small, electron rich aryl group 
(commonly 2-thienyl and 4-methoxyphenyl) as the ‘non-participating’ aryl ring. One 
directing group of particular superiority is the [2,2]paracyclophane moiety. Dimagno et 
al. showed the group to be capable of directing fluorination to even 2-thienyl and 4-
methoxyphenyl aromatics.
[144]
 
1.5.2.1 Mechanism and Selectivity 
The mechanism of fluorination at the I(III) centre has been investigated computationally 
by Togni et al. and shows why such directing groups can achieve regioselective 
fluorination, for the production of the 
18
F labelled target molecule.
[143]
  
 
Figure 7 – Reaction profile for the reductive elimination of an unsymmetrical iodonium 
bromide.
[143]
 
Nucleophilic attack at the I(III) centre proceeds via ligand exchange to form the T-
shaped nucleophile salt. Two T-shaped iodane isomers exist and can interconvert via a 
Y-shaped transition state. Ipso-attack of the nucleophile leads to functionalisation of the 
aromatic. The Gibbs free energy of each transition state is dependent on both the 
electronic and steric properties of the aromatics present. An electron rich arene will 
have a higher energy transition state and therefore directs functionalisation to the more 
electron poor aromatic. Selectivity complies with the Curtin-Hammett principle.
[143]
  
As alluded to above, the electronics of the aromatic are not the only factor influencing 
the regioselectivity of the fluorination. A steric consequence known as the ‘ortho effect’ 
can have a major influence on this selectivity. This effect occurs due to differences in 
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the steric interactions between the two isomers of an unsymmetrical diaryliodonium 
salt. In Figure 8 it is shown that the more sterically bulky / ortho substituted aromatic 
can either be found in the axial or equatorial position. The more compact axial produces 
a greater steric interaction than the roomier equatorial position. This increases the 
energy of the axial isomer (and its transition state) and hence, the isomer in which the 
sterically bulky / ortho substituted aromatic is equatorial is predominant. From the 
transition state it can be seen that this leaves the bulky aromatic substituent available for 
fluorination. Aside from this argument, the selectivity has also been partly attributed to 
the lipophilicity of the substituent. Hydrophobic groups create a ‘lipophilic 
microenvironment’ which improves the nucleophilicity of the [18F]fluoride 
nucleophile.
[119]
 
 
Figure 8 – Regioselectivity induced by the “ortho effect”. 
1.5.2.2 Utility 
The utility of diaryliodonium salts in radiotracer formation offers a selective and widely 
applicable methodology for the introduction of [
18
F]fluoride into a large number of 
functionalised arenes. Nevertheless, the use of iodonium salts for the introduction of 
fluoride cannot be described as general, with a large range of fluorination conditions 
reported for a range of substrates. The radical scavenger TEMPO has been shown in 
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some cases to increase the reproducibility and RCY of reactions,
[145,52,146]
 whilst in other 
cases TEMPO offers no improvement.
[119]
 Of even greater curiosity is the addition of 
water to these reactions which is avoided in many cases and can be critical to the 
success of the reaction in others.
[52,54,147]
 It has been speculated that beneficial addition 
of water could be attributed to the catalysed formation of an intimate ion-molecule pair 
produced under such conditions.
[54]
 Another factor alluded to is the improved solubility 
of the [
18
F]fluoride salts.
[52]
 
The production and fluorination of more complicated, biomedically relevant iodonium 
precursors has until recently also experienced difficulties. However, as the 
understanding and experience in this methodology has grown, the use of iodonium salts 
as precursors to form more complex, electron-rich radiotracers has seen much recent 
success.
[52,146,54]
 Scheme 20 shows some [
18
F]tracers synthesised using diaryliodonium 
salt precursors. 
 
Scheme 20 - [
18
F]tracers synthesised using diaryliodonium salt precursors. [
18
F]DAA1106 44 
synthesised by Zhang et al.
[148]
 PPARγ ligand 45 synthesised by Katzenellenbogen et al.[149] 
[
18
F]flumazenil 46 synthesised by Kim et al.
[150]
  2-aryl-6-[
18
F] fluorobenzothiazoles 47 synthesised 
by Kim et al.
[151]
 
18
F labelled mGluR5 radioligands 48 synthesised by Pike et al.
[152] 
The use of iodonium salts in the presence of a transition metal catalyst can also be 
fruitful for the introduction of fluorine. Scott et al. used mesityl-substituted iodonium 
salts for late stage [
18
F]fluorination in the presence of a copper catalyst.
[74]
 The 
selectivity for the radiofluorination is governed by sterics, with fluorination occurring at 
the smaller aryl group irrespective of its electronic properties. The methods utility for 
the production of a protected [
18
F]F-DOPA moiety 50 was successful, with a 
radiochemical conversion (RCC) of ~31% (Scheme 21). However, the isolated RCY of 
50 was 1% (non-decay corrected). 
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Scheme 21 - Copper catalysed fluorination of a mesityl diaryliodonium precursor. 
1.5.3 Other hypervalent precursors. 
Also of interest for 
18
F incorporation are iodonium ylides. Liang et al. recently 
published a procedure for the regiospecific fluorination of iodonium ylides.
[153]
 This 
attractive methodology was adapted from previous work and has also been reported by 
Barrio et al. for the synthesis of [
18
F]F-DOPA 9 via the appropriately functionalised 
precursor 51 (Scheme 22a).
[50]
 The advances reported by Liang and co-workers include 
the use of a spirocyclic iodonium ylide which provides a precursor more stable to I(III) 
decomposition and disproportionation. 
This class of hypervalent iodine compound lends itself well to the synthesis of electron 
rich aryl radiotracers: While the fluorination is proposed to occur through a similar 
intermediate to that of a diaryliodonium salt precursor,
[153]
 it is claimed to occur with 
complete regiospecificity.
[50]
 This is due to the presence of a carbon with carbanionic 
character producing a charge distribution which severely disfavours nucleophilic attack 
at the ylide auxiliary. The methodology has proven to be a reliable and suitable method 
for radiotracer production by its recent utility in the production of [
18
F]FPEB 54 
validated for human use (Scheme 22b).
[154]
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Scheme 22 – Iodonium ylides precursors for the production of 18F labelled tracers. a) Synthesis of a 
protected [
18
F]F-DOPA 52 compound from a meldrums acid derived iodonium ylide reported by 
Barrio et al.
[50]
 b) Production of [
18
F]FPEB 54 using Liang’s modified spirocyclic iodonium ylide 
methodology reported by Vasdev et al.
[154] 
The use of iodyl compounds as precursors for the synthesis of 
18
F labelled compounds 
isn’t common. However Barrio et al. have shown these hypervalent iodine species to be 
suitable precursors for fluorination with [
18
F]fluoride.
[155]
 Precursors are produced by 
oxidation of the iodine(I) compound with dimethyl dioxirane. The iodyl precursor can 
then undergo fluorination to yield the corresponding [
18
F]labelled product. Scheme 23 
shows the successful fluorination of the corresponding protected [
18
F]F-DOPA 
precursor 55. The explosive nature of the precursors may hinder the widespread utility 
of such compounds. 
 
Scheme 23 - Iodyl precursor 55 undergoes radiofluorination to yield the protected [
18
F]F-DOPA 
species 56.
[155]
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1.6  [18F]F-DOPA 
1.6.1 Introduction 
[
18
F]6-Fluoro-3,4-dihydroxy-L-phenylalanine ([
18
F]F-DOPA) 9 is a radiotracer of 
considerable interest due to its employment in the diagnosis and evaluation of diseases, 
including cancers
[1]
 and neurodegenerative disorders such as Parkinson’s disease.[4] The 
radiolabelled ʟ-DOPA behaves with similar kinetics and equivalent biochemical 
behaviour to its unlabelled analogue.
[156]
 After injection, [
18
F]F-DOPA 9 is subjected to 
the metabolism of ʟ-DOPA and is therefore transported into presynaptic neurons where 
aromatic ʟ-amino-acid decarboxylase (AAAD) converts the tracer into 
[
18
F]fluorodopamine ([
18
F]FDA) which is retained in catecholamine storage.
[157]
  
Importantly, unlike [
18
F]FDA, [
18
F]F-DOPA 9 can cross the blood-brain barrier.
[156]
 
This allows for uptake of the tracer in the dopaminergic cells in the brain where 
conversion to [
18
F]FDA is again facilitated by AAAD.
[156]
 Hence, the production and 
metabolism of dopamine can be monitored. This allows for diagnosis and investigation 
of diseases in which [
18
F]FDA production and metabolism is lacking or abnormal. Such 
conditions include Parkinson’s disease and schizophrenia.[4,158,159] Increased uptake into 
the brain can be accomplished by administering carbidopa to the patient prior to 
injection. This inhibits initial decarboxylation of [
18
F]F-DOPA 9 to [
18
F]FDA after 
injection, increasing the availability of [
18
F]F-DOPA 9 for transportation and 
accumulation in the brain.
[160]
  
Furthermore, [
18
F]F-DOPA 9 shows accumulation in cells with an increased amino acid 
uptake. This includes brain tumours and neuroendocrine tumours (NETs).
[1]
 Increased 
amino acid transport and AADC activity in neuroendocrine tumours are responsible for 
the greater accumulation of the tracer and its metabolites. Cerebral gliomas show an 
increased uptake of [
18
F]F-DOPA 9 due to over expression of the LAT1 transporter 
protein, giving the positive PET image.
[1]
 
It should be mentioned that the injected [
18
F]F-DOPA 9 undergoes a number of 
transformations during its metabolism (following that of ʟ-DOPA’s) and much of the 
activity injected will not be accumulated in the area under scrutiny.
[161]
  
While [
18
F]F-DOPA 9 has been known to be a useful radiotracer for over 30 years,
[162]
 
its widespread clinical use has been hampered by the lack of a robust, high yielding pro-
cess for incorporation of the 
18
F nuclide (t1/2 =  110 min). 
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1.6.2 Synthesis 
Recent Developments 
Currently [
18
F]F-DOPA 9 is produced by electrophilic destannylation of 57 with 
[
18
F]fluorine gas (Scheme 24).
[7]
 This reaction suffers from several disadvantages 
including poor radiochemical yield (RCY) and low specific activity (SA) due to the use 
of carrier added [
18
F]F2 gas. Furthermore, the procedure is unavailable to PET centres 
not equipped with [
18
F]F2 gas production facilities. 
 
 
Scheme 24 - Current electrophilic synthesis of [
18
F]F-DOPA 9 
Much research into [
18
F]F-DOPA 9 synthesis has been conducted in order to overcome 
these limitations, with a large focus on nucleophilic incorporation of no carrier added 
(n.c.a.) [
18
F]fluoride, due to the benefits already mentioned (Nucleophilic Synthesis, Pg. 
22). [
18
F]F-DOPA 9 with a high specific activity has become more sought after due to 
the tracers increasing importance in peripheral oncologic diagnosis. Employing [
18
F]F-
DOPA 9 with low specific activity requires an increased dose which can have severe 
adverse effects on the patient such as carcinoid crisis.
[163]
 
The advances in the nucleophilic incorporation of [
18
F]fluoride outlined above 
(Aromatic Incorporation of [
18
F]Fluoride, Pg. 25) have contributed significantly to 
providing alternative nucleophilic routes to this important tracer. Methods that have 
already been presented for their useful employment in [
18
F]F-DOPA 9 synthesis are 
outlined in Table 5 (Pg. 40). Some further advances in the synthesis of [
18
F]F-DOPA 9 
are described below. 
1.6.2.1 Synthesis with Diaryliodonium Salt Precursors. 
The synthesis of [
18
F]F-DOPA 9 using diaryliodonium salts is a recent development. 
Unfortunately, the reported synthesis and application are only covered by scant patent 
literature. The reported information is outlined below along with some further 
information provided by the website ‘http://www.gfpharma.com/’.[164,165] 
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DiMagno et al. investigated the synthesis of the diaryliodonium triflate 58(TfO)a,
[166]
 
which forms the [
18
F]iodonium fluoride in dry acetonitrile by anion exchange. 
Subsequent to a filtration to remove any insoluble salts, successful fluorination via 
breakdown of the iodonium fluoride 58(
18
F)a in a non-polar solvent yields the protected 
[
18
F]F-DOPA 59a. Deprotection with HBr produces [
18
F]F-DOPA 9 (Scheme 25). Such 
‘salt-free’ conditions can improve fluorinations using diaryliodonium salts.[167] 
Details of the reaction success are not disclosed in the patent. However, using an 
analogous precursor; ALPDOPA
TM
 58(TfO)b, Ground Fluor Pharmaceuticals Inc. 
claim >30-40% RCY, >4000 Ci/mmol SA and >98% ee when using diglyme as the 
breakdown solvent.
[164]
 
 
 
Scheme 25 - Diaryliodonium triflate precursor 58 undergoes anion exchange followed by thermal 
decomposition to yield [
18
F]F-DOPA 9 after a subsequent deprotection step.
[164,166]
 
High specific activity [
18
F]F-DOPA 9 (synthesised using the ALPDOPA
TM
 iodonium 
salt precurosor) has been used in a study to compare with [
18
F]F-DOPA 9 prepared by 
the traditional electrophilic method. It was found that imaging qualities in mice were 
identical. Using the high specific activity [
18
F]F-DOPA 9 was advantageous due to its 
facil production procedure and the lower administered mass of [
19
F]F-DOPA 9.
[168]
 
1.6.2.2 Multistep Syntheses 
Multistep synthesis provides a challenge for the production of 
18
F labelled compounds 
due to problems with complex automation. However, developments in this area are now 
providing methods for reliable nucleophilic [
18
F]F-DOPA 9 production.  
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Trasis have developed a reliable nucleophilic method by optimising and automating 
chemistry reported by Lemaire et al.
[169–171]
 The multistep synthesis involves 
nucleophilic aromatic substitution of an electron poor nitrobenzaldehyde 60 with 
[
18
F]fluoride. The activating aldehyde functionality is then converted to the iodide to 
give [
18
F]fluorobenzyl iodide 63. Enantioselective carbon-carbon bond formation with 
Schiff’s base 64 in the presence of a chiral phase-transfer catalyst is a key step and 
optimisation showed compounds 66 and 67 to be of equal efficacy for this 
transformation. The protected DOPA moiety 65 is produced with ≥97% ee and high 
specific activity (35000 Ci/mmol).
[165,169]
 Subsequent deprotection with HI yields 
[
18
F]F-DOPA 9 (Scheme 26). 
 
Scheme 26 - Multistep synthesis to [
18
F]F-DOPA using chiral phase-transfer catalysts.
[165]
 
 
In addition, ABX now provide a nitro precursor 68 for nucleophilic [
18
F]F-DOPA 9 
formation.
[23]
 The strategy makes use of previously developed carbonyl activating 
chemistry for the SNAr reaction with [
18
F]fluoride.
[172]
 After radio-fluorination is 
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achieved, the activating aldehyde group can be removed by a sequence of Baeyer-
Villiger oxidation and hydrolysis to give the desired hydroxyl functionality (Scheme 
27). 
 
Scheme 27 - Aldehyde activated [
18
F]fluorination of ABX’s nitro precursor 68 with [18F]fluoride.[23] 
A summary of the most promising syntheses for [
18
F]F-DOPA is shown in Table 5. 
Table 5 - Summary of the most promising syntheses for [
18
F]F-DOPA 9 
Precursor Method RCY (%) SA (Ci/ mmol) ee  
29 Nickel 15 ± 7 
p
 - - 
60 PTC Nitro (Trasis) >35 
uc 
35000 >97 
68 Nitro (ABX) 20 ± 7 - >99 
58b IS >30 – 40 4000 >98 
49 IS + Cu >1 
p uc
 290 - 
51 Ylide - - - 
55 Iodyl 5 – 10 
p 
- - 
32 BPin 12 - >99 
uc
 Uncorrected RCY. 
p 
Protected [
18
F]F-DOPA moiety. IS = Iodonium Salt. PTC = Phase-transfer Catalyst 
1.7 Conclusion 
[
18
F]F-DOPA 9 is a radiotracer of high interest for diagnosis and evaluation in oncology 
and central nervous system disorders. Its use has been impeded by the lack of a reliable 
automated, nucleophilic synthesis, but recent developments are now enabling access to 
this elusive tracer incorporating more of the requirements outlined for an “ideal 
synthesis”. Improvements in automation of multistep synthesis are providing robust, 
nucleophilic routes. Furthermore, developments in hypervalent iodine chemistry and 
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transition metal-mediated fluorinations are allowing fast nucleophilic reactions using 
bench stable and easily accessible precursors, providing excellent alternatives to the 
traditional electrophilic route. 
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2 
Synthesis of Iodonium Salt Precursors for the 
Formation of [
18
F]F-DOPA 
1.1 Introduction 
The synthesis and utility of iodonium salts for the synthesis of [
18
F]F-DOPA 9 is an area 
of substantial interest but has not experienced extensive investigation. Before 
commencing this research no academic publications were available, whilst scant patent 
literature was lacking in detail.
[1]
 Therefore, it seemed promising to investigate this 
avenue for a new precursor and synthesis strategy towards [
18
F]F-DOPA 9. 
Investigation into whether this approach would be suitable for conversion to a solid 
supported methodology is reported in chapter 3. 
1.2 Iodonium salt precursor synthesis 
Aims and Objectives 
 Produce and test simple iodonium salts for the formation of [19F]fluorobenzene 
77 and [
18
F]fluorobenzene [
18
F]77 
 Translate these reactions to the synthesis and testing of iodonium salt precursors 
for [
18
F]F-DOPA 9 production 
 Assess the possibility for adoption to a solid supported procedure 
 
1.2.1 Synthesis of simple iodonium salts for fluorination 
To probe the chemistry for iodonium salt synthesis and fluorination, a number of simple 
diaryliodonium salt precursors were targeted. This would allow for an understanding of 
the chemistry to be established before moving on to more elaborate syntheses for the 
production and testing of [
18
F]F-DOPA 9 precursors. 
Design of iodonium salt precursor: 
As mentioned in the introduction (Chapter 1, Pg. 31-22), the regioselectivity of the 
fluorination reaction is dictated by the electronic and steric properties of the two aryl 
substituents. With this in mind, the following precursor design was established (Figure 
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1). The two directing aromatics proposed were chosen for their highly electron rich 
nature. The high electron density should direct fluorination regioselectively to the other 
aryl moiety (Pg. 31). 
 
Figure 1 - Design of iodonium salt precursor 
Directing aromatic: 4-iodoanisole 
 
Figure 2 – Target precursor for [18F]fluorobenzene production: 4-methoxyphenyl(phenyl)iodonium 
salt 71(X). 
Two synthetic routes to the salt were investigated. Firstly, similar conditions were used 
to those reported by Carroll et al. for a solid supported synthesis (Chapter 3 Pg. 131). A 
second route proceeded via the anisole derived Koser compound 73 to give the 
iodonium tosylate (Scheme 1b). Reaction of the Koser reagent 73 with the stannane 
proceeded quantitatively when performed with a mixture of dichloromethane and 2,2,2-
trifluoroethanol. The use of fluorinated solvents to enhance reaction success when using 
hypervalent iodine species is well reported. It is suggested to occur due to stabilisation 
of charged intermediates by the polar solvent.
[2]
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Scheme 1 – Formation of simple diaryliodonium salts 71(TFA) and 71(TsO). a) Synthesis of 
diaryliodonium trifluoro acetate 71(TFA) via diacetate 72. b) Synthesis of diaryliodonium tosylate 
71(TsO) via Koser type reagent 73.  
Directing aromatic: 1,3,5-trimethoxy-4-iodobenzene 
 
Figure 3 - Target precursor for [
18
F]fluorobenzene production: 2,4,6-
trimethoxyphenyl(phenyl)iodonium salt 74(X). 
To probe the directing effect of the electron rich ring, a salt containing a 1,3,5-
trimethoxybenzene moiety was also synthesised (Scheme 2).  
 
Scheme 2 – Formation of iodonium tosylate 74(TsO) via reaction of Koser 76 with electron rich 
aromatic 75. 
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Both Koser reagent formation and reaction with electron rich aromatic 1,3,5-
trimethoxybenzene 75 to form iodonium tosylate 74(TsO) proceeded with good yields. 
1.2.1.1 ‘Hot’ Fluorinations using Automated Modules 
Testing of the simple iodonium salt precursors for the incorporation of [
18
F]fluoride was 
now looked into. As mentioned in the introduction, such reactions are carried out using 
automated systems contained in heavily shielded compartments called ‘hot cells’. The 
figure below shows the modules used for the automated reactions conducted. 
 
Figure 4 – Eckert and Ziegler modules used for radiofluorination reactions 
Manipulation of the different reaction components is achieved using a combination of 
valves and nitrogen pressure. Figure 5 shows a schematic of the module set up, as seen 
on the computer controlling the modular apparatus. 
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Figure 5 – Schematic of automated apparatus used for radiofluorination reactions 
During a standard reaction the following manipulations are carried out: 
1. Transfer of aqueous [18F]fluoride (delivered from the cyclotron) to the QMA 
(anion exchange resin) cartridge where [
18
F]fluoride is trapped and [
18
O]water is 
carried through to a waste vial. 
2. A solution of Kryptofix® (K222) K2CO3 is passed from its storage vial to the 
reaction vial via the QMA cartridge. The trapped [
18
F]fluoride is carried to the 
reaction vial during this process as a [
18
F]KF/K222 complex in aqueous 
acetonitrile solution. 
3. Azeotropic drying of the [18F]KF/K222 is now conducted. This is achieved by 
heating the reaction and subjecting the contents to vacuum followed by nitrogen 
flow multiple times. Acetonitrile (1 mL) is then transferred to the reaction vial 
before the drying process is again commenced. The azeotropic drying is carried 
out twice (2×1 mL acetonitrile). 
4. The precursor and reagents are transferred to the dried [18F]KF/K222 complex in 
the reaction medium and the reaction conducted in a sealed vessel. 
5. After completion of the reaction the entire mixture is ejected and analysis 
conducted to obtain radiochemical recovery (RCR), radiochemical conversion 
(RCC) and radiochemical yield (RCY). From the product vial, the crude reaction 
mixture can be transferred to the HPLC injection loop for preparative 
Pump 
Reactor 
MeCN MeCN 
Aqueous [18F]fluoride 
QMA 
Precursor 
vial 
To Product 
vial 
To HPLC 
K222  
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purification. Transfer to the injection loop is also possible directly from the 
reaction vial. 
1.2.1.2 Testing of [18F]fluorobenzene precursors 
‘Hot’ fluorination of the two [18F]fluorobenzene [18F]77 precursors occurred 
successfully with both electron rich aryl moieties providing excellent directing 
properties for the fluorination (Table 1). Both directing groups showed complete 
selectivity for the formation of [
18
F]fluorobenzene [
18
F]77 with no formation of [
18
F]4-
fluoroanisole or [
18
F]1,3,5-trimethoxy-4-fluorobenzene. In the case of precursor 
74(TsO) it shows that the highly electron rich nature of the aromatic has overcome any 
directing influence of an ‘ortho-effect’ which would direct fluorination for the 
formation of [
18
F]1,3,5-trimethoxy-4-fluorobenzene. 
Table 1 - ‘Hot’ fluorination of simple precursors 71(TFA) and 74(TsO) for the formation of 
[
18
F]fluorobenzene 
 
Precursor 
Scale (mmol) 
R X Solvent Conversion (%)* Recovery (%) RCY (%) 
0.12 H CF3CO2 MeCN 90 30 27 
0.12 H CF3CO2 toluene/MeCN (2/1) 91 25 23 
0.0047(2mg) H CF3CO2 MeCN/DMSO (6/1) 0 - 0 
0.029(10mg) H CF3CO2 MeCN/DMSO (6/1) 20 74 15 
0.12 OMe TsO MeCN/DMSO (6/1) 91 48 44 
0.06 OMe TsO MeCN/DMSO (6/1) 93 51 47 
*Conversion calculated from HPLC analysis  
It is apparent from the results that both precursors provide excellent radiochemical 
conversion (RCC) of [
18
F]fluoride to the desired [
18
F]fluorobenzene product [
18
F]77, 
without any significant advantage observed for using either precursor. Solvent 
conditions used thus far do not appear to have an effect on the RCC but certainly can be 
used to improve the RCY by improving the recovery of activity from the apparatus to 
the product vial. The use of acetonitrile/DMSO (6:1) as the reaction solvent 
significantly improved the recovery of activity contributing to the improved RCYs.  
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The effect of scale is also evident in Table 1. Despite the overwhelming excess of 
precursor compared to the [
18
F]fluoride (≈108 equivalents) the reaction does not take 
place on a 4.7 µmol mmol scale (2 mg) and affords poor conversion on a 29 µmol scale 
(10 mg). It is only once the precursor is present on 60 µmol scale that the reaction 
occurs satisfactorily. 
Radiochemical conversions were calculated using radio HPLC. When analysis was 
conducted with radio TLC, radiochemical conversion was diminished. The volatility of 
the product was assumed to be responsible. This has previously been observed.
[3]
 
1.2.1.3 Oxidation of 1,3,5-trimethoxy-4-iodobenzene 
Despite providing a useful comparison to the anisole derived salts 71(TFA) and 
71(TsO), the synthetic route used to produce the 1,3,5-trimethoxybenzene derived salt 
74(TsO) is not applicable for the production of the [
18
F]F-DOPA precursor using the 
commercially available methyl N-t-butoxycarbonyl-3,4-di(t-butoxycarbonyloxy)-6-
trimethylstannylphenylalanine 82. Therefore a synthetic strategy for the production of a 
1,3,5-trimethoxy-4-iodobenzene Koser reagent 79 was looked into (Table 2). 
 
Scheme 3 - Formation of 1,3,5-trimethoxy-4-iodobenzene 78 
Table 2 - Conditions for the attempted production of Koser reagent 79 
 
Entry Temp (°C) Solvent 
1 25 TFE/CH2Cl2 (1:1) 
2 25 CH2Cl2 
3 0 CH2Cl2 
 
After failure to produce the Koser type compound 79, attempts to synthesise the 
corresponding diacetate 80 were conducted. These compounds can show a greater 
stability to their Koser counterparts.
[4][5]
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Table 3 - Conditions for the attempted production of 80. 
 
Entry Temp (°C) Solvent 
1 0 CH2Cl2 
2 0 -> 25 CH2Cl2 
3 0 -> 25 TFE/CH2Cl2 (1:1) 
 
Diacetate 80 production also proved unsuccessful. Both oxidation to the Koser reagent 
79 and diacetate 80 gave complete degradation of starting material and showed no sign 
of product formation. It is proposed that this is due to the highly electron rich nature of 
the arene. This would cause the oxidised product to be very unstable. Such problems 
with electron rich substrates have been reported previously.
[4]
  
1.2.2 Production of [18F]F-DOPA precursor iodonium salts 
Synthesis of a precursor derived from the trimethoxybenzene moiety therefore, looked 
unfeasible. However, the synthesis route using 4-iodoanisole looked appropriate to 
adapt to the production of a protected DOPA functionalised anisyl iodonium salt 81(X). 
Therefore the following precursor was targeted (Figure 6). 
 
Figure 6 – Target precursor for the production of [18F]F-DOPA 9. 
Translation of the methods used for simple iodonium salt synthesis to produce an 
unsupported [
18
F]F-DOPA precursor was troublesome. Initial conditions using the 
diacetate 72 for reaction with stannane 82 in the presence of trifluoroacetic acid were 
unsuccessful (Scheme 4). 
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Scheme 4 – Attempts to produce iodonium salt 81(TFA) employing conditions used to produce 
iodonium salt 71(TFA). 
However, analysis of the partially purified (precipitated) product from the reaction of 
Koser reagent 73 with stannane 82 in dichloromethane (Table 4, entry 1) suggested 
some iodonium salt formation (Figure 7).  
 
Figure 7 – 1H NMR analysis of the iodonium salt 83(TsO) 
Shifts of the aromatic protons on the DOPA aromatic moiety from 7.23 and 7.12 to 8.33 
and 7.50 ppm, respectively, suggested the formation of an iodonium salt. However, the 
isolation of the product was not possible, making characterisation difficult. A number of 
impurities were still present after precipitation of the salt, the most prominent of which 
was p-toluenesulfonic acid. Different conditions were investigated to see if the reaction 
would proceed more cleanly (Table 4). 
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Table 4 – Initial reaction conditions for the production of iodonium salt 81(TsO) 
 
Entry Reaction Time (h) Temp (°C) Solvent Koser Equiv TsOH:Salt(81)* 
1 12 R.T CH2Cl2 1.2 4.5:1 
2 23 R.T CH2Cl2 1.5 4:1 
3 60 R.T TFE/CH2Cl2 (1:1) 1.2 14:1 
4 7 R.T TFE/CH2Cl2 (1:1) 1.2 2.5:1 
5 5 40 TFE/CH2Cl2 (1:1) 1.2 No Product 
6 10 0 TFE/CH2Cl2 (1:1) 1.2 3:1 
7 10 0 Toluene/TFE (3:1) 1.2 3:1 
*Determined by integration of the crude precipitate 
1
H NMR 
The significant p-toluenesulfonic acid impurity could be reduced by lowering the 
reaction time and temperature but was still a major component of the precipitate. Higher 
temperatures (Table 4, Entry 5) are detrimental to the reaction. Washing the precipitated 
crude product with water did not remove any of the p-TsOH impurities. 
Entries 3 to 7 in Table 4 utilise a fluorinated solvent. This is due to a number of 
publications that have reported such solvents to be beneficial in reactions involving 
hypervalent iodine species.
[2]
 Whilst observed for the synthesis of simple iodonium salt 
71(TsO) (Scheme 1), such benefits were not seen for the production of 81(TsO). 
Attempted Purification by Recrystallization 
A wide range of recrystallization conditions were attempted without success, including 
one method outlined below (Scheme 5). The procedure had been used successfully for 
the purification of other iodonium salts bearing complex functionality.
[6]
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Scheme 5 – Counter ion exchange and recrystallization of iodonium salts from aqueous solutions of 
NaPF6 (0.3 M). 
Recrystallization by counter ion exchange in water is an attractive purification strategy 
and worked well for the simple salt 71(TsO) (Scheme 5a). However, application for the 
work up of the functionalised salt 81(TsO) was unsuccessful, presumably due to the 
more lipophilic nature of the protecting groups (Scheme 5b).  
1.2.3 Alternative Syntheses for Precursor Formation 
Due to problems isolating the current precursor, other options for precursor formation 
were considered. Two different approaches were investigated. 
The first route was to alter the reactants and oxidise the iodoDOPA compound 83 for 
reaction with an electron rich aromatic compound (Scheme 6). The second strategy was 
to alter the target molecule slightly in the hope that an alternative precursor would be 
more easily isolated. An obvious choice for alteration was the ‘non-participating’ aryl 
ring as this would be easily implemented from similar starting materials (Scheme 7). 
The 2-iodo thienyl directing group was chosen due to its common utility in the synthesis 
of other iodonium salt precursors used in [
18
F]fluorination reactions.
[7,8]
 
1. The formation of a hypervalent protected iodoDOPA reagent for the reaction with an 
electron rich arylstannane. 
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Scheme 6 – Proposed synthesis of the iodonium salt precursor 86(X) via oxidation of an iodoDOPA 
moiety 83. 
2. The use of an alternative electron rich directing group . 
 
Scheme 7 – Proposed synthesis for an iodonium salt precursor bearing a 2-thienyl directing group 
89(X) 
1.2.3.1 Formation of a hypervalent protected iodoDOPA reagent 
Formation of the iodonium salt precursor via oxidation of the iodoDOPA moiety would 
provide a more advantageous synthesis route. The main advantage would be the 
avoidance of the undesirable stannylation step used in the synthesis of stannane 82. It 
would also allow for salt formation with electron rich aromatics not available for 
synthesis via the DOPA stannane 82, i.e. with 1,3,5-trimethoxybenzene. The strategy 
attempted is shown in Scheme 9. Formation of the protected iodoDOPA compound 83 
was achieved using a synthetic route reported by Dolle et al.
[9]
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Scheme 8 – Synthesis and attepted oxidation of protected iodoDOPA moiety 83 
After formation of the protected iodoDOPA moiety 83, the compound was subjected to 
oxidative conditions with the aim to produce a hypervalent species, i.e. the Koser 
reagent 85, diacetate 84 or iodonium salt 93.  
These preliminary investigations proceeded unprofitably. Therefore, further 
investigation was at this point abandoned, as the second strategy under investigation 
(changing the electron rich aryl group) was providing more promising results (see 
below). Further investigation into the methodology hypothesised was looked into later 
and is discussed in section 1.3.15 (Oxidation of IodoDOPA, Pg. 90). 
1.2.3.2 Use of an alternative electron rich directing group 
The use of a thiophene directing group was chosen due to its electron rich nature and 
previous utility in successful iodonium salt precursors for 
18
F labelling.
[14, 21]
 
The reaction of the stannane 82 with 2- (diacetoxyiodo)thiophene showed 
improvements with the reaction showing fewer impurities in the crude 
1
H NMR. 
However, the p-TsOH impurity was still present. Investigation into whether the 
impurity would remain after exchange of the counter ion was conducted. Thankfully the 
counter ion exchange (conducted by washing a dichloromethane solution of the crude 
salt with a saturated aqueous solution of KOTf) resulted in isolation of the pure 
iodonium triflate precursor 89(TfO). 
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A protocol was devised for the purification and isolation of the iodonium salts. The 
iodonium salt was first triturated before the precipitated crude was dissolved in 
dichloromethane. The solution was then washed with aqueous KX (to introduce the 
counter ion X) or water (to obtain the iodonium tosylate). A second trituration then 
provided the pure iodonium salt 89(X). 
 
Scheme 9 – Synthesis of 2-thienyliodonium tosylate 89(TsO) via diacetoxyiodothiophene 87. 
Further optimisation of salt formation is shown in Table 5 and leads to an acceptable 
yield of 44%. 
Table 5 – Optimisation for the synthesis of 89(TsO) 
 
Entry RT (h) Temp °C Diacetate / p-TsOH Equiv Yield (%) 
1 18 reflux 1.02 24 
2 24 50 1.02 25 
3 18 reflux 1.2 37 
4 18 reflux 1.5 44 
5
a
 18 reflux 1.5 24 
 a Reaction of isolated Koser rather than in situ produced Koser reagent. 
When using 1.02 equivalents of both, the diacetate and p-TsOH, some stannane 82 
remained unreacted. By increasing the equivalents of the Koser derivative (1.2 and 1.5 
equivalents), a higher conversion of stannane to the diaryliodonium salt was observed 
(Table 5, entries 3 and 4). The addition of 1.5 equivalents 72 was found to be the 
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optimum as the addition of larger amounts resulted in purification difficulties. The 
reaction with in situ produced Koser reagent 73 proceeded much better than when using 
the isolated Koser compound 73. 
Attempt to produce iodonium triflate precursor 89(TfO) directly 
As isolation of the pure iodonium triflate 89(TfO) was possible after counter ion 
exchange, it was briefly investigated if salt formation from in situ produced 2-
(bistriflateiodo)thiophene was possible. Unfortunately, this highly reactive species did 
not undergo successful reaction with arylstannane 82 (Scheme 10). 
 
Scheme 10 – Attempted salt 89(TfO) formation from in situ produced 2-iodo(bistriflate)thiophene  
1.2.3.3 Precursor Stability Testing 
It was decided that the precursor’s stability should be tested in a number of common 
solvents to prevent future use of unsuitable solvents for the fluorination reaction and 
other manipulations (Scheme 11). 
 
Scheme 11 – Precursor 89(TfO) stability in various solvents 
Iodonium triflate 89(TfO) proved to be stable in all solvents tested, showing convenient 
properties for its potential utility as a tracer precursor. 
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1.2.4 Preliminary Testing of the Precursor 
Testing the precursor’s suitability for fluorination was subsequently conducted. Firstly, 
‘cold’ fluorination was looked into using 19F NMR analysis to provide information 
about the regioselectivity of the fluorination. 
1.2.5 ‘Cold’ Fluorination of Iodonium Precursors 
Preliminary testing of the precursor for the formation of protected [
19
F]F-DOPA 95 was 
successful with 
19
F NMR experiments showing full selectivity for fluorination at the 
DOPA functionalised aromatic.  
A range of solvents were tested to discover if the regioselectively of the fluorination 
would be affected. This was carried out for both the simple and functionalised iodonium 
salts (Table 6). The use of the radical scavenger TEMPO is due to reports of improved 
yields and reproducibility when the fluorination is conducted with this additive.
[10]
 It is 
proposed that the radical scavenger helps to prevent the breakdown of the iodonium salt 
via radical pathways. 
Table 6 – ‘Cold’ fluorination selectivities for F-DOPA precursor 89(TfO) and fluorobenzene 
precursor 96(TfO) in different solvents 
 
a 
Compounds detected by 
19
F NMR. 
b
 PEG = Polyethylene glycol (Mn 380-420) 
Fluorination of the simple iodonium triflate 96(TfO) with caesium fluoride in the 
presence of TEMPO proceeded with full selectivity for fluorobenzene production in all 
solvents except for polyethylene glycol (PEG) in which neither product was observed. 
Fluorination of the functionalised iodonium triflate 89(TfO) also proceeded with 
excellent selectivity in the majority of solvents. Reactions in acetonitrile, DMF and 
Solvent Product Ratio for 89(TfO) (94:95)
a
 Product Ratio for 96(TfO) (94:77)
a
 
Acetonitrile 0:100 0:100 
DMSO Neither product observed 0:100 
DMF 0:100 0:100 
Benzene 0:100 0:100 
PEG
b
 Neither product observed Neither product observed 
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benzene all proceeded with complete selectivity for selective fluorination at the DOPA 
functionalised aromatic. In contrast to the simple iodonium salt reactions, neither 
product was observed when the reaction was performed in DMSO with the 
functionalised precursor. PEG again proved to be an unsuitable solvent for the 
fluorination. 
Confirmation of the iodonium triflates’ suitability as a precursor for the production of 
protected F-DOPA species 95 in the ‘cold’ fluorination experiments provided a proof of 
concept for production of [
18
F]DOPA using the synthesised precursor. It was now 
important to test the precursor’s suitability for fluorination of the DOPA aromatic under 
‘hot’ fluorination conditions. 
1.2.6 ‘Hot’ Fluorination of Iodonium Precursors 
Fluorination with [
18
F]fluoride proved unsuccessful (Table 7). These reactions were 
monitored by radio TLC and showed no conversion of [
18
F]fluoride to any non-polar 
18
F 
labelled product. 
Table 7 - Unsuccessful [
18
F]fluorination of isolated precursors 89(Br) and 89(TfO) 
 
Counter Ion (X
-
) Temperature (°C) Solvent 
TfO
-
 90 MeCN/DMSO (6:1) 
TfO
-
 90 MeCN/DMSO (3:1) 
Br
-
 90 MeCN 
TfO
-
 130 Toluene 
 
1.2.7 Potential Alterations for New Precursor Design 
With a number of conditions proving unfruitful, a careful analysis of the precursor was 
conducted and a number of changes looked plausible to test (Figure 8). 
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Figure 8 – Possible changes to the iodonium salt precursor 
 
Alterations to be considered for precursor design: 
a) Investigation into the effect of the ‘non-participating’ arene substituent on the 
fluorination reaction could also be conducted. The ideal directing group is not always 
predictable: Despite anisyl and thienyl groups commonly being used to direct 
nucleophilic fluorination, it has been shown that electron density of the directing group 
is not always proportional to the success of the fluorination reaction.
[11]
 
Tolyl and mesityl precursors 97(X) and 98(X) were targeted as new potential precursors 
along with the original anisyl directing group precursor 81(X) (Figure 10). 
 
Figure 9 - Possible targets to probe the directing group effect on the precursors efficacy 
The tolyl directing group was considered a suitable avenue of investigation due to its 
successful use in the synthesis of [
18
F]Flumazenil 46 (Scheme 13).
[11]
 Here, it 
outperforms anisyl, thienyl and other directing aromatics to produce the highest 
radiochemical yield. 
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Scheme 13 – Formation of [18F]Flumazenil 46 via fluorination of iodonium salt 99(TsO) in DMF.[11] 
The mesityl aromatic exhibits a considerable ortho effect and hence would not generally 
be considered suitable for use as a ‘non-participating’ directing group. However, 
Sanford et al. showed that the mesityl group can be used to direct fluorination to less 
bulky aromatics in the precence of a copper catalyst.
[12]
 Hence, the mesityl substituted 
precursor was also targeted. It is noteworthy that subsequent to these investigations, the 
methodology was adapted for the radiofluorination of a number of aromatic moieties by 
Sanford and Scott.
[13]
 
The anisyl functionalised salt 81(X) was targeted for those reasons already mentioned, 
namely due to its high electron density and utility in many other iodonium salt 
precursors. 
b) The ability to change the counter ion of the iodonium salt during the work up allows 
for facile preparation of precursors with a variety of anions. Investigation into the effect 
of the counter ion would be important, although this can be considered more of a ‘fine 
tuning’ alteration. Optimisation of other factors such as reaction conditions were a 
priority. 
c) It was considered that the full protection of the amine group might prove more 
suitable, as the presence of the N-H proton may have been interfering with the 
fluorination. Two simple strategies were available. DiBoc protection of the amine could 
be accomplished, or if a more robust protecting group was desired; phthalamide 
protection could be used (Figure 10). 
 
Figure 10 - Possible targets to test the influence of the amine protection strategy 
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d) The O-Boc protection of the hydroxyl functionalities provides an accessible and 
commercial stannane for the precursor synthesis. However, it was envisaged that 
changing the protection to a substituent that would further decrease the electron density 
at the aromatic would be beneficial. TFA protection was considered as a candidate for 
this protection. 
It was also considered that O-Me protection may deliver a more robust protection 
strategy for the precursor. This adaption would obviously come with the disadvantage 
of increased electron density at the aromatic desired for fluorination; hence, the 
regioselectivity of the fluorination would need to be investigated for such a precursor. 
1.2.8 Alternative ‘Non-Participating’ Arene Precursors (a) 
 
Figure 11 – Target precursors to probe the effect of the ‘non-participating’ arene functionality. 
1.2.9 Formation of salts with alternative directing groups 
The first alteration looked into was the synthesis of iodonium salt precursors with 
alternative directing aromatics. 
The first step was formation of the appropriate diacetate compounds and successful 
production of both hypervalent iodine compounds 102 and 103 was achieved using 
conditions adapted from the literature.
[14]
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Scheme 14 – Diacetate formation of 102 and 103 
 
Scheme 15 – Production of salts with alternative ‘directing’ arenes. 
Using the optimised conditions production of precursors with a tolyl and mesityl 
directing group were investigated. This was successful for the tolyl salt 97(TfO) but the 
pure mesityl salt 98(TfO) could not be isolated (Scheme 16). 
Using the optimised conditions, the anisyl salt could also be produced and isolated from 
both the Koser 73 and diacetate 72 starting materials in 37% and 30% yield, 
respectively (Scheme 16). 
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Scheme 16 – Formation of anisyl salt 81(X). a) Reaction of in situ produced Koser reagent 73 with 
arylstannane 84. b) Reaction of preformed Koser reagent 73 with arylstannane 82. 
Interestingly, the reaction proceeded with higher yields when the stannane was reacted 
with the in situ produced Koser reagent (compound 72 and p-toluenesulfonic acid) 
rather than preformed Koser reagent. This was also found to be the case for the 
thiophene derived salts (Table 5). It should be mentioned that diacetate 72 was now 
produced under improved conditions reported by Kraszkiewicz et al.
[15]
 (Chapter 4, Pg. 
164). 
1.2.10 Alteration of the counter ion (b) 
 
A number of counter ion exchanges had already been carried out previously and could 
be extended to those shown below (Scheme 17). It should be mentioned that exchange 
to the perchlorate anion did not proceed using the conditions below, but could be 
achieved using an exchange method developed by Dinkelborg et al.
[8]
 Here a reverse 
phase cartridge is used to trap the salt 89(TsO) and to perform the exchange. The ligand 
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exchange is characterised by the disappearance of the tosylate signals in the 
1
H and 
13
C 
NMR. 
 
Scheme 17 - Anion Exchange 
1.2.11 Suitability of Precursors Bearing Alternative Directing Arenes. 
Testing the suitability of the newly designed and produced iodonium salt precursors 
with altered directing arenes was conducted using the ‘cold’ fluorination conditions. 
Precursors with different counter ions were also tested. Results are shown in Table 8. 
Table 8 – ‘Cold’ fluorination of iodonium precursors bearing different directing arenes 
 
Entry Ar X F
-
 Source Product Ratio (95:Ar-F)
a
 
1 d TfO CsF 100:0 
2 c
b
 TfO CsF Neither product observed 
3 b TfO CsF 100:0 
4 a TfO KF/K222 100:0 
5 a Br CsF 100:0 
a 
Compounds detected by 
19
F NMR. 
b 
Impure product used due to isolation difficulties. 
Use of the impure mesityl salt 98(TfO) did not provide fluorination products for 
fluorination at either the DOPA or the mesityl moiety. However, the use of the other 
purified precursors was successful. All directing aryl groups produced the fluorinated 
DOPA compound 95 with full regioselectivity, as determined by 
19
F NMR. 
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For the tolyl functionalised salt the 
19
F chemical shift of both possible fluorinated 
products (95 and 4-fluorotoluene) were very similar (literature value for protected F-
DOPA 95 = –117.6 ppm in CDCl3,
[16]
 literature value for 4-fluorotoluene = –118.1 ppm 
in CDCl3
[17]
). Therefore a reference sample of 4-fluorotoluene was added to the NMR 
reaction mixture. This confirmed that 4-fluorotoluene was not produced in the reaction 
(chemical shift for added 4-fluorotoluene = –120.5 ppm). 
Changing the fluoride source to KF/K222 for the fluorination of iodonium salt 89(TfO) 
did not change the reaction outcome. Fluorination of the thiophene iodonium triflate 
precursor 89(TfO) with CsF has been described previously (Table 6). Alteration of the 
counter ion to the corresponding bromide 89(Br) also did not affect the reaction. 
Mechanistic Investigations Using Thienyl Salt 89(X) 
As such fluorination reactions are proposed to proceed via formation of an iodonium 
fluoride intermediate, it was investigated into whether such an intermediate 89(F) could 
be detected. The reaction reagents were combined and warmed beneath the 
decomposition temperature of the salt (Scheme 18). 
 
Scheme 18 – Ligand exchange to iodonium fluoride 89(F) from its corresponding iodide and 
tosylate salts 
Iodonium tosylate 89(TsO) and iodonium iodide 89(I) were tested. Both precursors 
showed evidence for ligand exchange to the iodonium fluoride giving characteristic 
peaks in the 
19
F NMR at –8.4 ppm.[6] Ligand exchange appeared to proceed more 
effectively with iodonium iodide 89(I). This stands in agreement with the literature, as 
the tosylate anion is reported to be a poor counter ion for fluorination reactions.
[8,18]
 
These results inspired variable temperature 
19
F NMR investigations to elucidate the 
temperatures required for intermediate and product formation. 
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1.2.11.1 Variable temperature investigations 
To gain a better insight into how the fluorination was proceeding, variable temperature 
19
F NMR was conducted. It was envisaged that the formation of intermediates could be 
visualised and a better understanding of the temperature dependence of the reaction 
could be attained (Table 9).   
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Table 9 - Variable temperature NMR analysis of the fluorination reaction with CsF 
 
Time (min) Temp (°C) Analysis* 
0-30 50 -8.4 ppm (iodonium fluoride 89(F)) 
30-45 55 -8.4 ppm (iodonium fluoride 89(F)) 
45-60 55 -8.4 ppm (iodonium fluoride 89(F)) 
60-75 60 -8.4 ppm (iodonium fluoride 89(F)) 
75-90 65 -8.4 ppm (iodonium fluoride 89(F)) 
90-105 70 -8.4 ppm (iodonium fluoride 89(F)) 
105-150 77 -8.4 ppm (iodonium fluoride 89(F)) and -119 ppm (95) 
*Recorded after time interval at temperature displayed 
The results gave strong evidence for the formation of iodonium fluoride 89(F) before 
thermal decomposition of the salt to yield fluorinated product 95 begins at 77 °C.  
Figure 12 shows the 
19
F NMR obtained at 60 °C, 70 °C and 77 °C.  
 
Figure 12 – Variable temperature analysis for the fluorination of 89(I) with CsF 
Min 60-75, 
60 °C 
Min 90-105, 
70 °C 
Min 105-150, 
77 °C 
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1.2.12 Alternative protection of the amine (c) 
 
Figure 13 – Possible alterations to the amine protection strategy of the precursor 
It was considered that the N-H proton on the monoprotected amine may be interfering 
with the radiofluorination. Therefore, it was decided that iodonium salt precursors with 
alternative full protections would be synthesised in order to test this hypothesis. Most 
easily adapted to the current synthesis was the production of a di-Boc protected amine. 
Another alternative protection was the phthalimide protection. 
1.2.12.1 Di-Boc Protected Amine 
 
Scheme 19 – Synthesis of stannane 104 for the formation of a precursor with a fully protected 
amine 
Synthesis of the tetraBoc stannane 104 was achieved by further protection of the already 
available triBoc stannane 82. The reaction proceeded in high yield in the presence of 
catalytic 4-(dimethylamino)pyridine (DMAP). TetraBoc aryl stannane 104 was then 
used for the formation of tetraBoc protected salts. 
1.2.12.2  Formation of TetraBoc Protected Iodonium Salt Precursors 
Firstly reaction with 4-iodo(diacetate)toluene 102 was investigated for the formation of 
tolyl functionalised precursor 105(TfO). 
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Scheme 20 - Attempts to synthesise tolyliodonium salt 105(TfO) with a fully protected amine  
Unfortunately, despite the impure product being observed in the crude, compound 
105(TfO) could not be isolated. Furthermore, decomposition of the product occurred 
after approximately 30 minutes in solution. This significant change in stability for the 
tetraBoc salt is surprising. 
Reaction of tetraBoc aryl stannane 104 with 2-iodo(diacetate)thiophene 87 however was 
more successful. Optimisation of the reaction is shown in Table 10. The pure thienyl 
salt 100(TsO) could be obtained in reasonable yield using 1.5 equivalence of in situ 
produced Koser reagent. Increasing the equivalence resulted in deprotection of one of 
the N-Boc groups (Table 10, Entry 5). Again the presence of TFE was detrimental to the 
reaction (Table 10, Entry 3). Iodonium bromide 100(Br) could also be obtained directly 
by washing with KBr rather than KI (Table 10, Entry 6).  
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Table 10 – Optimisation for the formation of Tetraboc protected iodonium salt precursors 
 
Entry X= Temp (°C) Solvent Diacetate Equiv Yield (%) 
1 I reflux MeCN/CHCl3 (1:5) 1.02 8 
2 I reflux MeCN/CHCl3 (1:5) 1.2 14 
3 I reflux MeCN/DCM/TFE (1:2.5:2.5) 1.2 - 
4 I reflux MeCN/CHCl3 (1:5) 1.5 29 
5 I reflux MeCN/CHCl3 (1:5) 2.0 - 
6 Br reflux MeCN/CHCl3 (1:5) 1.5 20 
 
The use of the optimised conditions with 4-(diacetoxyiodo)anisole 72 as the starting 
material also produced the anisyl tetraboc salt 106(X) in acceptable yields (Scheme 21). 
 
Scheme 21 - Synthesis of an anisyl iodonium salt 106(X) with a fully protected amine 
 
1.2.12.3  Phthalimide Protected Amine 
After successful production of tetraBoc protected precursors 100(X) and 106(X), a 
strategy for the formation of a phthalimide protected precursor was looked into. 
Initially, the appropriate aryl stannane 111 was synthesised (Scheme 22). 
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Scheme 22 – Synthesis of stannane 111 
The synthesis of stannane 111 adapting reported methods proceeded well.
[19,20]
 Further 
reaction of the stannane for the synthesis of iodonium salts gave mixed success. 
Unexpectedly, the reaction with 2-(diacetoxyiodo)thiophenene 87 did not proceed well 
under the optimum conditions. Again, the problem was isolating the pure hypervalent 
compound. Changing the work up of the reaction to chromatography purification also 
failed to isolate the pure iodonium salt (Scheme 23a). 
Reaction with 4-(diacetoxyiodo)anisole 72 under the optimised conditions however, 
proceeded satisfactorily and the product could be isolated by either precipitation or 
column chromatography (isopropanol and dichloromethane gradient) in 29% yield 
(Scheme 23b). 
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Scheme 23 – Salt formation with stannane 111. a) Unsuccessful reaction with 2-
(diacetoxyiodo)thiophene 87. b) Successful formation of the anisyl precursor 113(TsO). 
 
Attempted Production of Phthalimide Protected Iodonium Salt 113 via Oxidation 
of iodoDOPA moiety 110. 
Attempts were made to directly oxidise the iodoDOPA compound 111 in order to attain 
the thienyl iodonium salt 113(X) through this route. The slight alteration in protection 
of the iodoDOPA moiety did not alter this reaction and as with previous attempts 
(Scheme 9), the reaction was unsuccessful (Scheme 24). 
 
Scheme 24 – Direct oxidation of Phth protected iodoDOPA 110 
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1.2.13 Alteration of hydroxyl protecting groups (d) 
 
Figure 14 – Possible alteration to the hydroxyl protecting strategy of the precursor 
The final precursor alteration strategy outlined in Figure 8 was to change the hydroxyl 
protecting groups. We envisaged that TFA protection would decrease the electron 
density of the DOPA moiety, therefore possibly improving the compounds utility in the 
fluorination reaction. 
The synthesis of a TFA protected compound 115 was not trivial. When conditions were 
eventually established for the TFA protection (Table 11), it was found that the 
iodination of the TFA protected product 115 did not proceed as desired (Scheme 25).  
Table 11 – TFA protection of DOPA moiety 115 
 
Conditions Yield (%) 
TFAA, TEA, DMF 0 
TFAA, CH2Cl2 0 
TFAA, DMAP (0.4 equiv), MeCN 46 
TFAA, reflux 88 
 
 
Scheme 25 – Attempted iodination of 115 
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Due to these complications it was decided the strategy could be tested on some 
simplified precursors before lengthier synthesis was conducted to obtain the iodoDOPA 
target 116. Hence, the iodonium salts below 117 and 118 were targeted (Figure 15). It 
was hoped that the two precursors would reveal any advantages or disadvantages of the 
two differing protection strategies. 
 
Figure 15 - Two iodonium salts targeted to probe the effect of the hydroxyl protection. 
1.2.14  Protected Phenol salts 
O-Boc 4-iodophenol salts 
 
Figure 16 – Targeted OBoc protected iodonium salt precursor 117(X). 
Oxidation of O-Boc 4-iodophenol 119 with peracetic acid produced the corresponding 
diacetate 120 and was optimised to achieve a 59 % yield (Table 12).  
Table 12 – Optimisation for the formation of diacetate 120 
 
Entry Peracetic Acid Conc. (Wt. %) Temperature (°C) Yield (%) 
1 13 r.t. 31 
2 19.5 r.t. 27 
3 9.75 r.t. 40 
4 9.75 0 59 
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Subsequent reaction of the diacetate 120 with the 2-(tributylstannyl)thiophene under the 
previously optimised conditions produced the salt 117(X) in good yield. Counter ion 
exchange could also be achieved using the appropriate work up (Scheme 26). 
 
Scheme 26 – Production of thiophene derived salts 117(TsO) and 117(Br) 
1.2.14.1 Fluorination of O-Boc 4-iodophenol salts 
‘Cold’ fluorinations: 
Iodonium salt 117 was fluorinated with tetramethylammonium fluoride (TMAF) using 
conditions reported by DiMagno et al.
[6]
 Initial treatment with TMAF in acetonitrile 
affords the corresponding iodonium fluoride 117(F). Subsequent thermal breakdown 
was tested in both acetonitrile and toluene. The thermal breakdown in toluene is 
conducted after a filtration step: Initially, acetonitrile is removed by evaporation before 
solvation of the iodonium fluoride 117(F) in dry toluene. Filtration during transfer into 
a new vessel is conducted in order to remove any insoluble salts before the breakdown 
is performed. 
 
Scheme 27 – Cold fluorination of iodonium salts 117(Br) and 117(TsO). a) Fluorination in 
acetonitrile. b) Iodonium fluoride 117(F) formation in acetonitrile before thermal decomposition in 
toluene. 
Both conditions lead to the desired fluorinated product 121 as detected by 
19
F NMR. 
Iodonium bromides and tosylates were tolerated for this reaction. Unfortunately, 
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isolation of 121 was not possible using column chromatography due to the presence of 
impurities with the same Rf value. 
‘Hot’ Fluorinations: 
Table 13 – ‘Hot’ fluorination of iodonium salts 118 for the production of [18F]121 
 
Entry 
Reacton 
Time 
(min) 
Temp (°C) X Solvent 
Conversion 
(%)(HPLC) 
Recovery 
(%) 
RCY (%) 
1
a
 30 90 TsO MeCN/DMSO (5/1) 75 91 68 
2
a
 30 90 Br MeCN/DMSO (2/1) 64 70 45 
3
a
 30 90 TsO MeCN/DMSO (2/1) 47 60 28 
4
b
 30 90 TsO MeCN/DMSO (5/1) 90 35 32 
5
b
 20 
65(10min), 
110(10min) 
TsO MeCN/DMSO (5/1) 95 63 60 
6
bc
 5 100 TsO DMSO (2% H2O) no product n/a n/a 
7
b
 20 130 TsO DMF 46 47 22 
a
 0.1mmol precursor used. 
b
 0.05mmol precursor used. 
c
 No TEMPO used for this reaction 
The O-Boc protected iodonium salt precursors 117 performed well for the synthesis of 
[
18
F]O-Boc 4-fluorophenol [
18
F]121. HPLC analysis by co-elution with the produced 
19
F reference compound 121 was successful and showed good RCC to the product for 
the majority of conditions. 
It can be seen that the bromide counter ion slightly outperforms the tosylate (entry 2 vs 
entry 3). The ratio of acetonitrile to DMSO was also an important factor with a 5:1 ratio 
providing improved RCC (entry 1 vs entry 3). It should be mentioned that the iodonium 
bromide 117(Br) could not be tested under these conditions due to solubility issues. 
It was then tested if the amount of precursor 117 could be reduced. It was found that 
halving the quantity of the precursor to 0.05 mmol had no detrimental effect on the 
RCC (entry 1 vs entry 4). The lower radiochemical yield observed in entry 4 is due to 
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an unusually low recovery from the reaction vial. This was caused by a failure of the 
equipment. Loss of a portion of the reaction mixture occurred during transfer to the 
product vial due to a leak.  
Conditions to try and encourage the formation of the iodonium fluoride 117(
18
F) 
intermediate were also investigated (Entry 5). It was hypothesised that ligand exchange 
could be accelerated by heating the reaction mixture at temperatures below that for 
thermal breakdown of the iodonium fluoride 117(
18
F). Therefore, the reaction was 
heated at 65 °C before the thermal breakdown was induced at 110 °C. This gave an 
excellent RCC of 95%.  
Despite being encouraged by the excellent radiochemical conversions, radio TLC 
analysis did not agree with the radio HPLC analysis and suggested very poor 
conversions to the 
18
F labelled product [
18
F]121. This was unexpected and could not be 
attributed to the volatility of the product, as was assumed with [
18
F]fluorobenzene 
[
18
F]77  (Pg. 58). The cause for these analytical problems was eventually ascertained 
and is reported later in this chapter (Pg. 115). The figures below show the contradictory 
chromatograms obtained. 
 
Figure 17 – Radio TLC of reaction mixture containing [18F]O-Boc 4-fluorophenol [18F]121 
Radioactivity (Counts) 
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Figure 18 – Radio HPLC of reaction mixture containing [18F]O-Boc 4-fluorophenol [18F]121 
At this point other literature methods were tested to see if an improved TLC 
chromatogram would be obtained for these reported conditions. Entry 6 used reaction 
conditions adapted from those reported by Dinkelborg et al. for the formation of an 
18
F 
labelled gelatinase inhibitor.
[8]
 However, performing the reaction in DMSO with 
addition of water (2 vol%) gave no conversion of [
18
F]fluoride to product [
18
F]121.  
Entry 7 used conditions adapted from those reported by Coenen et al. for the formation 
of 4-[
18
F]fluorophenol.
[21]
 It was considered that higher temperature breakdown may 
produce an improved yield for the fluorination. The conversion analysed by radio HPLC 
was low while the radio TLC showed no change in result. 
  
Radioactivity (Counts) 
[18F]O-Boc 4-fluorophenol 
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TFA protected 4-iodophenol salt 
Oxidation of the TFA protected moiety proved more difficult than with the OBoc 
protected salt. No product could be isolated after treatment of 122 with peracetic acid 
(Scheme 28a). However, production of an iodonium salt was achieved via in situ 
formation of the Koser reagent 124 and reaction with the 2-(tributylstannyl)thiophene 
(Scheme 28b). Upon addition of methanol to the reaction there was a change of colour 
and the isolated salt was confirmed to be the unprotected 4-hydroxy substituted 
iodonium salt 125. While there is no strong evidence for the proposed intermediates, 
this observation suggested that the TFA protection became very labile once the 
iodonium salt 118(TsO) had been produced. This is possibly due to the electron 
withdrawing nature of the hypervalent iodine. It was thus decided that the TFA 
protection was unsuitable and plans to synthesise TFA protected iodonium salt were 
abandoned. 
 
Scheme 28 – Attempts to produce an O-TFA protected hypervalent iodoarene 118(TsO). 
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1.2.15 Oxidation of iodoDOPA 
Attempts to design a precursor synthesis via the oxidation of an iodoDOPA moiety had 
been briefly looked into at different stages in the investigation for different protecting 
group strategies (Scheme 29). For details of these reactions see Scheme 8 and 24. 
 
Scheme 29 – Failed attempts to oxidise iodoDOPA moieties previously seen in Schemes 8 and 24 
Whilst not looked into thoroughly at the time, further work was now conducted in this 
area due to the possible advantages of this synthesis route. These advantages included 
the removal of an undesirable stannylation reaction and difficult purification step. It was 
also considered that any residual tin not completely removed in the purification of the 
precursor may interfere with the fluorination reaction. The alternative synthesis would 
allow the synthesis of a precursor not exposed to potentially interfering tin reagents.  
Subjecting the protected iodoDOPA moiety 83 to the standard oxidative conditions for 
Koser reagent formation had proved unsuccessful. Both isolation of the desired Koser 
type compound and in situ reaction with an aryl stannane for the formation of a 
diaryliodonium tosylate 93 were unfruitful (Scheme 8).  
The formation of the corresponding iodoDOPA diacetate was then investigated. Due to 
the more robust nature of the phthalimide protection, compound 110 was chosen for 
diacetate 128 production using peracetic acid. 
 
Scheme 30 – Attempted oxidation of 110 to the corresponding diacetate 128. 
Oxidation to the diacetate 128 was not possible under the attempted conditions and only 
starting material with small amounts of undesirable products remained.  
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However, looking through some patent literature showed conditions for the very 
transformation needed: Work by Barrio et al. uses dimethyldioxirane (DMDO) as a 
clean oxidant for the formation of the diacetoxy and iodyl compounds 129 and 130, 
respectively (Figure 19). 
[22,23]
  
 
Figure 19 – Iodyl compound 130 and Diacetate 129 produced by oxidation using DMDO 
Due to the very clean nature of the reaction it was assumed that this would be 
worthwhile investigating for the synthesis of the diaryliodonium salt precursors. 
Formation and analysis of the dimethyldioxirane (DMDO) solution used: 
 
Figure 20 – Setup for DMDO production as described by Singh et al.[24] 
A solution of DMDO in acetone was produced by distillation using the above apparatus 
as previously reported.
[24]
 The DMDO solution obtained was stored in the freezer over 
Na2SO4. Under these storage conditions, the concentration of DMDO was not 
diminished after 2 weeks storage as was described by Fröhlich et al.
[25]
 Its concentration 
was assessed by oxidation of thioanisole to the corresponding sulfoxide and determined 
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by 
1
H NMR integration of the different phenyl protons according to the literature 
(Chapter 4; Pg. 198).
[26]
 
Oxidation to the iodyl compound 131 from iodoDOPA 110 proceeded very well 
(Scheme 31a), but unfortunately the diacetate 132 formation experienced problems with 
reproducibility (Scheme 31b). 
 
Scheme 31 – Oxidation reactions using DMDO. a) Oxidation of 110 to its corresponding iodoyl 
compound 131. b) Oxidation of 110 to its corresponding diacetate 132.  
It was hypothesised that under milder conditions using fewer equivalents of DMDO, 
oxidation to the iodosyl compound 133 would proceed more reliably. Subsequent 
reaction with acetic acid would in theory yield the desired diacetoxy iodoDOPA 
compound 132. Unfortunately, the preliminary conditions looked into generally 
proceeded with over-oxidation. Even using just one equivalent of oxidant at low 
temperatures produced a mixture of inseparable oxidised compounds 131 and 133 along 
with starting material (Scheme 32). 
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Scheme 32 – DMDO oxidations at lower temperature. a) Oxidation at low temperature with fewer 
equivalents of DMDO still yields the iodyl species 131. b) 1 equivalent of DMDO added at -40 °C 
yields a mixture of oxidised products 133 and 131. 
It was also looked into whether in situ produced DMDO could produce the diacetate 
132. This would also be much more convenient as it negates the need for a complex 
distillation set up. This unfortunately was unsuccessful (Scheme 33). 
 
Scheme 33 – Attempted diacetate formation using in situ produced DMDO as an oxidant. 
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1.3 Mid Chapter Summary 
A number of simple iodonium salt precursors have been synthesised and tested for their 
suitability for incorporation of 
18
F and 
19
F fluoride. Production and fluorination of 
simple diaryliodonium salt precursors proceeded well suggesting the methodology was 
worth investigating for [
18
F]F-DOPA 9 synthesis. 
 
Scheme 34 – ‘Hot’ and ‘cold’ fluorinations were tested for a variety of precursors. 
A procedure for the synthesis of protected DOPA functionalised iodonium salts was 
also established and optimised. Initial ‘cold’ fluorinations showed formation of the 
desired fluorinated product 95. However, ‘hot’ radio fluorination reaction conditions did 
not provide any labelled compound [
18
F]95 as determined by radio TLC. Therefore, 
using the optimised conditions, certain alterations to the iodonium salt precursor were 
investigated (Figure 21). 
Altering the precursor 
 
Figure 21 – Iodonium salt precursor design and possible areas for alteration. 
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a) Altering the directing arene 
 
Figure 22 – Alteration of the directing electron rich arene 
Altering the directing arene functionality was possible for anisyl and toly aromatics. 
Furthermore, ‘cold’ fluorination conditions showed that both precursors were suitable 
for directing fluorination to the DOPA aromatic. Isolation of the pure mesityl salt was 
unfortunately not possible. 
b) Changing the counter ion 
 
Scheme 35 – Anion exchange by simple work up alteration 
Counter ion exchange to a variety of anions was possible using a simple work up 
alteration.  
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c) Altering the amine protection 
 
Figure 23 – Alterations to the protecting strategy of the amine 
Both tetraBoc and phthalimide protected precursors could be produced. However, not 
all directing arene substituents could be tolerated. The tolyl iodonium salt proved 
unstable when the diBoc protected amine was present. Also the thienyl iodonium salt 
was not isolatable when functionalised with the phthalimide protected amine. 
d) Alteration of the hydroxyl protecting strategy 
 
Figure 24 – Alteration of hydroxyl protecting strategy to TFA protection is unsuitable 
Changing the OBoc protection to a TFA protection was problematic and testing of the 
strategy on simplified precursors suggested a high liability of the protecting group. The 
change in protection was therefore considered unsuitable for an alternative iodonium 
salt precursor. Production of a methoxy substituted precursor remains an option to be 
explored. 
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During the ‘hot’ fluorination testing of simple OBoc protected precursor 117 for the 
production of OBoc 4-[
18
F]fluorophenol [
18
F]121 (Scheme 36), a discrepancy between 
the TLC analysis and HPLC analysis was highlighted. 
 
Scheme 36 – Radiofluorination of 117(X) for the production of OBoc 4-[18F]fluorophenol [18F]121 
Alternative synthesis 
Synthesis of a suitable precursor via oxidation of iodoDOPA compounds 126 was 
unsuccessfully investigated (Scheme 37). Diacetate 132 formation was possible using 
DMDO as an oxidant in the presence of acetic acid. However, poor reproducibility 
hinders the use of this protocol for precursor synthesis.  
 
Scheme 37 – Oxidation of iodoDOPA moieties was unsuccessfull 
1.4 Outlook 
‘Cold’ Fluorination Reactions 
A number of precursors have shown their suitability for the fluorination of the protected 
DOPA aromatic. Quantitative analysis of these fluorination reactions however has not 
yet been conducted. Isolation of the fluorinated compound proved difficult, therefore 
preventing isolated yields being obtained. However, analysis using HPLC could provide 
a good platform to obtain accurate yields without isolation of the compound. 
‘Hot’ Fluorination Reactions 
Radiofluorination of the [
18
F]F-DOPA precursors has been unsuccessful as monitored 
by TLC. Further, investigation into the lack of conversion needs to be conducted. 
Furthermore, HPLC analysis using the appropriate 
19
F standards may provide a more 
sensitive technique for the detection of any product produced. A range of altered 
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precursors have been produced which are now available to test in the radiofluorination 
reaction. These results may reveal some of the problems responsible for the poor 
conversion. 
Discrepancies in Analysis of ‘Hot’ Fluorination Reactions 
The contradictory analysis of TLC and HPLC results was a strong concern. Original 
conflicting analysis of [
18
F]fluorobenzene [
18
F]77 was proposed to be due to the 
volatility of the product. However, analysis of the non-volatile compound OBoc 4-
[
18
F]fluorophenol [
18
F]121 also gave contradictory analysis. Investigation into the cause 
of these discrepancies is highly important in order to establish which analysis is correct 
and if the current conversions calculated by HPLC analysis are accurate. 
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1.5 Further investigation into the suitability of functionalised diaryl 
iodonium salts for the synthesis of [
18
F]F-DOPA 
The optimisation of precursor synthesis reported above allowed for the synthesis of a 
number of iodonium salts for [
18
F]F-DOPA 9 production with varying protecting 
strategies (Table 14). 
Table 1 – Yields for the synthesis of iodonium salts with varying protection groups 
 
Entry Ar NRR’ R’’ Yield (%) 
1 a NHBoc Et 44 
2 a NBoc
2
 Et 28 
3 a NPhth Me 0 
4 b NHBoc Et 60 
5 b NBoc
2
 Et 26 
6 b NPhth Me 29 
 
After devising this suitable protocol for precursor production, further investigation into 
the fluorination of these compounds was needed. 
Additionally, discrepancies in the analysis of the radiofluorination reaction were 
discovered. Radio HPLC and radio TLC gave contradictory results. Investigation into 
this problem was imperative if accurate conclusions were to be made. 
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1.6 Testing of precursors 
1.6.1 ‘Cold’ Fluorination 
Firstly, ‘cold’ fluorination of the tetraboc protected precursor 100(I) was conducted in 
order to check if the additional protection of the amine had any effect on the 
fluorination.  
 
Scheme 38 – Cold fluorination of precursor 100(I) 
The tetraboc protected precursor 100(I) was subjected to ‘cold’ fluorination conditions 
using cesium fluoride as the source of fluoride. Full selectivity for fluorination at the 
DOPA moiety was observed with just one signal detected by 
19
F NMR, corresponding 
to the fluorinated product 134. No isolated product could be obtained using 
chromatographic purification due to the presence of impurities with the same Rf value. 
1.6.2 ‘Hot’ Fluorination 
Investigations into the radiofluorination of precursor 100(I) were then conducted (Table 
15). 
Table 15 – Radiofluorination of tetraboc iodonium salt 100(I) 
 
Entry Scale (mmol) TLC Conversion (%)
a
 
1 0.084 5 
2 0.06 2.5 
           a
Unidentified [
18
F]fluorinated compound 
Reaction of the iodonium salt 100(I) with [
18
F]KF/K222 showed low radio TLC 
conversion to a fluorinated product 135. Conversion varied between 2.5% and 5% 
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depending on the quantity of precursor used. A greater quantity of precursor increased 
the radio TLC conversion.  
Attempted deprotections to yield [
18
F]F-DOPA 9 were unsuccessful with HPLC 
analysis showing no peak corresponding to [
18
F]F-DOPA 9 subsequent to the 
deprotection conditions (Scheme 39). 
 
Scheme 39 – Unpurified labelled compound 135 subjected to deprotection conditions 
It was unclear whether the radiofluorination or the deprotection had failed. 
Confirmation as to whether the unknown 
18
F labelled compound was the protected 
[
18
F]F-DOPA species [
18
F]134 was needed to address these uncertainties. This required 
the use of tetraboc [
19
F]fluoroDOPA 134 as a standard for HPLC analysis. 
As mentioned, attempts to isolate the [
19F]fluorinated product from the ‘cold’ 
fluorination reaction of the iodonium salts were unsuccessful. Therefore an alternative 
protocol was required. 
A publication by Ritter et al. describes a suitable procedure for the formation of a 
protected [
19
F]F-DOPA compound 134 from the corresponding aryl stannane 104.
[16]
 
Stannane 104 was available due to its application for the synthesis of the iodonium salt 
precursors 100 and 106. It therefore looked like an ideal route to the required 
[
19
F]standards 95, 134 and 136. 
The reaction proceeded well enough to obtain standards for all of the different protected 
salts. Interestingly, despite providing a clean 
1
H NMR spectrum, the triboc protected 
[
19
F]fluoroDOPA 95 was found to be impure by analytical HPLC using reverse phase 
conditions. Therefore the compound was further purified using a C-18 cartridge 
(Biotage
®
 KP-C18-HS 12g SNAP cartridge). This gave the product 95 with 
significantly enhanced purity (checked using HPLC), suitable to be used as a reference 
for the analysis of the ‘hot’ fluorinations. 
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Scheme 40 – Silver mediated electrophilic fluorination of stannanes 82, 104 and 111 for the 
production of [
19
F]standards 95, 134 and 136. 
The produced standards could now be used to aid the analysis of both the ‘hot’ and 
‘cold’ fluorination reactions. Firstly, addition of the standards to the ‘cold’ fluorination 
reaction mixtures confirmed the identity of the fluorinated product as the protected 
[
19
F]F
_
DOPA compound by 
19
F NMR. Furthermore, quantitative analysis could be 
conducted using HPLC.  
‘Cold’ fluorinations of DOPA precursors with quantitative analysis 
A paper published by DiMagno et al. describes the use of tetramethylammonium 
fluoride (TMAF) for the fluorination reaction of iodonium salts.
[6]
 This publication 
describes the production of fluoroarenes in good yields. Therefore, the use of this 
fluoride source looked very promising. The reagent was tested for the fluorination 
reactions of the iodonium bromide precursors produced (Table 16). 
Table 16 – ‘Cold’ fluorination of triboc protected iodonium salts with TMAF. 
 
Entry Ar Solvent Yield (%)
a
 
1 b DMSO 0 
2 b DMF 2 
3 b Acetonitrile 5 
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4
b 
b Toluene 2 
5 a Acetonitrile 3 
6
b 
a Toluene 5 
 
a
 Yields were calculated using HPLC analysis. 
b
 Iodonium fluoride 89(F) or 81(F) was produced in 
acetonitrile before removal of the solvent. Compound 89(F) or 81(F) was then re-dissolved in toluene and 
passed through a filter into a clean vessel for the thermal decomposition to 95. 
Aside from the reaction performed in DMSO, formation of the fluorinated product 95 
was observed in all reactions by 
19
F NMR. This was again confirmed by addition of the 
already isolated cold standard to the reaction mixture. Furthermore, the formation of 95 
was confirmed by HPLC. The formation of the iodonium fluoride intermediates 91(F) 
and 81(F) was also observed by 
19
F NMR in all cases (Table 17).  
Table 17 – Iodonium fluoride 19F NMR peak observed for iodonium salts 89(F) and 81(F) in the 
different reaction solvents 
 
Entry Ar Solvent δ (ppm) 
1 b DMSO -6.18 
2 b DMF -8.16 
3 b Acetonitrile -8.46 
4
 
b Toluene -8.30 
5 a Acetonitrile -8.45 
6
 
a Toluene -7.47 
 
It is unclear why thermal decomposition of the iodonium fluoride 81(F) in DMSO did 
not proceed to give the fluorinated product.  
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It was promising that no production of 4-fluoroanisole or 2-fluorothiophene was 
observed in any of the reactions showing that both directing groups tested gave the 
desired regioselectivity. The reaction proceeded with both the thiophene and the anisole 
derived iodonium salts. Neither ‘non-participating’ arene showed a clear advantage over 
the other. All yields, determined by HPLC, varied between 2% and 5%. The use of 
toluene as a break down solvent did not benefit the reaction as described by DiMagno et 
al.
[6]
 
Due to the low yields and the moisture sensitive nature of the reaction it was 
investigated whether more stringent drying of the reagents would benefit the reaction. In 
this study solutions of the iodonium salts 81(F) and 89(F) were dried over molecular 
sieves for 24 h before addition to the NMR tube containing TMAF under nitrogen 
atmosphere. These extra measures did not benefit or change the results of the reaction in 
any way. 
1.6.3 Radiofluorinations evaluated with HPLC analysis 
Despite the low yields of the ‘cold’ reaction, further investigation into the ‘hot’ reaction 
was now conducted. Firstly, radiofluorination of tetraboc precursor 100(I) was 
conducted to discover whether the identity of the 
18
F labelled compound was the 
tetraboc protected [
18
F]F-DOPA compound [
18
F]134. 
 
Scheme 41 – Radiofluorination of precursor 100(I) 
The production of tetraboc [
18
F]F-DOPA [
18
F]134 was confirmed by HPLC analysis of 
the reaction mixture. This was conducted with and without the addition of the cold 
standard to the sample. However, the tetraboc [
18
F]F-DOPA [
18
F]134 was a minor 
product among many other side products showing the reaction had not proceeded 
cleanly and that the RCY was significantly lower than that calculated from radio TLC 
conversion. 
Radiofluorination of the triboc precursors 81 and 89 was also re-evaluated to check if a 
small amount of product was detectable using the radio HPLC analysis (Table 18). 
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Table 18 – Radiofluorination of triboc protected iodonium salts 89 and 81 
 
Entry
a Temp 
(°C)
 X
- 
Ar
 
Solvent
 Conversion 
(%)(HPLC)
 
Recovery 
(%)
 
RCY 
(%)
 
1
 90
 
Br
- 
b MeCN/DMSO (5/1)
 
25
 
77
 
19
 
2
 90
 
Br
- 
a
 
MeCN/DMSO (2/1)
 
19
 
68
 
13
 
3
 130
 
Br
- 
b
 
DMF
 
8
 
42
 
3
 
4
 90
 
Br
- 
b
 
MeCN
 
5
 
65
 
3
 
5
 130
 
Br
- 
b
 
DMSO
 
0
 
-
 
-
 
6
 130
 
Br
- 
b
 
DMSO (2 % H2O) 0
 
-
 
-
 
7
b
 130 Br
-
 b DMF 0 - - 
a
Reactions were carried out using 0.04-0.06 mmol precursor, 
b
Reaction carried out with 0.02 mmol 
precursor in accordance to literature.
[8,27]
 
Interestingly, the HPLC analysis showed that radiofluorination of triboc precursors 
proceeded much more efficiently than with tetraboc protected precursor 100(I). Further 
optimisation of the reaction showed that addition of DMSO to the reaction improved the 
conversion from 5% to 25%. Additionally, these conditions obtained high 
radiochemical recovery (RCR) from the reaction vessel. Reactions in DMSO alone, like 
those performed with [
19
F]fluoride, did not proceed with or without the addition of a 
small quantity of water. The addition of water to DMSO has been crucial for the success 
of other fluorinations using iodonium salts.
[8]
 
DMF was tolerated as a reaction solvent but reactions did not proceed as well as in a 
mixture of DMSO and acetonitrile. Both radiochemical conversion and radiochemical 
recovery were diminished (entry 3). The use of DMF with lower precursor quantity 
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produced no desired product (entry 7). Scale seems to play a significant role in the 
reaction as seen with the basic precursors (Table 19).  
It had been observed previously that the quantity of precursor had an influence on the 
success of the radiofluorination of the iodonium salts (Table 1). Further investigation 
into the effect of the quantity of precursor used on the reaction was therefore conducted. 
Such optimisation was important with regards to avoiding the waste of valuable 
precursor used in future investigations. 
Table 19 – Effect of precursor quantity on reaction success.  
 
Entry 
Scale 
(mmol) 
X
-
 
Solvent Volume  
(ml) 
Salt Conc  
(mmoldm
-3
) 
Conversion 
(%)(HPLC) 
Recovery 
(%) 
RCY 
(%) 
1 0.03 Br
-
 1.5 20 52 79 41 
2 0.015 Br
-
 0.75 20 0 76 0 
3 0.015 Br
-
 1.5 10 75 66 50 
4
a
 0.015 Br
-
 1.5 10 0 na 0 
5 0.015 Br
-
 1.5 10 0 na 0 
6 0.015 TfO
-
 1.5 10 0 na 0 
      a
 Reaction carried out in MeCN/DMSO (3:1) 
The results obtained were unusual. Entry 3 shows a very good conversion and 
radiochemical yield while entry 2 with the same quantity of precursor but a lower 
volume was completely unsuccessful. Entry 3 shows what appeared to be the optimal 
conditions but further reactions using this quantity of precursor showed problems with 
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reproducibility (entries 4 to 6). This helped to explain the unusual results when using a 
lower quantity of precursor (0.015 mmol).  
The negative result obtained for entry 2 indicates that the quantity of precursor is of 
importance rather than its concentration (entry 1 vs entry 2). While this is not true for 
entry 3, the result can be discounted due to the reactions irreproducibility. 
Table 20 – Addressing the reproducibility of the radiofluorination reaction 
 
Entry 
Scale 
(mmol) 
X- Solvent 
Conversion (%) 
(HPLC) 
RCY 
(%) 
1 0.015 Br
-
 
MeCN/DMSO 
(2:1) 
75 50
ab 
2 0.030 OTf
-
 
MeCN/DMSO 
(2:1) 
76 47
b 
3 0.030 OTf
-
 
MeCN/DMSO 
(2:1) 
81 <5 
4 0.030 Br
-
 
MeCN/DMSO 
(2:1) 
50 <5 
a 
Irreproducible result obtained (See Table 19), 
b
Erroneous results obtained due to errors in HPLC 
analysis (See following Section) 
The issue of reproducibility could be solved by increasing the quantity of precursor 
used. 0.03 mmol produces the fluorinated product [
18
F]95 successfully using a mixture 
of acetonitrile and DMSO (2:1) (Table 20, entry 2).  
RCC (calculated from radio HPLC analysis) varied from 50% to 81%. Changing the 
counter ion of the precursor had little effect on the reaction, the triflate counter ion 
provided slightly improved results.  
1.7 Establishing reasons for discrepancies in analysis 
After finding a reproducible method for the production of protected [
18
F]F-DOPA 
[
18
F]95 it was essential to establish the reason for inconsistency between the radio TLC 
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and radio HPLC. It was decided that the ambiguity would be solved if the 
18
F labelled 
product could be isolated using semi-preparative HPLC. Once isolated, the yield could 
be obtained by measurement in a well counter before radio TLC and HPLC analysis 
were conducted. This would give an indisputable yield whilst also revealing which 
analytical technique was giving an incorrect result. Therefore, the semi preparative 
version of the analytical reverse phase column was obtained (Chapter 4, Pg. 182). 
Isolation of the product was successful using conditions optimised on the analytical set 
up. The obtained product was measured in a well counter revealing a very low decay 
corrected radiochemical yield of 0.15%. Further analysis showed that the TLC condition 
used gave the expected chromatogram; with the protected [
18
F]F-DOPA [
18
F]95 product 
moving with the solvent front (Figure 25).  
 
Figure 25 – Radio TLC of HPLC purified [18F]95 
The HPLC revealed just one peak giving a radiochemical purity of > 95% (Figure 26). 
 
Figure 26 – Radio HPLC chromatogram for isolated [18F]95 
Radioactivity (Counts) 
Radioactivity (Counts) 
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Measuring the activity of the semi preparative column after the purification in a well 
counter revealed that the vast majority of the radioactivity remained on the column. This 
suggested that the majority of the activity was not passing through the column for 
detection by the radio detector, thus giving erroneous analysis of the reaction mixture. 
The trapping / removal of the starting [
18
F]fluoride or another highly polar analogue 
looked probable due to the abundance of polar radioactivity observed when analysis was 
conducted on the crude reaction mixture using the radio TLC. 
This was surprising as the analytical HPLC of the [
18
F]KF/K222 had previously been run 
(Figure 27). This was firstly to determine the retention time of the fluoride and secondly 
to check if the starting fluoride was passing through the column. The ‘trapping’ of the 
[
18
F]fluoride on the column had already been considered as a reason for the analytical 
problems. It transpires that while a small quantity passes through the column giving the 
obtained chromatogram, the vast majority does not pass through the column for 
analysis. This was further confirmed by injection of azeotropically dried [
18
F]KF/K222 in 
acetonitrile on to the semi preparative column resulting in the same observation, with 
very little elution of any radioactive component. 
 
Figure 27 - HPLC chromatogram of [
18
F]KF/K222 in acetonitrile 
As a consequence, the HPLC shows analysis of the non-polar radioactive components 
produced from the [
18
F]fluoride. Rather than revealing the conversion of [
18
F]fluoride to 
the product, it indicates the purity/ ratio of the labelled organic components that have 
been produced. 
This discovery had significant implications to the research so far conducted. Thus, 
radiochemical conversions (RCCs) calculated from HPLC analysis are erroneous and 
can only indicate the ratio of labelled components. Radiochemical yields (RCYs) 
calculated from the analysis must also be disregarded.  
Radioactivity (Counts) 
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The investigation had, however, established two important points: Firstly, the reaction 
was proceeding with very low conversion of [
18
F]fluoride to product. Secondly, HPLC 
analysis was an unreliable tool in this case for monitoring the success of the reaction. 
Hence, two areas needed to be looked into: 
1. What adjustments could be made to improve the conversion of [18F]fluoride? 
2. Why was the HPLC system giving incorrect results and how could this be 
resolved? 
1.8 Modifications to improve the conversion of [18F]fluoride to product 
Protecting groups of precursor: The majority of the optimisation had been conducted 
with the triboc protected precursors 89 and 81. This left the tetraboc and phthalimide 
protected precursors to be tested under the optimum conditions (Table 20, entries 2-4). 
Furthermore, the synthesis and testing of a precursor bearing methoxy protection rather 
than O-Boc for the hydroxyl groups remained of interest. 
Precursor purity: Changing the work-up process to isolate the iodonium salt precursors 
with a greater purity. Recrystallization methods had proved unsuccessful but conditions 
published by Scott et al. for the chromatographic purification of iodonium salts looked 
like a promising alternative.
[13]
 It should be mentioned that NMR analysis of the 
precipitated precursor showed that it is of a high purity already. 
Reaction Conditions: The fact that the conversion of [
18
F]fluoride to product was very 
low suggested a possible problem with the initial ligand exchange to form the iodonium 
fluoride intermediate. Investigation into conditions to encourage this anion exchange 
was a priority. 
1.8.1 Investigation into the fluorination of precursors with alternative protections 
Investigations into the effect of different protecting strategies on the radiofluorination 
reaction were conducted. Two areas were focused on: 
Alternative amine protection: The precursors synthesised with alternative amine 
protection needed to be subjected to the optimised conditions (Table 20, entries 2-4). 
Synthesis and testing of methoxy-protected precursors: A route needed to be 
established for the production of methoxy-protected precursors 137(X). Investigations 
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into the potential advantages and problems of this more robust protecting strategy could 
then be conducted. 
The precursors to be tested are shown in Figure 28. 
 
Figure 28 – Precursors with alternative protections to test under optimised radiofluorination 
conditions. a) N-Phthalimide protected Precursor 113(X). b) N-DiBoc protected Precursor 106(X). 
c) O-Me protected Precursor 137(X). 
1.8.1.1 Alternative amine protections 
Precursors 113(Br) and 106(Br) were submitted to the optimised reaction conditions to 
check for their efficacy in the fluorination reaction (Scheme 42). 
 
Scheme 42 – Radiofluorination of precursors with alternative protections. a) Fluorination of 
phthalimide protected precursor 113(Br). b) Fluorination of NBoc2 protected precursor 106(Br). 
No product was detected for the fluorination reaction of phthalimide protected precursor 
113(Br) under the optimised conditions. This was determined using analytical HPLC 
with a coeluted standard. The reaction of the tetraboc protected precursor 106(Br) was 
successful.  However, the reaction proceeded less cleanly than with the triboc protected 
precursor and isolation of the product using semi preparative HPLC was not possible. 
Conversion was too small to be detected by radio TLC. 
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1.8.1.2 Methoxy protected iodonium precursor 
With the alternative amine protection strategies proving detrimental to the reaction, an 
alternative hydroxyl protection was considered. As mentioned earlier (Pg. 71), the use 
of a methoxy protection for the hydroxyl groups would offer a robust alternative to the 
O-Boc protection. 
The use of methoxy protection is not ideal for the electronics of the DOPA aromatic 
ring as the increased electron density may alter the selectivity of the fluorination. 
Furthermore, conditions for MeO deprotection are harsher than those needed for OBoc 
deprotection. However, such protection strategies have been used commonly for 
previously reported [
18
F]F-DOPA precursors by Gouverneur, Scott and 
DiMagno.
[13,28,29]
 Consequently, deprotection strategies are well established and 
furthermore the protection is compatible under a range of fluorination conditions. 
Investigation to probe whether the more robust nature of the MeO protection may 
benefit the iodonium salt precursor was therefore conducted. 
Synthesis of the appropriate stannane 141 was accomplished using conditions published 
by Gouverneur for the synthesis of iodoDOPA moiety 140
[30]
 followed by stannylation 
using the previously employed conditions
[20]
 (Scheme 43).  
 
Scheme 43 – Synthesis of stannane 141 
Reaction of the stannane with diacetate 72 under the previously optimised conditions 
proceeded with good yield. In fact no heating was necessary as the reaction showed 
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significant depletion of the in situ produced Koser-type compound 73 immediately after 
addition of the stannane. This was evaluated by observing the depletion of the 
characteristic yellow colour of the Koser to a colourless solution. The reaction was left 
overnight as TLC revealed a small quantity of stannane remained unreacted. Anion 
exchange to the corresponding iodonium bromide 137(Br) occurred quantitatively by 
washing with aqueous saturated KBr (Scheme 44). 
 
Scheme 44 – Formation of MeO protected iodonium precursor 137TsO and 137Br. 
The faster transformation and higher yields observed in this case are likely due to the 
aryl stannanes increased electron density (due to the methoxy substituents) and 
therefore greater reactivity. 
1.8.1.3 Attempts to improve the synthesis of MeO protected precursor 137 
Direct salt formation with ‘unactivated’ DOPA moiety 139 
After the success of the previous reaction, it was speculated that the ‘unactivated’ 
protected DOPA aromatic 139 may be electron rich enough for direct reaction with in 
situ produced Koser 73. This would attractively remove two steps (including a very 
unappealing stannylation) along with two difficult chromatographic purifications. 
Unfortunately, the preliminary experiment was unsuccessful.  
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Scheme 45 – Attempted synthesis of precursor 137(TsO) via DOPA moiety 139. 
Oxidation of iodoDOPA 
Oxidation of the iodoDOPA moiety 140 was also explored. The diacetate product 142 
offers a possible route to the iodonium salt precursor which avoids the unattractive 
stannylation step. As with the previous attempts to oxidise protected iodoDOPA 
compounds (Pg. 90), this transformation was unsuccessful (Scheme 46).  
 
Scheme 46 – Attempted oxidation of iodoDOPA moiety 140 using conditions reported by Ishihara et 
al.
[31]
 
1.8.1.4 Testing of MeO Protected Precursor 137 
After the successful production of methoxy protected iodonium salt 137, its utility as a 
precursor for radio fluorination of the DOPA aromatic was tested. First, the appropriate 
standard 143 was synthesised for radio HPLC analysis (Scheme 47). 
 
Scheme 47 – Synthesis of MeO protected [19F]F-DOPA standard 143. 
Synthesis of the protected [
19
F]F-DOPA compound 143 was conducted in the usual 
manner. Unfortunately, the purification of the standard proved very difficult. Reverse 
phase HPLC analysis did not provide full separation under the usual conditions used 
(Figure 29) therefore eliminating the possibility of purification using a C-18 cartridge.  
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Figure 29 – C-18 HPLC analysis of impure standard 143 
However, the impure standard was used to analyse the success of the reaction.  Scheme 
48 shows the radiofluorination of precursor 137(Br) under the optimised conditions. 
 
Scheme 48 – Radiofluorination of iodonium salt 137(Br) using the optimised conditions 
HPLC revealed the production of the 
18
F labelled protected DOPA moiety [
18
F]143 with 
a purity of 90% but again TLC conversion was too small to be calculated. Thus, while 
the new precursor 137(Br) was as effective as triboc precursor 81(Br), no significant 
improvement resulted from the change in protecting strategy. 
1.9 Probing the problems behind the HPLC analysis 
After finding what was causing the erroneous HPLC analysis, it was looked into 
whether any such problems had been observed by others in the field. The use of HPLC 
for determining the success of radiofluorination reactions is common.
[18,32]
 
Communication with several radiochemists in industry revealed that our situation was 
unusual. Recommendations to further dilute the sample with water did not produce any 
difference to the chromatogram. Analysis of the reaction sample after removal of the 
guard column was conducted in order to check if contaminants on this part of the 
column were trapping the [
18
F]fluoride, but this was not the case. 
Eventually changing the solvent system provided us with a chromatogram that signalled 
the presence of a significant amount of another radioactive species. Chromatograms 
obtained using the original solvent system (acetonitrile and water) and the new solvent 
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system (acetonitrile and aqueous ammonium formate solution 50 mM) are shown in 
Figure 30 - 32.  
 
Figure 30 - [
18
F]Triboc F- DOPA [
18
F]95 analysis: Gradient: 80% MeCN in H2O (0.01% formic 
acid) (Isocratic) 
 
Figure 31 - [
18
F]MeO Protected F-DOPA [
18
F]143 analysis: Gradient: 60% MeCN in H2O (0.01% 
formic acid) (Isocratic) 
 
Figure 32 - [
18
F]MeO Protected F-DOPA [
18
F]143 analysis: Gradient: 60% MeCN: 40% Aqueous 
Ammonium Formate (50mM) (Isocratic) 
The unreacted [
18
F]fluoride passes through the column, but not as a peak that can be 
analysed with any specificity. However, this analysis at least gives an indication of the 
true state of the reaction mixture. 
Further discussion with radiochemists from Imanova revealed that very low isolated 
radiochemical yields despite promising radiochemical conversion (RCC) had been an 
Radioactivity (Counts) 
Radioactivity (Counts) 
Radioactivity (Counts) 
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issue for them and others in the field.
[33]
 Examples in the literature include the work by 
Scott et al. in which only 1% non-decay corrected product was isolated from a 
conversion of 31%.
[13]
 A more suitable method for analysis clearly needs to be 
established for such reactions. 
Subsequent to our investigations, a paper on the retention of [
18
F]fluoride on reverse 
phase HPLC columns was published by Bormans et al.
[34]
 The paper describes a number 
of factors that can influence the retention of [
18
F]fluoride. A brief overview of the 
papers findings is given below, along with the original conditions used for our 
analytical system for comparison. 
Factors affecting [
18
F]fluoride retention when using reverse phase HPLC: 
1. The pH of the eluent 
2. The type of column 
3. Composition of the buffer 
4. Concentration of the organic component 
5. Nature of organic component 
The pH has a significant effect on the retention of [
18
F]fluoride with low pH giving the 
highest retention. For the tested column (XBridge C18), with an eluent pH of 2, the 
recovered radioactivity was 42.4±11.6% whilst pH 4 - 9 gave recoveries above 90%. 
The type of column also had a strong influence on the retention of [
18
F]fluoride. 
Columns were tested at pH 3 and 5. The highest retention of fluoride was found when 
using the Phenomenex C18 column (radioactivity recovered: pH 3 = 16.6±17.3%, pH 5 
= 90.7±3.5%), whilst Hamilton PRP-1 column showed the lowest retention 
(radioactivity recovered: pH 3 = 95.3±1.2%, pH 5 = 97.4±1.6%). 
The type of buffer had only a limited influence on the retention of [
18
F]fluoride. A 
slightly higher recovery of radioactivity was found when using sodium phosphate buffer 
compared to sodium acetate buffer: Sodium phosphate buffer (pH 5, 12.5 mM)/MeCN 
(95/5), recovery = 93.4±1.8%. Sodium acetate buffer (pH 5, 12.5 mM)/MeCN (95/5), 
recovery = 87.2±2.3%. 
 Synthesis of Iodonium Salt Precursors for the Formation of [
18
F]F-DOPA Ch2 
118 
 
However, when using 0.1% TFA H2O/ 0.1% TFA MeCN (95/5) (pH 1.7) as the eluent 
the radioactivity recovered was severely diminished (recovery = 34.5±9.9%). This is in 
agreement with observations regarding the pH (see above). 
 [
18
F]fluoride retention on the column was found to slightly increase with higher 
concentrations of the eluents’ organic component. The conditions tested were; sodium 
phosphate buffer (pH 3, 12.5 mM)/MeCN (95/5) and sodium phosphate buffer (pH 3, 
12.5 mM)/MeCN (50/50). When the mobile phase contained acetonitrile at 50%, the 
recovered radioactivity from the column diminished to 62.0±8.1% from 72.2±8.0% at 
5% acetonitrile. 
The tested organic components were ethanol and acetonitrile. Recovery of radioactivity 
was tested at both pH 3 and 5. Ethanol showed a greater recovery of [
18
F]fluoride from 
the column than acetonitrile using 95/5 aqueous/organic conditions: H2O/EtOH (95.5) 
radioactivity recovered: pH 3 = 81.2±5.1%, pH 5 = 100.0±3.8%). H2O/MeCN (95.5) 
radioactivity recovered: pH 3 = 72.2±6.0%, pH 5 = 93.4±1.8%). 
Table 21 - Summary and Comparison 
Literature conditions producing an 
increased retention of [
18
F]fluoride 
Our initial conditions used for radio 
HPLC analysis 
Low pH 
 
pH 1.7 
The Phenomenex C18 column shows a 
significantly higher retention of  
[
18
F]fluoride than the others tested 
Column used: Phenomenex C18 column 
 
Addition of 0.1 % TFA to mobile phase 
 
Addition of 0.1 % TFA to mobile phase 
 
High organic component in mobile phase 
 
0.1% TFA H2O/ 0.1% TFA MeCN -
between (10/90) and (30/70) depending on 
the compound. 
 
Using acetonitrile for the organic 
component gives a higher retention of 
[
18
F]fluoride than ethanol 
 
Acetonitrile used as organic component of 
mobile phase 
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Looking at the summary above, it is evident why the original radio HPLC conditions 
used gave analytical problems and provided erroneous results. 
Bormans et al. suggest that the retention is produced by a low binding affinity to silica 
based columns and showed that retention could be alleviated by saturation with 
[
19
F]fluoride. 
The authors also highlight a number of papers in which radio HPLC analysis with a low 
pH mobile phase has been used to determine the radiochemical purity of a radiotracer, 
potentially giving misleading results. 
1.10 Alternative work-up to improve precursor purity 
With the alternative protection strategies not providing a solution to the poor RCYs, 
investigations into alternative work-ups that might provide a purer and therefore more 
suitable precursor were conducted. After failing to recrystallize the iodonium salts, 
chromatographic purification was investigated. Firstly, column chromatography using a 
gradient of acetone and hexane reported by DiMagno et al. was looked into, but gave 
unsatisfactory results with significant quantities of the compound being retained on the 
column. A solvent system of isopropanol and dichloromethane reported by Scott et al., 
however, gave excellent results.
[13]
 Separation of a very small amount of impurity from 
the precipitated product (approx. 2% impurity) was achieved using this method. The 
chromatogram for the purification run on an automated Biotage® system is shown in 
Figure 9. The impurity could not be identified due to the small quantities available for 
analysis. 
 
Figure 33 – Chromatogram for purification of precursor 81(TsO) 
Iodonium salt precursor 81(TsO) 
Impurity 
       = Gradient (% 
of isopropanol in 
dichloromethane). 
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After isolation of the iodonium salt 81(TsO) from the pure fractions as a gum, the salt 
was re-precipitated and dried ready for testing under radiofluorination conditions.  
1.10.1 Testing of column purified iodonium salt 81(TsO) 
The purified iodonium salt gave no improvement to the reaction, which again proceeded 
with low radiochemical yields (Table 22). The reaction was also performed without the 
radical scavenger TEMPO. No difference in the reaction was observed under these 
conditions (Table 22, entry 2).  
Table 22 – Fluorination results for iodonium salt 81(TsO) with and without TEMPO 
 
Entry TEMPO (equiv) RCY (%) 
1 0.7 <5 
2 0 <5 
 
1.10.2 Attempts to encourage iodonium fluoride formation 
Due to the low conversion of [
18
F]fluoride to labelled product it was hypothesised that 
low conversion to the iodonium fluoride intermediate could be responsible. To try and 
encourage ligand exchange to the iodonium fluoride the reactants were first warmed to a 
temperature at which breakdown of the iodonium salt would not occur but may 
encourage the ligand exchange. Breakdown of the salt was then achieved by subsequent 
heating to 90 °C (Scheme 49). 
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Scheme 49 – Fluorination of iodonium tosylate 137(TsO) under conditions to encourage ligand 
exchange 
Unfortunately, these preliminary investigations showed no improvement in 
radiochemical yield (RCY). 
1.11 Conducting literature radiofluorination procedures using the Eckert 
and Ziegler equipment 
The lack of success in optimisation of the radiofluorination reaction prompted a look 
into the success of other reactions employing the Eckert and Ziegler equipment used for 
the fluorination. 
1.11.1 Minimalist radiofluorination of iodonium salts 
One recent publication looked of interest due to its simplicity of procedure and 
methodology. The use of iodonium salts without any additives provides a simple and 
minimalist approach to fluorination. Firstly, the [
18
F]fluoride is eluted from the QMA 
cartridge by a solution of the iodonium salt in methanol. Evaporation of the methanol is 
then conducted before resolvation of the iodonium salt and [
18
F]fluoride in the solvent 
of choice. The reaction is then heated to induce breakdown of the salt, generating the 
fluorinated product(s). Precursor 146 was chosen as the substrate for this reaction. 
Scheme 50 shows the synthesis of the precursor 146 and subsequent radiofluorination 
reaction.  
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Scheme 50 – Synthesis and radiofluorination of iodonium salt 146 for [18F]4-fluorobenzaldehyde 
production under minimalistic conditions 
The reaction was successful (showing product formation in the HPLC analysis) but 
again proceeded with poor radiochemical conversion (measured by radio TLC).  
Investigation into the analytical procedures used in the publication shows that yields 
were determined using radio HPLC. In light of the work published by Bormans et al.
[34]
 
further investigation by the publishers may be needed to ascertain whether these results 
are accurate. 
1.11.2 Copper catalysed fluorination of a boronic ester precursor 32 
Another investigation considered worthwhile was the production of protected [
18
F]F-
DOPA 143 using the method reported by Gouverneur et al. (Scheme 51b). The 
synthesis of the precursor was adapted slightly to the following route as protected 
iodoDOPA compound 140 was already available to us from the synthesis of iodonium 
salt 137 (Scheme 51a).  
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Scheme 51 – a) Synthesis and b) Radiofluorination of boronic ester 32 using conditions reported by 
Gouverneur et al.
[28] 
Repeating the literature procedure was successful with the reaction proceeding with a 
RCC of 34% as measured by radio TLC. It should be noted that confirmation of the 
products’ identity by coelution with a cold standard 143 was not performed as this 
compound was not available at the time of the experiment.  
The results suggest that while the Eckert and Ziegler set up is appropriate for certain 
radiofluorination methods, the use of iodonium salts with the current set up certainly 
needs further optimisation. This irreproducibility is a concern especially for such 
conditions described in Scheme 50b where minimalistic conditions should greatly 
simplify reproduction of the reported reaction. 
1.12 Isolation of the protected DOPA moiety 
The use of semi preparative HPLC for the purification and isolation of [
18
F]95 was 
successful. However, it is also long winded and loss of some product during transfer to 
the injection loop was unavoidable using the Eckert and Ziegler set up (Figure 34). This 
encouraged investigation into a cartridge purification.  
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Figure 34 – HPLC purification system for isolation of 18F labelled compounds 
Using a Waters
TM
 alumina cartridge to remove the remaining fluoride was successful 
providing the product with a radio TLC purity of 80% (20% [
18
F]fluoride) and radio 
HPLC purity of 82%. RCR was 3%, providing a decay corrected RCY of 2% (based on 
a purity of 64%). This is a much improved RCY compared to that obtained using HPLC 
purification (0.15%). The product [
18
F]95 could also be trapped on a C-18 cartridge 
before elution with ethanol to provide the product with an improved purity of 94%. This 
seems a more suitable purification strategy before conducting the required deprotection 
as valuable time is saved, therefore improving the non-decay corrected yields.  
1.13 Conclusion 
A number of iodonium salt precursors for [
18
F]F-DOPA synthesis have been 
synthesised and tested under radiofluorination conditions. The reaction proceeds to 
produce the desired radiolabelled products [
18
F]95, [
18
F]134 and [
18
F]143, but 
unfortunately RCYs are low.  
Attempts to improve radiochemical yields by altering the precursor and aspects of the 
reaction conditions were all unsuccessful, although an improved isolated yield could be 
obtained using cartridge based purification. This came at the cost of lower 
radiochemical and chemical purity.  
Significant problems with analysis of the radiofluorination reactions were discovered 
and addressed. This highlights an important issue for analysis of radiofluorination 
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reactions. Furthermore, it emphasises the value of isolated radiochemical yields for 
confirmation of calculated yields from radio HPLC and TLC. Indeed, a quick look 
through the literature on radiofluorination of iodonium salts showed publications that 
reported yields based only on HPLC analysis.
[18,32]
 More robust analysis for 
radiofluorination reactions needs to be implemented across the field. 
1.14 Outlook 
For the current method to be of use as a synthesis route to [
18
F]F-DOPA 9, considerable 
optimisation needs to be conducted to improve RCYs. If improvements to the 
radiochemical yield can be made, the simplicity of precursor production and the 
stability of the iodonium salt compounds would make this a very attractive route for 
nucleophilic synthesis of this radiotracer.  
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3 
Solid Supported Iodonium Salts for  
Fluorinations 
1.1 Introduction 
Solid-phase organic synthesis may be defined as ‘synthesis in which the starting 
material and synthetic intermediates are linked to an insoluble support’.[1] The use of a 
solid support for synthesis was first reported by Merrifield in 1963.
[2]
 Merrifield utilised 
chloromethyl functionalised resin for the production of peptides. It was shown that solid 
supported synthesis could provide a simple and quick methodology for synthesising 
such molecules. 
Since this pioneering work, the use of polymer bound precursors and reagents have 
become widespread in organic synthesis.
[3–6]
 The general advantage provided by the 
methodology is the ability to mechanically separate intermediates from reagents and 
solvents.
[1]
 This relies on using a polymer support with the correct properties with 
regards to insolubility, robustness and swelling behaviour. Most commonly used are 
polystyrene supports. These resins are cross-linked with divinylbenzene (DVB) to 
varying degrees depending on the properties desired. 1-2% cross-linking with DVB is 
typical as this provides a desirable balance between high insolubility and robustness 
(increasing with DVB cross-linking) and good swelling behaviour (decreasing with 
DVB cross-linking).
[5]
 Other resins used for solid phase synthesis include TentaGel and 
ArgoGel resins. These resins are co polymers of weakly cross-linked polystyrene/DVB 
and linear poly(ethylene glycol).
[7]
 
Functionalization of the solid support varies with its demands. Commonly used starting 
functionalities include the use of polymer bound alkyl halides or alcohols for ether 
linkage to the resin. Alkyl amino functionality is also popular for linker attachment 
using the more robust amide bond formation. This is a frequent strategy for synthesis 
requiring resilience to strongly acidic conditions. Some commercially available, 
functionalised polystyrene supports are shown in Figure 1. 
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Figure 1 – Commercially available resins. a) Amino methyl resin. b) Merrifield resin c) Wang resin 
The cleavage of the polymer-bound molecule is a key step in solid-supported organic 
synthesis and can be used to introduce functionality into the molecule being cleaved. 
This includes the introduction of halogens such as fluorine.
[4]
 The use of solid-supported 
precursors for the introduction of the 
18
F isotope during this cleavage step has already 
been described in Chapter 1 (Pg. 29). Both introduction by electrophilic and 
nucleophilic methods found utility. 
More appropriate to this work is the use of solid-supported iodonium salts for the 
introduction of fluorine. Work in this area includes radiofluorination of solid supported 
iodonium salt precursors for the production of [
18
F]fluorobenzene and [
18
F]fluorouracil 
reported by Brady et al.
[8]
 Scheme 1 shows the radiofluorination of solid-supported 
[
18
F]fluorouracil precursor 148(TfO). 
 
Scheme 1 - Radiofluorination of solid supported [
18
F]fluorouracil precursor 148
[8]
 
Furthermore, a patent published by Carroll et al. shows the synthesis of diaryliodonium 
salt precursors for radiofluorination linked to an amino resin via amide linkage.
[9]
 Here, 
a solid supported precursor for the production of [
18
F]F-DOPA 9 is described. The 
patent therefore provided a solid platform to expand on and is the basis for the earlier 
work in this chapter. 
1.2 Results and Discussion 
1.2.1 Initial Investigations into a solid Supported Precursor for [18F]F-DOPA 
Synthesis 
The investigations started with precursor synthesis, with an initial focus on a precursor 
for the production of [
18
F]fluorobenzene [
18
F]77. 
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Resin Functionalisation 
As alluded to above, a synthesis route for the production of solid supported 
diaryliodonium salts was reported by Carroll et al.
[9]
 providing a suitable starting point. 
The strategy uses amide bond formation as the key step, linking the precursor to the 
resin. Amino methyl functionalised polystyrene resin is used for coupling to the 
following carboxylic acids 150 and 151(TFA).  
 
Figure 2 – Two carboxylic acids for the formation of a solid supported iodonium salt precursor. a) 
Iodoaryl linker 150 for amide coupling followed by oxidation to the iodonium salt. b) Iodonium salt 
functionalised linker 151(TFA) ready for amide coupling to the amine resin. 
The two carboxylic acids 150 and 151(TFA) provide two possible routes to the same 
resin bound precursor. Linker 150 takes part in subsequent transformations to produce 
the polymer supported iodonium salt while amide linkage of 151(TFA) to the amino 
methyl resin affords the resin bound precursor directly. The two routes are shown in 
Scheme 2 and Scheme 3. 
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Route A using linker 150 
 
Scheme 2 – Synthesis of resin bound iodonium salt 155(TFA) via linker 150 
Route B using linker 151(TFA) 
 
Scheme 3 - Synthesis of resin bound iodonium salt 155(TFA) via linker 151(TFA) 
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Route A was chosen for the investigation as the patent revealed a higher loading with 
regards to iodine for this method (11.59% I for route A vs 7.49% I for route B using 
elemental analysis). 
Synthesis of carboxylic acid linker 150 
Formation of the iodoaryl-linker 150 was very successful with both the formation and 
hydrolysis of ethyl 6-(4-iodophenoxy) hexanoate 152 proceeding with excellent yields 
(Scheme 4). 
 
Scheme 4 – Formation of iodoaryl linker 150 
However, functionalisation of the amino methyl resin with the aforementioned linker 
150 proved to be troublesome and only a low functionality could be attained (Table 1, 
entries 1-3). A number of different conditions were used to try and obtain a more 
adequate loading (Amide coupling of linker to the resin as shown in Table 1). 
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Amide coupling of linker to resin 
Table 1 – Optimisation for amide coupling of linker 150 to aminomethyl resin 
 
Entry Resin 
Coupling 
Agent 
Time 
(h) 
DIPEA 
Equiv 
Solvent mmolg
-1
 Yield (%)
a,
 E/A (% I) 
1 aminomethyl DPPC 18 2.25 CH2Cl2 0.36 37 3.5 
2 aminomethyl DPPC 18 2.25 CH2Cl2 0.27 18 - 
3 aminomethyl DPPC 18 2.25 CH2Cl2 0.17 12 - 
4 aminomethyl DPPC 18 2.25 CH2Cl2 0.66 44 - 
5 aminomethyl DPPC 25 3 CH2Cl2 0.49 33 - 
6 aminomethyl DPPC 25 3 DMF 0.07 4 - 
7 aminomethyl T3P 48 2 EtOAc 0.33 37 - 
8 aminomethyl T3P 25 2 DMF 0.19 13 - 
9 aminomethyl T3P 25 2 CH2Cl2 0.29 19 - 
10 tris (aminoethyl) T3P 65 2 EtOAc 1.73 69 12.32 
11 tris (aminoethyl) DPPC 43 2.25 CH2Cl2 2.11 85 13.6 
 
 
After analysis of entries 1-3 showed inconsistent and poor yields the procedure was 
carried out under inert conditions to afford an increase in the loading (entry 4). All 
future experiments were carried out under inert conditions (entries 5-11). Despite the 
improvement, yields were still poor and repeats of the experiment gave inconsistencies 
in the loading.  
Increasing in the equivalents of diisopropylethylamine was unsuccessful in increasing 
the loading (entry 5). The use of anhydrous DMF as solvent was also tested as such 
polar aprotic solvents can give beneficial ‘swelling’ of the support. However, this was 
detrimental to the reaction (entries 6 and 8). The use of T3P (propylphosphonic 
anhydride) as a coupling agent also failed to improve functionalisation of the support in 
a number of solvents (entries 7-9). 
a Yields based on gain in mass of resin or by elemental analysis when available (See supplementary information for details). 
DIPA = Diisopropylethylamine, DPPC = Diphenylphosphoryl Chloride, T3P = Propylphosphonic anhydride 
b Calculated as a percentage of the maximum possible loading of the amine functionalization (loading = 1.5-3.0 mmolg-1 
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The poor results prompted a test reaction in which the amide linkage was performed 
between the 6-(4-iodophenoxy)hexanoic acid 150 and aniline to give 158 in excellent 
yield (Scheme 5). 
 
Scheme 5 – Amide coupling of linker 150 to aniline 
These results implied complications had originated from the solid supported amine and 
a solution was realised by the use of an alternatively functionalised resin. Coupling 
reactions with tris (aminoethyl) resin gave substantially improved loading with both 
coupling agents (Table 1, entries 10 and 11). This suggested that a steric effect from the 
resin may have inhibited penetration of the reagents to the supports functionalised sites. 
The optimized conditions for iodoaryl functionalisation of the resin are shown below 
(Scheme 6). 
 
Scheme 6 – Amide coupling of linker 150 to tris (2-aminoethyl)amine resin 
Oxidation and iodonium salt formation 
Oxidation of the supported iodoaryl moiety with peracetic acid proceeded to give 
diacetate 160 in ≈97% yield before addition of tri-n-butylphenyltin and TFA afforded 
the solid supported diaryliodonium salt 161(TFA) in ≈58% yield. The entire precursor 
synthesis is shown in Scheme 7. 
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Scheme 7 – Production of solid supported iodonium salt precursor 161(TFA). 
Radiofluorination of Solid Supported Resin 
Fluorination of the solid supported salt produced [
18
F]fluorobenzene [18F]77. The 
product was characterised by HPLC (Figure 3) showing a 74% conversion and 12% 
RCY (Scheme 8). TLC showed a radiochemical conversion of 3% and can be 
considered the true result of the reaction due to the problems discovered with the HPLC 
analysis (Chapter 2, Pg. 115). 
 
Scheme 8 – ‘Hot’ fluorination of polymer supported iodonium salt precursor 161(TFA) 
Identity of the radiolabelled compound was confirmed by co-elution with a ‘cold’ 
standard 77. 
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Figure 3 - Product sample spiked with fluorobenzene reference 
In order to achieve the maximum potential of the solid-supported methodology, it was 
proposed that solid-supported TEMPO could be used in conjunction with the solid-
supported precursor 161(TFA). This meant that in the event of a clean and selective 
reaction it should be possible to isolate pure product with simple cartridge purification. 
The reaction with solid-supported TEMPO (2.0 mmol g
-1
), however, was not as 
successful as that reported for the unsupported TEMPO. Not only did the extra resin in 
the reaction mixture cause an increase in the amount of activity retained by the resin 
(12% unsupported TEMPO, 19 % supported TEMPO) but the radio HPLC analysis 
showed a significant increase in impurities (Figure 4). 
 
Figure 4 – Solid-supported TEMPO reaction 
Production of solid supported [
18
F]F-DOPA precursor 
Formation of a solid supported [
18
F]F-DOPA precursor 162 was unsuccessful. The same 
conditions used for the formation of the fluorobenzene precursor were employed aside 
from the addition of methyl N-t-butoxycarbonyl-3,4-di(t-butoxycarbonyloxy)-6-
trimethylstannylphenylalanine 82 instead of the tri-n-butylphenyltin (Scheme 9). 
[18F]Fluorobenzene 
Fluorobenzene reference 
[18F]Fluorobenzene 
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Scheme 9 – Attempted synthesis of polymer supported [18F]F-DOPA precursor 162(TFA) 
The change in mass of the resin suggested a loading of 1.26 mmol g
-1
 (88%). However, 
elemental analysis was inconsistent with this and suggested that impurities remained on 
the resin. Attempts to produce protected [
18
F]F-DOPA 9 were unsuccessful using the 
supported precursor providing further evidence for the previous reactions failure. 
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Using a Solid Support for the Production of 
18
F Labelled Prosthetic Groups 
I am very grateful to Wilke de Vries (Erasmus student) for his hard work on this project. 
The 
18
F labelling of other simple molecules using solid supported precursors appeared 
an attractive avenue of investigation. Two compounds considered for their valuable 
application were [
18
F]4-fluorobenzaldehyde [
18
F]38 and [
18
F]4-fluorophenol.  
[
18
F]4-fluorobenzaldehyde ([
18
F]FBA) [
18
F]38 is a prosthetic group used for the 
18
F 
labelling of peptides. Conjugation to unprotected peptides can be achieved under mild 
conditions via oxime formation with aminooxy-functionalised peptides.
[10]
 
The second target, [
18
F]4-fluorophenol, is an important 
18
F labelled synthon for the 
production of labelled molecules bearing [
18
F]4-fluorophenoxy functionality. The 
labelled species is employed in the synthesis of a number of valuable tracers of 
biological interest.
[11,12]
 
With these targets in mind, the following solid supported precursors were proposed 
(Figure 5).  
 
Figure 5 – Proposed solid supported precursors. a) Precursor for [18F]FBA production. b) 
Precursor for [
18
F]4-fluorophenol production. 
Synthesis of the corresponding unsupported analogues would also provide important 
information for comparison.  
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Precursors for [
18
F]FBA production 
Investigations begun with attempts to synthesise the precursors for [
18
F]FBA 
production; iodonium salts 163(Br) and 166(Br) (Figure 6). 
 
Figure 6 – Target precursors for [18F]FBA production. a) Solid supported precursor. b) Solution 
phase precursor 
 
Scheme 10 – Attempted synthesis of solid supported [18F]FBA precursor 163(Br) 
Solid supported diacetate compound 160 was produced using the methods previously 
reported (Pg. 135). Reaction of the diacetate with the boronic acid 145 was, however, 
problematic. A very low increase in the mass of the resin suggested a low conversion of 
the diacetate to the diaryliodonium salt 163(Br). Attempted fluorination of the 
supported precursor did not produce the desired fluorinated product 38, providing 
further evidence for the lack of success in the previous step (Scheme 11). 
 
Scheme 11 – Attempted fluorination of solid supported precursor 163(Br) 
To probe the iodonium salt forming reaction further, the corresponding solution phase 
reaction was carried out (Table 2, Entry 1). This confirmed that the reaction was not 
proceeding satisfactorily. This is presumably due to the electron rich nature of the 
hypervalent iodine compound as reaction with (diacetoxyiodo)benzene proceeds well as 
described in the previous chapter (Chapter 2, Pg. 122, Scheme 50).  
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Table 2 – Conditions attempted for the production of iodonium salt 166 from boronic acid 145 
 
Entry Reagents (order of addition) Time Solvent Temperature Yield (%) 
1 Boronic Acid 145 
1. BF3 · Et2O 
2. Diacetate 72 
 
10 min 
1 h
a
 
CH2Cl2    
  0 °C 
  0 °C → rt 
18 
2 Boronic Acid 145 
1. Diacetate 72 
2. BF3 · Et2O 
 
10 min 
40 + 120 min
b
 
CH2Cl2   
 -41 °C 
 -41 °C → rt 
- 
3 Boronic Acid 145 
1. BF3 · Et2O 
2. Diacetate 72 
 
10 min 
1 h
a
 
EtOAc   
  0 °C 
  0 °C → rt 
- 
4 Diacetate 72 
1. TsOH · H2O 
2. Boronic Acid 145 
 
30 + 30min
c
 
18 h 
CH2Cl2   
 -41 °C → rt 
   rt 
- 
5 Diacetate 72 
1. TsOH · H2O 
2. Boronic Acid 145 
 
30 + 30 min
c
 
1 h 
MeCN, 
+ CHCl3(1:5) 
  
  0 °C → rt 
   rt 
- 
6 Diacetate 72 
1.  Boronic acid 145 
 
1 h
a
 
CH2Cl2   
  0 °C → rt 
- 
a 
Reaction was left at room temperature for 1 hour after removal from cooling bath. 
b
 Reaction was left at 
room temperature for 120 minutes after removal from cooling bath. 
c
 Reaction was left at room 
temperature for 30 minutes after removal from cooling bath. 
The initial conditions used provided the iodonium salt in poor yield. Attempts to 
improve the yield by tuning reaction conditions were unsuccessful. Lowering the 
temperature and changing the order of addition of reagents produced no product (entry 
2). Changing the solvent to ethyl acetate was also unsuccessful (entry 3). Furthermore, 
reaction directly with the diacetate (entry 6) or with in situ produced Koser reagent 73 
gave no iodonium salt product (entries 4 and 5).  
Previous synthesis of iodonium salts had proceeded well using aryl stannanes. 
Therefore, the appropriate aryl stannane was produced for utility in the synthesis of 
diaryliodonium salt 166 (Scheme 12). 
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Scheme 12 – Synthesis of aryl stannane 168 
Aryl stannane 168 was produced using a procedure recently reported in a patent by Liu 
et al. in good yield.
[13]
 However, reactions with in situ produced Koser again failed to 
produce the iodonium salt 166(Br) (Scheme 13). 
 
Scheme 13 – Attempted reactions for the production of iodonium salt 166(Br) from aryl stannane 
168 
Due to the difficulties in synthesising the desired precursors for [
18
F]FBA production, 
investigation moved on to synthesising precursors for the second target; [
18
F]4-
fluorophenol (Figure 7). 
Precursors for [
18
F]4-fluorophenol production 
As well as the solid supported precursor 164(Br), compounds 169(Br) and 170(Br) 
were targeted. This would allow comparison of the supported method with precursor 
formation and fluorination in solution phase. 
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Figure 7 – Proposed precursors for the production of O-benzyl [18F]4-fluorophenol. a) Solid 
supported precursor 164(Br). b) Anisole derived solution phase precursor 169(Br). c) Linker 
derived solution phase precursor 170(Br). 
Iodonium salt 170(Br) was targeted first to probe the reactivity of the linker moiety. 
Furthermore, subsequent transformation would provide a carboxylic acid for linkage to 
the amino methyl resin (Scheme 14). The initial synthesis route is shown below. 
 
Scheme 14 – Synthesis of iodonium salt 170(Br) via Aryl BPin moiety 172 
Firstly, aryl BPin moiety 172 was synthesised by benzyl protection of 4-iodophenol and 
subsequent coupling reaction with bis(pinocolato)diboron. Subsequent reaction with 
diacetate 156 produced the desired product but with poor yields so an alternative 
approach was investigated. 
Improved synthesis 
It was found that significant improvements to the yield could be made by using a 
slightly altered synthetic strategy (Scheme 15).  
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Scheme 15 – Synthesis of iodonium salt precursor 170(TsO) via diacetate 173 
Rather than oxidation of iodophenol ether 152, oxidation of the O-benzyl 4-iodophenol 
171 was conducted. Optimisation for the oxidation of aryl iodide 171 is shown in Table 
3. 
Table 3 – Conditions explored for the formation of diacetate 173 
Entry Reagents and Solvent Time (h) Temp. (°C) Yield (%) 
1 NaIO4, NaOAc, AcOH, Ac2O 2 120 Impure 
2 NaIO4, NaOAc, AcOH, Ac2O 24 80 48 
3 AcOOH, CH2Cl2 2 rt 0 
4 Selectfluor®, AcOH, MeCN 5 rt 95 
 
The use of Selectfluor® as an oxidant in acetonitrile and acetic acid proved optimal, 
giving quantitative yield of the corresponding diacetate. 
Conversion of the diacetate to the Koser derivative 174 followed by reaction with 
electron rich aromatic 175 gave the desired iodonium tosylate 170(TsO) in excellent 
yields. The iodonium salt 170(TsO) could then be hydrolysed using TFA in water. 
Coupling to the solid support was then possible using the standard conditions (Scheme 
16).  
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Scheme 16 – Synthesis of solid supported precursor 164(Br) 
Synthesis of the solution phase iodonium bromides was also successful (Scheme 17). 
Iodonium tosylate 169(TsO) could be produced using an analogous procedure for 
reaction with anisole. The isolated iodonium tosylates 169(TsO) and 170(TsO) were 
then converted to their respective iodonium bromides 169(Br) and 170(Br) by washing 
with aqueous KBr (sat.). 
 
Scheme 17 – Production of iodonium bromides 169(Br) and 170(Br) 
Fluorination of iodonium salt precursors 
After the synthesis of iodonium precursors 169(Br) and 170(Br), it was important to 
test their efficacy in the fluorination reaction. Optimisation was conducted using 
iodonium salt 169(Br) with TMAF as the source of nucleophilic fluoride (Table 4). 
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Table 4 – Fluorination of solution phase iodonium salt precursor 169(Br) 
 
Entry Solvent Conc. of 166(Br) [mol dm
-3
] TMAF (Equiv) Yield (%)
a
 
1 MeCN 0.05 1 13 
2 DMF 0.05 1 7 
3 DMSO 0.05 1 8 
4 MeCN 0.025 1 5 
5 MeCN 0.0125 1 5 
6 MeCN 0.05 2 20 
7 MeCN 0.05 4 22 
      a Yields determined using GC analysis 
Optimal conditions were found using GC analysis of the reaction mixture subsequent to 
the thermal breakdown. Of the solvents tested acetonitrile gave the best result giving a 
13% yield. When performed in DMF or DMSO the yields obtained dropped to 7% and 
8% respectively. Decreasing the concentration of the iodonium bromide 169(Br) was 
detrimental to the reaction. Yields could be improved by increasing the equivalents of 
TMAF; 2 equivalents increasing the yield to 20% and 4 equivalents giving 22%. 
When performing the optimised fluorination reaction with precursor 170(Br) the yields 
improved to 30% of the desired fluorinated product 165 (Scheme 18). 
 
Scheme 18 – Fluorination of linker derived iodonium salt precursor 170(Br) 
This showed that the linker moiety was beneficial for the fluorination reaction. The 
solid supported precursor was now investigated. 
 Solid Supported Iodonium Salts for Fluorinations Ch3 
146 
 
Fluorination of the solid supported precursor 
Fluorination of the solid supported precursor was successful giving yields between 22% 
and 24% depending on the scale of the reaction (Table 5). The results show that the 
reaction is reproducible and scalable. 
Table 5 – Fluorination of solid supported iodonium salt precursor 164(Br) 
 
Entry Scale (mmol resin) Yield (%)
a
 
1 0.013 22 
2 0.06 24 
   a Yields determined using GC analysis 
The high number of equivalents used for the cold fluorination reactions mean that 
conditions are far from emulating those used for the ‘hot’ fluorination. Testing of the 
solid supported precursor under radiofluorination conditions needs to be conducted as 
this application is where such a precursor would be of greatest value. 
1.3 Conclusion 
A number of synthetically relevant iodonium salt precursors have been synthesised on a 
solid support. The utility of these compounds has been shown for the production of 
19
F 
bearing aromatics as well as for the production of [
18
F]fluorobenzene [
18
F]77. The 
successful radiofluorination shows a proof of concept for the production of valuable 
18
F 
labelled synthons / prosthetic groups using this method.  Furthermore, the importance of 
the resin functionality has been demonstrated. Limitations of amino methyl 
functionalised resin for amide linkage were discovered. The problem was addressed by 
the use of a resin with improved amine availability for a much improved loading via 
amide bond formation. 
The production of a resin bound precursor for [
18
F]FBA [
18
F]38 production could not be 
realised using the linker strategy investigated here. However, the production of such a 
precursor with an alternative linker seems a promising area of investigation. A proposed 
synthesis using Wang resin is outlined below (Scheme 19). It is envisaged that the 
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electronics of the hypervalent species 180 will be more suitable for iodonium salt 
formation, as seen in the solution phase (Chapter 2, Pg. 122, Scheme 50). 
 
Scheme 19 – Proposed synthesis of alternative solid supported precursor for [18F]FBA 
Production of a solid supported precursor for O-benzyl 4-fluorophenol was successful. 
An efficient route via diacetate 173 was established for the synthesis of the resin bound 
iodonium salt and proceeded with excellent yields. This method provides a promising 
alternative strategy to those previously reported for the synthesis of resin bound 
iodonium salts. Fluorination of the precursor was successful providing moderate yields 
of the fluorinated product 165. Adaption of this procedure for the incorporation of 
[
18
F]fluoride would provide a suitable method for the production of a valuable PET 
synthon.  
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General Description: 
All chemicals were purchased from Sigma Aldrich, Alfa Aesar, Apollo, Fluorochem 
and ABX and used without further purification unless otherwise stated. 
Tetramethylammonium fluoride (TMAF) was used in a glove box under inert 
conditions. Dry solvents were obtained from an MBRAUN SPS-800 solvent 
purification system. Acetonitrile-d3 was stored under argon over molecular sieves. All 
reactions involving air- or moisture- sensitive reagents were carried out under an argon 
atmosphere using oven-dried glasswear. 
13
C and 
1
H NMR spectra were recorded on 
Bruker DPX 250, Bruker DPX 400 or Bruker DPX 500 spectrometers. 
19
F NMR spectra 
were recorded on an Oxford 300 spectrometer.  Chemical shifts were referenced to the 
residual proton solvent peaks (
1
H: CDCl3, δ 7.26; MeOD, δ 3.31; CD3CN, δ 1.94; 
(CD3)SO, δ 2.50), solvent 
13
C signals (CDCl3, δ 77.16; MeOD, δ 49.00; CD3CN, δ 
118.26; (CD3)2SO, δ 39.52). Signals were reported in ppm, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, b = broad), coupling constant in Hz, 
integration. Infrared specta were recorded using a Perkin Elmer, Spectrum 100, FT-IR 
spectrometer. Selected peaks were reported in cm
-1
. Mass spectra were recorded by the 
EPSRC National Mass Spectrometry Facility in Swansea. High resolution mass spectra 
(HRMS) were recorded using positive electrospray ionisation (ESI) or atmospheric 
pressure chemical ionisation (APCI). GC analysis was carried out on an Agilent 7890A 
GC system using an Agilent19091J413 (30 m × 320 µm × 0.25 µm) column and helium 
as the carrier gas with a constant column flow of 2.26 mL/min. The injector temperature 
was held constant at 220 ºC and the GC oven temperature program was: 60 ºC hold 10 
min, ramp 2 ºC/min to 75 ºC, then ramp 20 ºC/min to 220 ºC. Elemental analysis was 
carried out by Medac Ltd. Reactions were monitored using thin layer chromatography 
(TLC) carried out on Merck Kieselgel 60 F254 plates. HPLC analysis was performed 
using an AGILENT Technology 1200 Series System. 
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General Procedures (‘Cold’ Chemistry) 
General procedure for the formation of diaryl iodonium salts suitable for [
18
F]F-DOPA 
production from diacetate (GP1) 
To a stirred suspension of either 2-(diacetoxy)iodothiophene 87 or 4-
(diacetoxy)iodoanisole 72 (0.44 mmol) in acetonitrile (5 mL) at 0 °C was added p-
TsOH∙H2O (84 mg, 0.44 mmol) before immediate dilution with chloroform (25 mL). 
The appropriate protected 6-(trimethylstannyl)-ʟ-DOPA reagent (82, 104, 111 or 141) 
(0.29 mmol) in chloroform (5 mL) was added dropwise. The reaction mixture was 
stirred for 18 h at 50 °C for 72 and reflux for 87. The reaction mixture was cooled to 
room temperature and the solvent was removed under reduced pressure. The residue 
was dissolved in CH2Cl2 (40 mL) and washed with water / saturated KX (X = TfO, Br, 
or I) solution (3 × 40 mL). The organic layer was passed through a phase separator and 
concentrated under reduced pressure to give the crude product as a yellow oil. The 
product was triturated with hexane from a minimum amount of CH2Cl2 and diethyl 
ether (1:1). The precipitate was collected on a Telos
®
 phase separator and washed with 
hexane. The collected precipitate was removed from the phase separator with CH2Cl2. 
The CH2Cl2 was removed before the product was triturated once more with hexane from 
a minimum amount of CH2Cl2 and diethyl ether (1:1). Removal of the solvent under 
reduced pressure gave the product as a colourless solid. 
General procedure for the formation of diaryl iodonium salts suitable for [
18
F]F-DOPA 
production from hydroxyl(p-tosyloxy)iodoarenes (GP2) 
73 or 88 (0.44 mmol) was added to acetonitrile (5 mL) at 0 °C before immediate 
dilution with chloroform (25 mL). Boc protected 6-(trimethylstannyl)- ʟ -DOPA ethyl 
ester 82 (200 mg, 0.29 mmol) in chloroform (5 mL) was added dropwise. The reaction 
mixture was heated to 50 °C and stirred for 18 h. The reaction mixture was cooled to 
room temperature and the solvent was removed under reduced pressure. The residue 
was dissolved in CH2Cl2 (40 mL) and washed with water / saturated KX (X = TfO, Br, 
or I) solution (3 × 40 mL). The organic layer was passed through a phase separator and 
concentrated under reduced pressure to give the crude product as a yellow oil. The 
product was triturated with hexane from a minimum amount of CH2Cl2 / diethyl ether 
(1:1). The precipitate was collected on a Telos
®
 phase separator and washed with 
hexane. The collected precipitate was removed from the phase separator with CH2Cl2. 
The CH2Cl2 was removed before the product was triturated once more with hexane from 
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a minimum amount of CH2Cl2 / diethyl ether (1:1). Removal of the solvent under 
reduced pressure gave the product as a colourless solid. 
Cold Fluorinations 
General Procedure for cold fluorination in acetonitrile, DMF and DMSO (GP3) 
In a glove box tetramethylammonium fluoride (TMAF) (3.9 mg, 0.04 mmol) was added 
to a NMR tube before it was sealed with a rubber septum and removed from the glove 
box. Iodonium salt precursor (0.04 mmol) was dissolved in the appropriate dry 
deuterated solvent (1 mL) and added to the TMAF by injecting the solution through the 
septum equipped with an argon balloon. The reaction mixture was heated in a silicon oil 
bath at 120 °C for 30 min before being removed and cooled to room temperature. The 
reaction was monitored by 
19
F NMR and HPLC. 
General Procedure for cold fluorination in toluene (GP4) 
In a glove box tetramethylammonium fluoride (TMAF) (3.9 mg, 0.04 mmol) was added 
to a NMR tube before it was sealed with a rubber septum and removed from the glove 
box. Iodonium salt precursor (0.04 mmol) was dissolved in dry d3-MeCN (1 mL) and 
added to the TMAF by injecting the solution through the septum equipped with an 
argon balloon. The acetonitrile was removed under vacuum and before addition of dry 
toluene (1 mL). The reaction mixture was heated in a silicon oil bath at 120 °C for 30 
min before being removed and cooled to room temperature. The reaction was monitored 
by 
19
F NMR and HPLC. 
General procedure for the fluorination of solution phase iodonium salt precursors at 90 °C 
(GP5) 
In a glove box tetramethylammonium fluoride (TMAF) was added to a NMR tube 
before it was sealed with a rubber septum and removed from the glove box. Iodonium 
salt precursor was dissolved in the appropriate dry deuterated solvent and added to the 
TMAF by injecting the solution through the septum equipped with an argon balloon. 
The reaction mixture was heated in a silicon oil bath at 90 °C for 1 h before being 
removed and cooled to room temperature. The reaction was monitored by 
19
F NMR and 
GC. 
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General procedure for the fluorination of solid-supported iodonium salt precursors (GP6) 
In a glove box tetramethylammonium fluoride (TMAF) was added to a reaction vessel 
containing supported iodonium salt before it was sealed with a rubber septum and 
removed from the glove box. The appropriate dry deuterated solvent was added to the 
TMAF and precursor by injection through the septum equipped with an argon balloon. 
The reaction mixture was heated in a silicon oil bath at 90 °C for 1 h before being 
removed and cooled to room temperature. The reaction was monitored by 
19
F NMR and 
GC. 
Calculation of yields for solid supported compounds 
Amide coupling 
Tris(aminoethyl)amino resin was purchased with an N loading of 3.5 – 5.0 mmolg-1 
equating to an amine functionality of 1.75 – 2.5 mmolg-1. Yields for the loading of the 
support were calculated by the gain in weight of the solid support and given as a 
percentage of the maximum possible gain in weight (2.5 mmol of functionalization). 
mmol loading = ∆Mass/∆Mr 
Yield = mmol loading/2.5 mmolg
-1
 
For certain experiments the support was submitted for elemental analysis to show that 
the gain in weight was accurate in calculating the loading with regards to iodine (Table 
S1). 
Table S1: 
Reaction Calculated I% EA I% 
T3P Coupling  
(Chapter 4, Table 1, Entry 10) 
13.54 12.32 
DPPC Coupling  
(Chapter 4, Table 1, Entry 11) 
13.69 13.60 
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Oxidation 
Yields for the loading of the support were calculated by the gain in weight of the solid 
support and given as a percentage of the maximum possible gain in weight (mmol of 
functionalisation calculated for the previous step). 
Iodonium salt formation 
Yields for the loading of the support were calculated by the gain in weight of the solid 
support and given as a percentage of the maximum possible gain in weight (mmol of 
functionalisation calculated for the previous step). 
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Radiochemistry 
Materials and Methods 
All solvents and reagents were commercially available and used without further 
purification unless otherwise stated. Dry solvents were purchased from Sigma Aldrich. 
HPLC grade acetonitrile was purchased from Fisher Scientific. H2
18
O was purchased 
from Nukem. QMA-light Sep-Pak cartridges, Sep-Pak alumina cartridges and Sep-Pak 
C18 cartridges were purchased from Waters. QMA-light Sep-Pak cartridges were pre-
treated with sodium bicarbonate solution (8.4 wt.%, 5 mL) and sterile water (5 mL) 
before use. Alumina cartridges were pre-treated with sterile water (10 mL). Sep-Pak 
C18 cartridges were pre-treated with ethanol (10 mL) and sterile water (10 mL). Radio 
TLC was carried out on Macherey-Nagel pre-coated TLC-sheets POLYGRAM
®
 SIL G 
(0.2 mm silica gel) using 100% acetonitrile as the mobile phase. Radio HPLC analysis 
was performed using an AGILENT Technology 1200 Series System. Manipulations 
were carried out using an Eckert and Ziegler Modular-Lab automated radiochemistry 
synthesis platform. Nitrogen was used as a pressurizing gas during automated 
manipulations. [
18
F]Fluoride was produced by 
18
O(p,n)
18
F reaction with H2
18
O as the 
target using an IBA Cyclone 18/9 cyclotron. Reactions were performed with a starting 
activity of approximately 2 GBq (aqueous [
18
F]fluoride). 
General Procedures (‘Hot’ Chemistry) 
General procedure for n.c.a. [
18
F]fluoride incorporation using iodonium salts (GP7) 
[
18
F]Fluoride delivered from the cyclotron as an aqueous solution (≈2 GBq) was trapped 
on a pre-treated QMA cartridge to remove the 
18
O enriched water. The [
18
F]fluoride was 
eluted with a kryptofix carbonate solution (0.6 mL) (0.3 mL MeCN, 0.3 mL H2O, 22.8 
mg Kryptofix 2.2.2, 8.4 mg K2CO3) into a 5 mL V-shaped vial. The mixture was dried 
under a flow of nitrogen and reduced pressure at 120 °C for 440 seconds. The residue 
was azeotropically dried twice with the addition of acetonitrile (2 × 1 mL). Distillation 
was achieved by heating at 120 °C under a flow of nitrogen for 440 seconds. To the 
dried [
18F]KF • Kryptofix 222 • K2CO3 salt was added iodonium precursor and (2,2,6,6-
tetramethylpiperidin-1-yl)oxy (TEMPO) (0.7 equiv) in the described solvent(s). The 
reaction was heated at the described temperature for 30 min before being cooled to 
room temperature. The reaction mixture was ejected into a sterile vial and the activity 
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was measured in a well counter to calculate the radiochemical recovery (RCR). The 
reaction mixture was analysed using radio HPLC and radio TLC. 
Definitions 
Radiochemical Yield (RCY) 
Radiochemical yield refers to the percentage of total radioactivity incorporated into the 
radiolabelled compound being synthesised. This is given as a decay corrected value. 
Radiochemical Conversion (RCC) 
Radiochemical conversion refers to the conversion of the starting material 
([
18
F]fluoride) to radiolabelled product. This is given as a percentage of the total 
radioactivity of these components. 
Radiochemical Recovery (RCR) 
Radiochemical recovery refers to the percentage of the total starting radioactivity that is 
recovered from the reaction in the product vial. This is given as a decay corrected value. 
Measurements of Radiochemical Yield (RCY) 
Isolated Compounds 
The decay corrected radiochemical yields were calculated by measurement of the 
isolated 
18
F-labelled product in a Campitec CRC-25PET well counter. The activity 
present was divided by the decay corrected activity of [
18
F]fluoride delivered by the 
cyclotron and converted to a percentage. 
Unisolated Compounds 
Radiochemical yield for unisolated compounds were calculated by TLC conversion 
whilst taking into account the radiochemical purity found using HPLC analysis. 
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Ethyl (S) 2-((di-tert-butoxycarbonyl)amino)-3-(2-4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl-4,5-dimethoxyphenyl)propanoate (32) 
 
Bis(pinacolato)diboron (109 mg, 0.43 mmol), Pd(dppf)Cl2·CH2Cl2 (16 mg, 0.02 mmol) 
and KOAc (115 mg, 1.17 mmol) were added to a round bottom flask under nitrogen. 
Dry DMF was added and the mixture was purged with nitrogen for 15 min. IodoDOPA 
compound 147 (227 mg, 0.39 mmol) in dry DMF was added and the mixture was heated 
to 80 °C and stirred for 18 h. The reaction mixture was allowed to cool to room 
temperature and brine was added before extraction with Et2O. The combined organic 
extracts were washed with brine, dried over MgSO4 and concentrated in vacuo. The 
crude product was purified by column chromatography (10% - 25% EtOAc in hexane) 
to give the product 32 as a colourless solid (141 mg, 62%, m.p. 67-78 °C (lit. 58-60 
°C)).
[1]
  
1
H NMR (400 MHz, CDCl3) δ ppm: 7.26 (s, 1H), 6.57 (s, 1H), 5.25 (dd, J = 11.2, 3.9 
Hz, 2H), 4.28 – 4.17 (m, 2H), 4.02 (dd, J = 13.5, 3.9 Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 
3.11 – 3.04 (ABX system, bm, 2H), 1.34 (s, 18H), 1.33 (s, 6H), 1.31 (s, 6H), 1.30 (t, J = 
7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 170.5, 152.0, 150.8, 146.9, 138.8, 
118.6, 114.3, 83.4, 82.3, 61.0, 60.2, 56.1, 55.6, 35.2, 27.8, 24.9, 24.8, 14.3;
 11
B NMR 
(161 MHz, CD3Cl) δ ppm: 31 (bs). In accordance with literature data.
[1]
 
[
18
F]4-Fluorobenzaldehyde ([
18
F]FBA) ([
18
F]38) 
 
The reaction was performed according to literature procedure.
[2]
 [
18
F]Fluoride delivered 
from the cyclotron as an aqueous solution was trapped on a pre-treated QMA cartridge 
(from the male side) to remove the 
18
O enriched water. The cartridge was washed with 
MeOH (1 mL) before elution of the [
18
F]fluoride into a reaction vial with a solution 146 
(5 mg, 0.013 mmol) in MeOH (500 µL). Methanol was evaporated under reduced 
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pressure at 70 °C for 3 min. After cooling to room temperature, DMF (500 µL) was 
added. The reaction mixture was heated at 115 °C for 5 min. The mixture was cooled 
down to room temperatureand water (4 mL) was added before elution of the mixture 
into a sterile vial. The reaction was analysed by radio HPLC and radio TLC. 
Production of protected [
18
F]4-fluorobenzaldehyde [
18
F]38 was confirmed by 
comparison with a cold standard. 
 
 
Analytical HPLC Conditions 
Column:  Analytical Phenomenex Synergi 4 μm Hydro‐RP 80 C‐18 4.6 × 250 mm 
column 
Gradient: 70% MeCN in H2O (0.01% TFA) 
Flow Rate: 1 mL/min 
Benzene (4-methoxyphenyl) iodonium trifluoroacetate (71(TFA)) 
 
Radioactivity  
(Counts) 
 
UV (mAU) 
 
[
18
F]38 
38 
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4-diacetoxyiodoanisoloe (1.0 g, 2.8 mmol) in CH2Cl2 (10 mL), was cooled to -40 °C 
and treated with tri-n-butylbhenyltin (0.96 mL, 2.9 mmol) and trifluoroacetic acid (0.45 
mL, 5.88 mmol). The reaction was stirred for 1 h whilst it was allowed to warm to room 
temperature. The reaction was concentrated under vacuum before being triturated in 
diethylether to produce the salt as a fluffy white solid (0.76 g, 63%, m.p. 160-161 °C 
(lit. 146-148 °C)).
[3]
 
1
H NMR (250 MHz, MeOD) δ ppm: 8.04 – 8.16 (m, 4H), 7.68 (t, J = 7.44 Hz, 1H), 
7.52 (t, J = 7.7 Hz, 2H), 7.07 (d, J = 9.1 Hz, 2H), 3.85 (s, 3H); 
13
C NMR (63 MHz, 
MeOD) δ ppm: 164.5, 138.6, 136.0, 133.5, 133.1, 118.9, 116.7, 104.6, 56.4; 19F NMR 
(300 MHz, MeOD) δ ppm: -79.3. In accordance with literature data.[3] 
Benzene (4-methoxyphenyl) iodonium tosylate (71(TsO)) 
 
To a stirred solution of 4-methoxy Koser reagent (0.13 g, 0.31 mmol) in CH2Cl2 (3 mL) 
and TFE (3 mL) was added tri-n-butylphenyltin (0.084 mol, 0.26 mmol) to give an 
orange / pink solution. The reaction was stirred at room temperature for 2 h before being 
concentrated under vacuum. The product was triturated in diethyl ether to produce the 
salt as a fluffy white solid (0.13 g, 0.26 mmol, 100%, 155-157 °C (lit. 143-146 °C)). 
1
H NMR (250 MHz, MeOD) δ ppm: 8.03 – 8.22 (m, 4H), 7.61 – 7.79 (m, 3H), 7.54 (t, J 
= 7.85 Hz, 2H), 7.25 (d, J = 8.5 Hz, 2H), 7.09 (d, J = 9.2 Hz, 2H) 3.87 (s, 3H), 2.39 (s, 
3H); 
13
C NMR (63 MHz, MeOD) δ ppm: 164.1, 143.6, 141.5, 138.5, 135.9, 133.2, 
132.9, 129.8, 126.9, 118.7, 116.5, 104.5, 56.3, 21.3. In accordance with literature data.
[4]
 
(4-phenyl)(4-methoxyphenyl)iodonium hexafluorophosphate (71(PF6)) 
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Iodonium tosylate 71(TsO) (0.10 g, 0.21 mmol) was dissolved in water (25 mL). NaPF6 
(0.11 g, 0.63 mmol) was added to the solution. The product crystallised as a white solid 
(81 mg, 85%, m.p. 111-114 °C). 
1
H NMR (400 MHz, CD3CN) δ ppm: 7.96 – 8.07 (m, 4H), 7.70 (t, J = 7.5 Hz, 1H), 7.53 
(t, J = 7.9 Hz, 2H), 7.06 (d, J = 9.2 Hz, 2H), 3.83 (s, 3H); 
13
C NMR (125 MHz, CD3CN) 
δ ppm: 164.6, 138.8, 135.9, 134.0, 133.5, 119.4, 115.0, 102.2, 56.8; 19F NMR (300 
MHz, CD3CN) δ ppm: -72.7 (d, 
1
JP-F = 707.3 Hz). In accordance with literature data.
[5]
 
4-(Diacetoxy)iodoanisole (72) 
 
72 was synthesized according to a literature procedure.
[6]
 NaIO4 (2.20 g, 10.3 mmol) 
and AcONa∙3H2O (2.90 g, 22 mmol) were suspended in a stirred mixture of AcOH and 
Ac2O (16.5 mL) (10:1). 4-Iodoanisole (2.34 g, 10 mmol) was added, and the mixture 
was stirred at reflux for 2 h, cooled to room temperature and poured into water (40 mL). 
The oily residue was extracted with CH2Cl2 (3 × 40 mL). The organic extracts were 
washed with water, dried over MgSO4 and concentrated under vacuum to give a pale 
yellow solid. Trituration with diethyl ether gave the product as a white solid (2.97 g, 
84%, m.p. 90-92 °C (lit. 92-96 °C).
[6]
 
1
H NMR (250 MHz, CDCl3) δ ppm: 8.01 (d, J = 9.1 Hz, 2H), 6.96 (d, J = 9.1 Hz, 2H), 
3.86 (s, 3H), 2.00 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 176.3, 162.1, 137.1, 
116.6, 111.5, 55.5, 20.3. In accordance with literature data.
[6]
 
Hydroxy(p-tosyloxy)iodo-4-methoxybenzene  (73) 
 
Hydroxy(p-tosyloxy)iodo-4-methoxybenzene 73 was synthesised according to the 
literature.
[8]
 4-iodoanisole (0.50 g, 2.14 mmol) was dissolved in CH2Cl2 (3 mL) and 
treated with mCPBA (0.77%) (0.48 g, 2.14 mmol) followed by p-TsOH•H2O (0.41 g, 
2.14 mmol). The solution was stirred at room temperature for 10 min before addition of 
diethyl ether to precipitate the product. The product was isolated by filtration and dried 
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briefly under suction to give the product as a colourless powder (0.61 g, 67%, m.p. 
decomposition at room temperature).
[7]
 
1
H NMR (250 MHz, MeOD) δ ppm: 8.31 (d, J = 9.1 Hz, 2H), 7.69 (d, J = 8.2 Hz, 2H), 
7.35-7.07 (m, 4H), 3.94 (s, 3H), 2.37 (s, 3H); 
13
C NMR (63 MHz, MeOD) δ ppm: 
165.2, 142.8, 141.8, 139.9, 129.7, 126.8, 118.1, 111.7, 56.4, 21.2. In accordance with 
the literature.
[7]
 
Benzene (1,3,5-methoxyphenyl) iodonium tosylate (74(TsO))  
 
To a stirred solution of 1,3,5-trimethoxybenzene in TFE (4.5 mL) was added Koser 
reagent (76). The reaction mixture was stirred for 2 h at room temperature. MeOH was 
added to the reaction mixture and the solvents were removed under vacuum. Trituration 
in diethyl ether gave the pure product as a pale brown solid (0.42 g, 87%, 178-181 °C 
(Lit. 178-180 °C)).
[8]
 
1
H NMR (250 MHz, MeOD) δ ppm: 7.95 (d, J = 8.4 Hz, 2H), 7.70 (t, J = 8.2 Hz, 1H),  
7.62 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 7.6 Hz, 2H), 7.23 (d, J = 7.4 Hz, 2H), 3.98 (s, 6H), 
3.89 (s, 3H), 2.37 (s, 3H); 
13
C NMR (63 MHz, MeOD) δ ppm: 168.7, 161.4, 143.6, 
141.6, 136.1, 135.7, 133.0, 132.7, 129.8, 126.9, 115.9, 92.8, 86.1, 57.7, 56.7, 21.3. In 
accordance with literature data.
[8]
 
1,3,5-methoxybenzene (75) 
 
Phloroglucinol (2.0 g, 12.34 mmol) and K2CO3 (5.97 g, 43.19 mmol) were dissolved in 
acetone (20 mL). Dimethylsulfate (5.85 mL, 61.7 mmol) was added and the reaction 
mixture was stirred at reflux under nitrogen for 48 h. The reaction mixture was 
concentrated under vacuum and partitioned between diethyl ether and water. The ether 
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layer was washed with NaOH (1 N) and brine, dried over MgSO4 and concentrated 
under vacuum. Trituration in hexane gave the product as a pale yellow solid (1.94 g, 
93%, 50-53 °C (lit. 51-53 °C)).
[9]
 
1
H NMR (250 MHz, CDCl3) δ ppm: 6.09 (s, 3H), 3.77 (s, 9H). In accordance with 
literature data.
[10]
 
Koser reagent (76) 
 
76 was synthesised according to a literature procedure.
[7]
 To a stirred solution of 
iodobenzene (2.0 g, 9.80 mmol) in CH2Cl2 (6 mL) and TFE (6 mL) was added mCPBA 
(1.69 g, 9.80 mmol). The reaction was left for 10 min before the addition of TsOH.H2O 
(1.87 g, 9.80 mmol). The solution was stirred at room temperature for 30 min before 
being concentrated under a stream of nitrogen. The product was triturated in diethyl 
ether, filtered and dried under vacuum to afford the product as a fluffy white solid (3.39 
g, 88%, 133-136 °C (Lit. 139-140 °C)).
[11]
 
1
H NMR (250 MHz, MeOD) δ ppm: 8.36 (d, J = 7.4 Hz, 2H), 7.85 (t, J = 7.5 Hz, 1H), 
7.73 – 7.67 (m, 4H), 7.23 (d, J = 8.4 Hz, 2H), 2.37 (s, 3H); 13C NMR (125 MHz, 
(CD3)2SO) δ ppm: 144.9, 138.1, 134.5, 132.4, 131.1, 128.22, 125.5, 123.6, 20.8. 
Procedure for n.c.a. [
18
F]fluoride incorporation using resin bound iodonium salt 161(TFA) 
for the production of [
18
F]fluorobenzene ([18F]77) 
 
[
18
F]Fluoride delivered from the cyclotron as an aqueous solution was trapped on a pre-
treated QMA cartridge to remove the 
18
O enriched water. The [
18
F]fluoride was eluted 
with a Kryptofix 2.2.2 carbonate solution (0.6 mL) (0.3 mL MeCN, 0.3 mL H2O, 22.8 
mg Kr-2.2.2, 8.4 mg K2CO3) into a 5 mL V-shaped vial. The mixture was dried under a 
flow of nitrogen and reduced pressure at 120 °C for 440 seconds. The residue was 
azeotropically dried twice with the addition of acetonitrile (2 × 1 mL). Distillation was 
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achieved by heating at 120 °C under a flow of nitrogen for 440 seconds. The dried 
[
18F]KF•Kr222•K2CO3 salt was re-dissolved in acetonitrile and to a sealed vial 
containing the supported iodonium precursor  161(TFA) (0.103 g, 0.12 mmol, 
1.16mmol g
-1
) and TEMPO (6.56 mg, 0.042 mmol). The reaction mixture was then 
heated at 90 °C for 15 min on a hot plate. The product solution was removed from the 
support by filtration. Analysis with radio TLC showed a RCC of 3%. Product identity 
was confirmed by radio HPLC. 
Radio HPLC of reaction mixture 
 
Analytical HPLC Conditions 
Column:  Analytical Phenomenex Synergi 4 μm Hydro‐RP 80 C‐18 4.6 × 250 mm 
column 
Gradient: 30% MeCN in H2O (0.01% TFA) to 70% MeCN in H2O (0.01% TFA) over 
14 min  
Flow Rate: 1 mL/min 
Radio TLC of reaction mixture (Mobile phase: 100% MeCN): 
[
18
F]77 
77 
Radioactivity  
(Counts) 
UV (mAU) 
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Procedure for n.c.a. [
18
F]fluoride incorporation using solution phase iodonium salts for the 
production of [
18
F]fluorobenzene ([18F]77) 
 
[
18
F]Fluoride delivered from the cyclotron as an aqueous solution was trapped on a pre-
treated QMA cartridge to remove the 
18
O enriched water. The [
18
F]fluoride was eluted 
with a Kryptofix 2.2.2 carbonate solution (0.6 mL) (0.3 mL MeCN, 0.3 mL H2O, 22.8 
mg Kr-2.2.2, 8.4 mg K2CO3) into a 5 mL V-shaped vial. The mixture was dried under a 
flow of nitrogen and reduced pressure at 120 °C for 440 seconds. The residue was 
azeotropically dried twice with the addition of acetonitrile (2 × 1 mL). Distillation was 
achieved by heating at 120 °C under a flow of nitrogen for 440 seconds. The iodonium 
salt precursor in the appropriate solvent(s) was added to the dried 
[
18F]KF•Kr222•K2CO3. The reaction was heated at the described temperature for 30 min 
before elution into a sterile vial. The reaction was analysed by radio HPLC and radio 
TLC. 
 
 
 
 
Radioactivity  
(Counts) 
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Radio HPLC of reaction mixture 
 
Analytical HPLC Conditions 
Column:  Analytical Phenomenex Synergi 4 μm Hydro‐RP 80 C‐18 4.6 × 250 mm 
column 
Gradient: 50% MeCN in H2O (0.01% TFA) Isocratic 15 min, linear increase from 50% 
to 100% MeCN in H2O (0.01% TFA) 4 min, linear decrease from 100% to 50% MeCN 
in H2O (0.01% TFA) 4 min, 50% MeCN in H2O (0.01% TFA) Isocratic 3 min. 
Flow Rate: 1 mL/min 
2-iodo-1,3,5-methoxybenzene (78) 
 
78 was synthesised according to a literature procedure.
[13]
 1,3,5-trimethoxybenzene, I2 
and UHP were all separately finely powdered in a mortar. 1,3,5-trimethoxybenzene 75 
(1.0 g, 5.94 mmol) and I2 (0.76 g, 2.98 mmol) were added to a 25 mL RBF and shaken 
vigorously befor addition of UHP (0.335 g, 3.56 mmol). The reaction mixture was 
agitated at 45 °C for 92 h. Saturated NaS2O3 solution (90 mL) was added and the 
[
18
F]77 
77 
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resulting precipitate was stirred at room temperature for 1 h before filtration. The crude 
product containing starting material was purified by column chromatography (9 : 1; Pet 
Ether : EtOAc) to give the pure product as white crystals (1.02 g, 59%, 118-120 °C (Lit. 
120-122 °C)).
[13]
 
1
H NMR (250 MHz, MeOD) δ ppm: 6.18 (s, 2H), 3.90 (s, 6H), 3.86 (s, 3H); 13C 
NMR (125 MHz, (CD3)2SO) δ ppm: 161.9, 159.3, 91.6, 66.3, 56.4, 55.5. In accordance 
with literature data.
[13]
 
 [N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)- ʟ -phenylalanine ethyl ester]-6-
(4-anisyl)iodonium tosylate  (81(TsO)) 
 
Using GP1 the product was obtained as a colourless solid (159 mg, 60%, m.p. 84-
90 °C). 
IR νmax (cm
-1
; neat) 1767, 1705, 1485, 1369, 1250, 1240, 1150, 1119, 1007, 820, 681; 
1
H NMR (400 MHz; CDCl3) δ ppm: 7.85 (d, J = 9.1 Hz, 2H), 7.79 (s, 1H), 7.45 (d, J = 
8.2 Hz, 2H), 7.33 (s, 1H), 7.03 (d, J = 7.9 Hz, 2H), 6.84 (d, J = 9.2 Hz, 2H), 5.98-5.79 
(bm, 1H), 4.74-4.43 (bm, 1H), 4.28-4.09 (m, 2H), 3.80 (s, 3H), 3.43-3.35 (ABX system, 
bm, 2H), 2.31 (s, 3H), 1.53 (s, 9H), 1.52 (s, 9H), 1.35 (s, 9H), 1.25 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 171.3, 162.1, 149.7, 149.6, 145.2, 142.2, 142.2, 
139.2, 138.7, 136.8, 131.4, 128.4, 125.8, 125.2, 117.4, 115.7, 104.4, 84.4, 79.6, 61.7, 
55.5, 53.1, 39.0, 28.1, 27.5, 27.5, 21.1, 14.0; HRMS (ESI) [M-TsO]
+
 found 758.2026 
calc. 758.2032 [C33H45INO11]
+
. 
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[N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)- ʟ -phenylalanine ethyl ester]-6-
(4-anisyl)iodonium bromide  (81(Br)) 
 
Iodonium tosylate 81(TsO) (63 mg, 0.068 mmol) was dissolved in CH2Cl2 50 mL and 
washed with aqueous KBr (0.2 M, 3 × 50 mL) and the organic layer was passed through 
a phase separator. The solvent was removed before the product was triturated with 
hexane from a minimum amount of CH2Cl2 and diethyl ether (1:1). Removal of the 
solvent under reduced pressure gave the product as a colourless solid (57 mg, 100%, 
m.p. 92-102 °C). 
IR νmax (cm
-1
; neat) 2980, 1769, 1711, 1487, 1370, 1250, 1154, 1123, 822; 
1
H NMR 
(400 MHz; CDCl3) δ ppm: 7.90 (d, J = 9.2 Hz, 2H), 7.74 (s, 1H), 7.31 (s, 1H), 6.87 (d, 
J = 9.2 Hz, 2H), 5.30-5.17 (bm, 1H), 4.72-4.62 (bm, 1H), 4.31-4.17 (m, 2H), 3.81 (s, 
3H), 3.47 – 3.22 (ABX system, bm, 2H), 1.52 (s, 18H), 1.39 (s, 9H), 1.28 (t, J = 7.1 Hz, 
3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 171.2, 161.7, 149.8, 149.6, 144.9, 142.4, 
137.8, 135.9, 131.0, 125.5, 121.0, 117.4, 110.1, 84.5, 84.4, 80.0, 61.8, 55.5, 53.3, 39.4, 
28.2, 27.5, 27.5, 14.1; HRMS (ESI) [M-Br]
+
 found 758.2023 calc. 758.2032 
[C33H45INO11]
+
. 
[N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)- ʟ -phenylalanine ethyl ester]-6-
(4-anisyl)iodonium  triflate  81(TfO) 
 
Iodonium tosylate 81(TsO) (0.136 mg, 0.146 mmol) was dissolved in CH2Cl2 50 mL 
and washed with aqueous KOTf (0.2 M, 3 × 50 mL) and the organic layer was passed 
through a phase separator. The solvent was removed before the product was triturated 
with hexane from a minimum amount of CH2Cl2 and diethyl ether (1:1). Removal of the 
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solvent under reduced pressure gave the product as a white solid (128 mg, 97%, m.p. 
78-80°C). 
IR νmax (cm
-1
; neat) 1771, 1707, 1572, 1487, 1371, 1248, 1152, 1123, 1026, 637; 
1
H 
NMR (400 MHz; CDCl3) δ ppm: 7.92 (d, J = 9.2 Hz, 2H), 7.71 (s, 1H), 7.44 (s, 1H), 
6.96 (d, J = 9.2 Hz, 2H), 5.59-5.45 (m, 1H), 4.65-4.51 (m, 1H), 4.33-4.14 (m, 2H), 3.85 
(s, 3H), 3.52 -3.24 (ABX system, bm, 2H), 1.53 (s, 9H), 1.52 (s, 9H), 1.41 (s, 9H), 1.28 
(t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 171.2, 163.0, 155.4, 149.5, 
149.4, 145.7, 142.8, 138.6, 137.4, 130.8, 125.9, 120.2 (q, J = 320.2 Hz, 1C), 118.1, 
113.9, 102.3, 84.9, 84.8, 80.4, 62.2, 55.6, 53.8, 40.1, 28.1, 27.4, 27.4, 13.8; 
19
F NMR 
(300 MHz, CDCl3) δ ppm: –78.3; HRMS (ESI) [M-TfO]
+
 found 758.2028 calc. 
758.2032 [C33H45INO11]
+
. 
[N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)- ʟ -phenylalanine ethyl ester]-6-
(4-anisyl)iodonium  iodide  81(I) 
 
Iodonium tosylate 81(TsO) (66 mg, 0.071 mmol) was dissolved in CH2Cl2 (50 mL) and 
washed with aqueous KI (0.2 M, 3 × 50 mL) and the organic layer was passed through a 
phase separator. The solvent was removed before the product was triturated with hexane 
from a minimum amount of CH2Cl2 / diethyl ether (1:1). Removal of the solvent under 
reduced pressure gave the product as a pale yellow solid (59 mg, 94%, m.p. 82-85 °C). 
The iodonium iodide is unstable during the work up and should be isolated as quickly as 
possible. If left to precipitate too long, a pink solution indicates the decomposition of 
the salt. 
IR νmax (cm
-1
; neat) 2980, 1767, 1709, 1572, 1487, 1369, 1252, 1150, 1121, 1020, 824; 
1
H NMR (500 MHz, CDCl3) δ ppm: 7.92 (d, J = 9.0 Hz, 2H), 7.84 (s, 1H), 7.31 (s, 1H), 
6.88 (d, J = 9.0 Hz, 2H), 5.36-5.23 (bm, 1H), 4.72-4.54 (bm, 1H), 4.31-4.10 (bm, 2H), 
3.81 (s, 3H), 3.48-3.32 (ABX system, bm, 2H), 1.52 (s, 9H), 1.52 (s, 9H), 1.40 (s, 9H), 
1.26 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 171.1, 162.1, 155.2, 
149.8, 149.6, 145.0, 142.6, 137.4, 136.6, 130.6, 125.7, 120.4, 117.8, 109.0, 84.7, 84.6, 
 Experimental Ch4 
173 
 
80.5, 62.3, 55.6, 53.6, 40.0, 28.3, 27.6, 27.5, 14.2; HRMS (ESI) [M-I]
+
  found 758.2025 
calc. 758.2032 [C33H45INO11]
+
. 
N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-trimethylstannyl- ʟ -
phenylalanine ethyl ester  (82) 
 
82 was synthesised according to the literature.
[14]
 To a solution of triboc-6-iodo-ʟ-
DOPA ethyl ester 83 (1.00 g, 1.54 mmol) in anhydrous dioxane (25 mL) under argon 
and protected from light was added tetrakis triphenylphosphine palladium (0.089 g, 
0.077 mmol) and hexamethylditin (0.93 g, 2.85 mmol, 0.59 mL). The mixture was 
stirred at reflux for 6 h before being cooled to room temperature and filtered. The 
filtrate was diluted with EtOAc, washed with water and brine, dried over MgSO4 and 
concentrated to dryness. The residue was purified by flash chromatography 
(hexane/ethyl acetate, 21:5) to give the product as a colourless solid (0.525 g, 50%, m.p. 
41-45 °C). The data were consistent with those reported in the literature measured in 
CD2Cl2.
[14]
  
1
H NMR (400 MHz, CDCl3) δ ppm: 7.26 (s, with tin satellites J
3
Sn-H = 47.7 Hz, 1H), 
7.12 (s, with tin satellites J
4
Sn-H = 15.4 Hz, 1H), 4.88 (bd, J = 8.8 Hz, 1H), 4.48 (bdd, J 
= 15.0, 8.0 Hz, 1H), 4.16 (q, J = 7.2 Hz, 2H), 3.10-2.99 (ABX system, bm, 2H), 1.54 (s, 
9H), 1.53 (s, 9H), 1.39 (s, 9H), 1.20 (t, J = 7.0 Hz, 3H), 0.35 (s, with tin satellites J
2
Sn-H 
= 54.8 Hz, 9H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 171.9, 155.0, 150.7, 150.5, 142.5, 
141.3, 141.4, 140.7, 130.0 (s, with tin satellites J
2
Sn-C = 39.2 Hz, 1C), 123.3 (s, with tin 
satellites J
2
Sn-C = 42.2 Hz, 1C), 83.4, 79.8, 61.3, 54.3, 40.3, 28.1, 27.5, 27.5, 13.9, -8.0 
(s, with tin satellites J
1
Sn-C = 355.3 Hz, 3C). 
N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-iodo-ʟ-phenylalanine ethyl ester  
(83) 
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83 was synthesised according to the literature.
[15]
 To a round bottom flask containing I2 
(1.46 g, 5.80 mmol) and PhI(CF3CO2)2 (3.09 g, 6.96 mmol) under argon was added 
freshly distilled CH2Cl2 (40 mL). The mixture was stirred at 0 °C for 15 min before 
addition of tribocDOPA ethyl ester (3.0 g, 5.8 mmol) in CH2Cl2 (10 mL). The reaction 
was kept at 0 °C for 15 min before being stirred at room temperature overnight. 
Following dilution with CH2Cl2 (40 mL) the reaction mixture was washed with 1 M 
Na2S2O3 (2 × 50 mL), water, brine and being dried over MgSO4. The solvent was 
removed under vacuum and the product was purified by column chromatography 
(hexane/ethyl acetate, 5:1) to give 83 as a colourless solid (1.64 g, 43%, m.p. 43-48 °C). 
The data were consistent with those reported in the literature measured in CD2Cl2.
[15]
 
1
H NMR (400 MHz, CDCl3) δ ppm: 7.72 (s, 1H), 7.13 (s, 1H), 5.06 (bd, J = 9.2 Hz, 
1H), 4.58 (bdd, J = 15.0, 7.8 Hz, 1H), 4.23-4.09 (m, 2H), 3.32-3.03 (ABX system, bm, 
2H), 1.54 (s, 18H), 1.40 (s, 9H), 1.21 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) 
δ ppm: 171.6, 155.0, 150.2, 150.2, 142.6, 141.5, 138.2, 133.4, 124.2, 95.4, 84.1, 84.0, 
79.9, 61.6, 53.5, 42.5, 28.3, 27.6, 14.0. 
Bis(trifluoroacetoxy)iodobenzene  (S1) 
 
Bis(trifluoroacetoxy)iodobenzene S1 was synthesised according to the literature.
[16]
 To 
a solution of iodobenzene (5.0 g, 24.5 mmol, 2.7 mL) in TFA (75 mL) and chloroform 
(25 mL) was added Oxone
®
 (5.6 g, 36.8 mmol) with stirring at room temperature. The 
reaction mixture was stirred at room temperature for 2 h. The solvent was evaporated 
under vacuum and the residue was treated with chloroform. The mixture was filtered 
and the filtrate was evaporated under reduced pressure to give the product as a pale 
yellow solid. Recrystallisation from chloroform and hexane gave the product as a white 
solid (6.4 g, 55% (90% purity), m.p. 110-114 °C (lit. 121-125 °C)).
[16]
 
1
H NMR (400 MHz, CDCl3) δ ppm: 8.26-8.10 (m, 2H), 7.81-7.70 (m, 1H), 7.65-7.60 
(m, 2H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 161.1 (q, J = 41.2 Hz, 2C), 135.1, 133.7, 
132.0, 122.7, 112.8 (q, J = 288.5 Hz, 2C). 
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2-(Diacetoxy)iodothiophene (87) 
 
2-(Diacetoxy)iodothiophene 87 was synthesised according to the literature.
[17]
 Sodium 
perborate tetrahydrate (29.23 g, 190 mmol) was added portion wise over 30 min to a 
solution of 2-iodothiophene (4.0 g, 19 mmol, 2.1 mL) in acetic acid (150 mL). The 
temperature was raised to 50 °C and the mixture stirred for 6 h. The reaction mixture 
was filtered and the filtrate was concentrated under reduced pressure. The product was 
extracted in CH2Cl2 and washed with water before being dried over MgSO4 and 
concentrated under vacuum. Trituration in diethyl ether gave the product as a colourless 
solid (2.9 g, 40% (85% purity), m.p. 118-112 °C (lit. 120-122 °C)).
[17]
 
1
H NMR (250 MHz, CDCl3) δ ppm: 7.78 (dd, J = 3.8, 1.2 Hz, 1H), 7.64 (dd, J = 5.4, 
1.2 Hz, 1H), 7.13 (dd, J = 5.4, 3.8 Hz, 1H), 2.02 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 
ppm: 176.9, 139.0, 134.8, 128.5, 106.1, 20.3. 
Hydroxy(p-tosyloxy)iodo-2-thiophene  (88) 
 
88 was synthesised according to the literature.
[18]
 To a suspension of 2-
(diacetoxy)iodothiophene (200 mg, 0.61 mmol) in acetonitrile (5 mL) was added p-
TsOH∙H2O (116 mg, 0.61 mmol). The mixture was stirred at room temperature for 1 h 
before addition of diethyl ether and ethyl acetate (2:1) (15 mL) to precipitate the 
product. The product was isolated by filtration and dried briefly under suction to give 
the product as a white powder (0.2 g, 82%, m.p. decomposition at room temperature).
[18]
 
1
H NMR (250 MHz, MeOD) δ ppm: 8.24 (dd, J = 3.9, 1.2 Hz, 1H), 8.10 (dd, J = 5.3, 
1.2 Hz, 1H), 7.70 (d, J = 8.3 Hz, 2H), 7.37 (dd, J = 5.3, 3.9 Hz, 1H), 7.23 (d, J = 8.5 
Hz, 2H), 2.37 (s, 3H); 
13
C NMR (100 MHz, MeOD) δ ppm: 144.5, 142.8, 141.8, 140.6, 
130.8, 129.7, 126.7, 107.6, 21.2. In accordance with the literature data.
[18]
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[N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester]-6-(2-
thienyl)iodonium tosylate  (89(TsO)) 
 
Using GP1 the product was obtained as a white solid (116 mg, 44%, m.p. 80-84 °C). 
IR νmax (cm
-1
; neat) 1769, 1707, 1487, 1369, 1252, 1152, 1121, 1030, 1007, 679; 
1
H 
NMR (500 MHz; CDCl3) δ ppm: 7.95 (s, 1H), 7.75 (dd, J = 3.8, 0.9 Hz, 1H), 7.50 (dd, J 
= 5.3, 1.1 Hz, 1H), 7.28 (s, 1H), 7.25 (d, J = 8.9 Hz, 2H), 7.00 (d, J = 8.1 Hz, 2H), 6.95 
(dd, J = 5.3, 3.9 Hz, 1H), 6.12-5.89 (bm, 1H), 4.66-4.49 (bm, 1H), 4.27-4.10 (bm, 2H), 
3.64-3.34 (ABX system, bm, 2H), 2.29 (s, 3H), 1.51 (s, 9H), 1.51 (s, 9H), 1.33 (s, 9H), 
1.23 (t, J = 7.1 Hz, 1H); 
13
C NMR (126 MHz, CDCl3) δ ppm 171.3, 155.7, 149.7, 
149.5, 145.4, 142.2, 141.6, 139.6, 139.5, 138.4, 135.3, 131.5, 129.3, 128.6, 125.7, 
125.0, 118.6, 99.7, 84.5, 84.5, 79.6, 61.7, 53.0, 39.1, 28.2, 27.5, 27.5, 21.2, 14.0; HRMS 
(ESI) [M-TsO]
+
 found 734.1483 calc. 734.1490 [C30H41INO10S]
+
. 
[N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester]-6-(2-
thienyl)iodonium bromide  89(Br) 
 
Iodonium tosylate 89(TsO) (62 mg, 0.069 mmol) was dissolved in CH2Cl2 (50 mL) and 
washed with aqueous KBr (0.2 M, 3 × 50 mL) and the organic layer was passed through 
a phase separator. The solvent was removed before the product was triturated with 
hexane from a minimum amount of CH2Cl2 and diethyl ether (1:1). Removal of the 
solvent under reduced pressure gave the product as a colourless solid (55 mg, 99%, m.p. 
84-94 °C). 
IR νmax (cm
-1
; neat) 1767, 1713, 1489, 1370, 1252, 1154, 1123, 1019, 802; 
1
H NMR 
(400 MHz; CDCl3) δ ppm: 8.05 (s, 1H), 7.70 (dd, J = 3.8, 1.2 Hz, 1H), 7.53 (dd, J = 
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5.3, 1.2 Hz, 1H), 7.34 (s, 1H), 7.01 (dd, J = 5.2, 3.8 Hz, 1H), 5.55-5.28 (bm, 1H), 4.85-
4.62 (bm, 1H), 4.29-4.13 (bm, 2H), 3.62-3.43 (ABX system, bm, 2H), 1.53 (s, 9H), 1.52 
(s, 9H), 1.40 (s, 1H), 1.25 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 
171.2, 155.4, 149.7, 149.5, 145.1, 142.5, 137.5, 137.5, 134.0, 131.2, 129.0, 125.3, 
123.0, 107.2, 84.5, 84.4, 79.9, 61.8, 53.2, 39.5, 28.2, 27.5, 27.5, 14.1; HRMS (ESI) [M-
Br]
+
 found 734.1485 calc. 734.1490 [C30H41INO10S]
+
. 
[N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester]-6-(2-
thienyl)iodonium iodide  89(I) 
 
Iodonium tosylate 89(TsO) (42 mg, 0.046 mmol) was dissolved in CH2Cl2 (50 mL) and 
washed with aqueous KI (0.2 M, 3 × 50 mL) and the organic layer was passed through a 
phase separator. The solvent was removed before the product was triturated with hexane 
from a minimum amount of CH2Cl2 and diethyl ether (1:1). Removal of the solvent 
under reduced pressure gave the product as a yellow solid (35 mg, 90%). 
1
H NMR (250 MHz; CDCl3) δ ppm: 8.43 (s, 1H), 8.03 (dd, J = 3.8, 1.3 Hz, 1H), 7.91 
(dd, J = 5.4, 1.2 Hz, 1H), 7.50 (s, 1H), 7.20 (dd, J = 5.3, 3.9 Hz, 1H), 4.54 – 4.39 (m, 
1H), 4.22 (q, J = 7.1 Hz, 2H), 3.65 – 3.18 (ABX system, bm, 2H), 1.53 (s, 9H), 1.52 (s, 
9H), 1.40 (s, 9H), 1.26 (t, J = 7.2 Hz, 3H). 
[N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester]-6-(2-
thienyl)iodonium perchlorate  89(ClO4) 
 
Counter ion exchange was achieved using a method reported in the literature.
[20]
 
Iodonium tosylate 89(TsO) (55 mg, 0.061 mmol) was absorbed onto a Biotage
®
 KP-
C18-HS 12 g SNAP cartridge in a minimum amount of acetonitrile. The RP column was 
eluted with aqueous KClO4 (0.1%, 50 mL) followed by elution with water (50 mL). The 
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salt was then eluted from the column using a gradient of acetonitrile in water (20% - 
90%). The acetonitrile was removed under reduced pressure before the water was 
removed by lyophilisation to give the product as a fluffy colourless solid (15 mg, 30%, 
m.p. 96-107 °C). 
IR νmax (cm
-1
; neat) 1765, 1707, 1686, 1491, 1372, 1252, 1150, 1123, 1094, 621; 
1
H 
NMR (400 MHz; CDCl3) δ ppm: 7.99 (dd, J = 3.9, 1.2 Hz, 1H), 7.85 (s, 1H), 7.72 (dd, J 
= 5.4, 1.2 Hz, 1H), 7.48 (s, 1H), 7.16 (dd, J = 5.4, 3.9 Hz, 1H), 5.62 (d, J = 8.1 Hz, 
1H), 4.66-4.50 (bm, 1H), 4.38-4.08 (bm, 2H), 3.65 – 3.31 (ABX system, bm, 2H), 1.53 
(s, 9H), 1.53 (s, 9H), 1.42 (s, 9H), 1.29 (t, J = 7.2 Hz, 3H); HRMS (ESI) [M-ClO4]
+
 
found 734.1485 calc. 734.1490 [C30H41INO10S]
+
. 
N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester  92 
 
92 was synthesised according to the literature.
[14]
 To a suspension of 3,4-dihydroxy-ʟ-
phenylalanine (2.5 g, 12.7 mmol) in ethanol (15 mL), cooled to 0 °C, was added SOCl2 
(7.55 g, 4.6 mL, 63.5 mmol) dropwise over 30 min. The reaction was stirred at 0 °C for 
2 h before being left to warm to room temperature overnight. The reaction was 
concentrated under vacuum, dissolved in ethyl acetate and washed with 10% aq 
Na2CO3, water and brine before being dried over MgSO4. The solvent was removed to 
give the crude the 3,4-dihydroxy-ʟ-phenylalanine ethyl ester (hydrochloride salt) as a 
yellow oil. The product could be isolated as a solid by addition of CH2Cl2 followed by 
removal of the solvent to give the product as a pale yellow solid (1.64 g, 55%, m.p. 84-
85 °C). The data were consistent with those reported in the literature measured in 
CDCl3.
[14]
 However it was found that the solidified product was more soluble and gave 
better spectra in MeOD. 
3,4-Dihydroxy-ʟ-phenylalanine ethyl ester (hydrochloride salt)  
1
H NMR (400 MHz, MeOD) δ ppm: 6.68 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 2.1 Hz, 1H), 
6.49 (dd, J = 8.0, 2.1 Hz, 1H), 4.13 (q, J = 7.1 Hz, 1H), 3.61 (t, J = 6.5 Hz, 1H), 2.87-
2.76 (ABX system, m, 2H), 1.22 (t, J = 7.1 Hz, 1H); 
13
C NMR (63 MHz, MeOD) δ 
ppm: 176.0, 146.4, 145.4, 129.5, 121.7, 117.4, 116.4, 62.0, 56.8, 41.2, 14.5. 
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To a solution of L-DOPA ethyl ester (hydrochloride salt) (1.07 g, 4.58 mmol) in DMF 
(10 mL), cooled to 0 °C, was added triethylamine (1.58 g, 15.61 mmol, 2.18 mL) 
followed by di-tert-butyldicarbonate (3.61 g, 16.55 mmol, 3.8 mL) in DMF (3 mL). The 
reaction was stirred at 0 °C for 2 h followed by 48 h at room temperature. The solution 
was diluted with ethyl acetate and washed with water and brine before being dried over 
MgSO4. Removal of the solvents gave the crude triboc L-DOPA ethyl ester which was 
purified by column chromatography (hexane:ethyl acetate, 5:1) to give the pure product 
as a colourless foam (2.09 g, 87%). The data were consistent with those reported in the 
literature measured in CD2Cl2.
[14]
 
1
H NMR (400 MHz, CDCl3) δ ppm: 7.23-6.95 (m, 3H), 5.01 (bd, J = 8.1 Hz, 1H), 4.54 
(bdd, J = 14.0, 6.4 Hz, 1H), 4.15 (q, J = 7.2 Hz, 2H), 3.08 (bd, J = 5.9 Hz, 2H), 1.54 (s, 
18H), 1.42 (s, 9H), 1.22 (t, J = 7.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 171.4, 
155.0, 150.6, 150.5, 142.2, 141.4, 134.7, 127.1, 123.9, 122.9, 83.6, 79.9, 61.4, 54.2, 
37.5, 28.2, 27.5, 27.3, 14.0. 
N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-fluoro-ʟ-phenylalanine ethyl 
ester  (95) 
 
95 was synthesised using a literature procedure.
[20]
 To triboc-6-(trimethylstannyl)-ʟ-
DOPA ethyl ester 82 (500 mg, 0.727 mmol) in acetone (14 mL) at room temperature 
was added Ag2O (8.34 mg, 0.036 mmol), NaHCO3 (122 mg, 1.45 mmol), KOTf (136 
mg, 0.727 mmol) and selectfluor
®
 (387 mg, 1.09 mmol). The reaction mixture was 
stirred for 5 h at 65 °C in a sealed vial. After cooling to room temperature the reaction 
mixture was filtered through a pad of celite, eluted with CH2Cl2 and the filtrate was 
concentrated in vacuo. The residue was purified by chromatography (hexane:EtOAc, 
5:1), to give the product as a colourless oil (87 mg, 22%). The data were consistent with 
those reported in the literature measured in CD2Cl2.
[20,21]
 
1
H NMR (500 MHz, CDCl3) δ ppm: 7.06 (d, J
4
F-H = 7.1 Hz, 1H), 7.00 (d, J
3
F-H = 9.6 
Hz, 1H), 5.08 (bd, J = 7.6 Hz, 1H), 4.52 (bm, 1H), 4.15 (q, J = 7.1 Hz, 2H), 3.16-3.03 
(ABX system, bm, 2H), 1.52 (s, 9H), 1.52 (s, 9H), 1.40 (s, 9H), 1.21 (t, J = 7.2 Hz, 3H); 
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13
C NMR (126 MHz, CDCl3) δ ppm: 171.3, 158.0 (d, JF-C = 245.9 Hz, 1C), 150.1, 
141.9 (d, JF-C = 11.3 Hz, 1C), 138.5, 125.2 (d, JF-C = 5.7 Hz, 1C), 121.4 (d, JF-C = 18.3 
Hz, 1C), 110.6 (d, JF-C = 27.1 Hz, 1C), 84.1, 83.8, 79.9, 61.6, 53.4, 31.4, 28.2, 27.5, 
13.9; 
19
F NMR (300 MHz, CDCl3) δ ppm: –117.4; HRMS (ESI) [M+NH4]
+
 found 
561.2806 calc. 561.2818 [C26H38FNO10+NH4]
+
. 
[
18
F]N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-fluoro-ʟ-phenylalanine 
ethyl ester  ([
18
F]95) 
 
Radiofluorination was achieved using GP7. The reaction was analysed using radio 
HPLC and radio TLC. For purification, the reaction mixture was loaded onto the HPLC 
sample loop. Reverse phase purification was performed using a semi-prep Agilent 1200 
column (4 mL/min, 70% MeCN in H2O containing 0.01% formic acid). The gamma 
peak was collected (retention: 7.5 min – 8.5 min) and the activity of the isolated product 
was measured using a Campitec CRC-25PET well counter. A 100 µL sample was taken 
for HPLC analysis to confirm the product as the protected [
18
F]F-DOPA. 
Alternatively, the reaction mixture could be directly eluted though a Sep-Pak alumina 
cartridge (prewashed with distilled water (10 mL)) into the product vial. The alumina 
cartridge was then eluted with acetonitrile (2 mL) to provide the partially purified 
product. Further purification could be achieved by elution of this mixture on to a Sep-
Pak C18 cartridge followed by elution of the product [
18
F]95 with ethanol (2 mL). 
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HPLC of crude reaction mixture shows [
18
F]95 co-eluted with cold standard 95 
 
 
HPLC of purified [
18
F]95* 
 
*Retention time differs from that above due to ageing of the column, having been 
performed months apart. 
Analytical HPLC Conditions 
Column:  Analytical Phenomenex Synergi 4 μm Hydro‐RP 80 C‐18 4.6 × 250 mm 
column 
Gradient: 80% MeCN in H2O (0.01% TFA) 
Flow Rate: 1 mL/min 
Purification HPLC conditions: 
[
18
F]95 
95 
Radioactivity  
(Counts) 
 
UV (mAU) 
 
Radioactivity  
(Counts) 
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Column: Semi-prep Phenomenex Synergi 4 μm Hydro‐RP 80 C‐18 10 × 250 mm 
column  
Gradient: 70% MeCN in H2O (0.01% TFA) 
Flow Rate: 4 mL/min 
TLC: [
18
F]96 after Sep-Pak alumina cartridge 
 
HPLC: [
18
F]95 after Sep-Pak alumina cartridge 
 
HPLC: [
18
F]95 after Sep-Pak C-18 cartridge 
 
[
18
F]95 
[
18
F]95 
Radioactivity  
(Counts) 
 
Radioactivity  
(Counts) 
 
Radioactivity  
(Counts) 
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Analytical HPLC Conditions 
Column:  Analytical Phenomenex Synergi 4 μm Hydro‐RP 80 C‐18 4.6 × 250 mm 
column 
Gradient: 80% MeCN in aqueous ammonium formate (50mM) 
Flow Rate: 1 mL/min 
Phenyl(thiophen-2-yl)iodonium triflate (96(TfO)) 
 
Trifluoromethanesulfonic acid (54 µL, 92 mg, 0.61 mmol) was added to a solution of 2-
(diacetoxy)iodo thiophene 87 (0.2 g, 0.61 mmol) in MeCN (2.5 mL) at -40 °C with 
stirring. The solution was diluted with chloroform (15 mL) and tributylphenyltin (0.2 
mL, 0.22 g, 0.6 mmol) in chloroform (5 mL) was added portion wise. The mixture was 
allowed to warm to room temperature before being stirred for 1 h. The volatiles were 
removed under a stream of nitrogen. Trituration with Et2O gave the product as a beige 
powder (0.233 g, 89%). 
1
H NMR (250 MHz, MeOD) δ ppm: 8.16 (d, J = 7.4 Hz, 2H), 8.01 (dd, J = 3.8, 1.2 Hz, 
1H), 7.89 (dd, J = 5.4, 1.2 Hz, 1H), 7.69 (t, J = 7.5 Hz, 1H), 7.54 (t, J = 7.7 Hz, 1H), 
7.18 (dd, J = 5.4, 3.9 Hz, 1H). In accordance with literature data.
[22]
 
[N-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester]-6-(4-
tolyl)iodonium tosylate  (97(TfO)) 
 
Using GP1 (on a 0.16 mmol scale, with KOTf wash) the product was obtained as a 
white solid (85 mg, 59%, m.p. 78-81 °C). 
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1
H NMR (500 MHz; CDCl3) δ ppm: 7.86 (d, J = 8.4 Hz, 2H), 7.76 (s, 1H), 7.45 (s, 1H), 
7.27 (d, J = 8.6 Hz, 2H), 5.56 (d, J = 7.6 Hz, 1H), 4.57 (d, J = 7.2 Hz, 1H), 4.34 – 4.11 
(m, 2H), 3.50 – 3.23 (ABX system, bm, 2H), 2.42 (s, 3H), 1.53 (s, 9H), 1.52 (s, 9H), 
1.40 (s, 9H), 1.28 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 171.3, 155.6, 
149.8, 149.7, 146.0, 144.0, 143.1, 139.0, 135.3, 133.3, 131.3, 126.3, 120.4 (q, J = 320.0 
Hz, 1C), 113.6, 110.6, 85.1, 85.2, 80.7, 62.5, 54.02, 40.5, 28.3, 27.6, 21.5, 14.1; HRMS 
(ESI) [M-TfO]
+
 found 742.2069 calc. 742.2083 [C33H45INO10]
+
. 
[N-di-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester]-6-
(2-thienyl)iodonium bromide  (100(Br)) 
 
Iodonium bromide 100(Br) was produced by washing the crude iodonium tosylate 
100(TsO) in CH2Cl2 with aqueous KBr (0.2 M, 3 × 50 mL). The organic layer was 
passed through a phase separator. The solvent was removed before the product was 
triturated with hexane from a minimum amount of CH2Cl2 / diethyl ether (1:1). The 
precipitate was collected on a Telos
®
 phase separator and washed with hexane. The 
collected precipitate was removed from the phase separator with CH2Cl2. The CH2Cl2 
was removed before the product was triturated once more with hexane from a minimum 
amount of CH2Cl2 and diethyl ether (1:1). Removal of the solvent under reduced 
pressure gave the product as a colourless solid (64 mg, 20%, m.p. 107-110 °C).  
1
H NMR (400 MHz, MeOD) δ ppm: 8.30 (s, 1H), 8.05 (dd, J = 3.8, 1.1 Hz, 1H), 7.95 
(dd, J = 5.3, 1.0 Hz, 1H), 7.48 (s, 1H), 7.22 (dd, J = 5.3, 4.0 Hz, 1H), 5.23 (dd, J = 8.4, 
6.0 Hz, 1H), 4.26 (q, J = 6.9 Hz, 2H), 3.90-3.45 (m, 2H), 1.53 (s, 18H), 1.46 (s, 18H), 
1.31 (t, J = 7.1, Hz, 3H); HRMS (ESI) [M-Br]
+
 found 834.2023 calc. 834.2015 
[C35H49INO12]
+
. 
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[N-di-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester]-6-
(2-thienyl)iodonium iodide  (100(I)) 
 
Iodonium iodide 100(I) was produced by washing the crude iodonium tosylate 
100(TsO) in CH2Cl2 with aqueous KI (0.2 M, 3 × 50 mL). The organic layer was passed 
through a phase separator. The solvent was removed before the product was triturated 
with hexane from a minimum amount of CH2Cl2 / diethyl ether (1:1). The precipitate 
was collected on a Telos
®
 phase separator and washed with hexane. The collected 
precipitate was removed from the phase separator with CH2Cl2. The CH2Cl2 was 
removed before the product was triturated once more with hexane from a minimum 
amount of CH2Cl2 and diethyl ether (1:1). Removal of the solvent under reduced 
pressure gave the product as a yellow solid (122 mg, 29%, m.p. 84-88 °C).  
1
H NMR (250 MHz, MeOD) δ ppm: 8.30 (s, 1H), 8.04 (dd, J = 3.9, 1.3 Hz, 1H), 7.92 
(dd, J = 5.5, 1.2 Hz, 1H), 7.47 (s, 1H), 7.21 (dd, J = 5.4, 3.9 Hz, 1H), 5.31 – 5.14 (m, 
1H), 4.26 (q, J = 6.9 Hz, 2H), 3.90 – 3.44 (ABX system, bm, 2H), 1.53 (s, 9H), 1.52 (s, 
9H), 1.46 (s, 18H), 1.31 (t, J = 7.1 Hz, 3H). 
(Diacetox) iodotoluene (102) 
 
102 was synthesised according to the literature.
[17]
 Sodium perborate tetrahydate (10.6 
g, 69 mmol) was added portion wise over 30 min to a solution of 4-iodotoluene (1.5 g, 
6.9 mmol) in acetic acid (50 mL). The temperature was raised to 50 °C and the mixture 
stirred for 6 h. The reaction mixture was filtered and the filtrate was concentrated under 
reduced pressure. The product was extracted in CH2Cl2 and washed with water before 
being dried over MgSO4 and concentrated under vacuum. Trituration in diethyl ether 
gave the product as a colourless solid (1.34 g, 46% (79% purity)).  
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1
H NMR (250 MHz, CDCl3) δ ppm: 7.97 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.2 Hz, 2H), 
2.44 (s, 3H), 2.00 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 176.5, 142.8, 135.1, 
131.9, 118.4, 21.7, 20.5. In accordance with literature data.
[23]
 
 (Diacetox) iodomesitylene (103) 
 
103 was synthesised according to the literature.
[17]
 Sodium perborate tetrahydate (6.7 g, 
43 mmol) was added portion wise over 30 min to a solution of 2-iodomesitylene (1.06 
g, 4.3 mmol) in acetic acid (30 mL). The temperature was raised to 50 °C and the 
mixture stirred for 6 h. The reaction mixture was filtered and the filtrate was 
concentrated under reduced pressure. The product was extracted in CH2Cl2 and washed 
with water before being dried over MgSO4 and concentrated under vacuum. Trituration 
in diethyl ether gave the product as a colourless solid (1.08 g, 66% (95% purity), m.p. 
155-157 °C (lit. 160-163 °C)).
[24]
  
1
H NMR (250 MHz, CDCl3) δ ppm: 7.45 (s, 1H), 3.05 (s, 3H), 2.70 (s, 1H), 2.32 (s, 
3H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 176.7, 143.4, 141.5, 129.6, 129.1, 26.9, 21.4, 
20.3. In accordance with literature data.
[24]
 
N-di-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-trimethylstannyl-ʟ-
phenylalanine ethyl ester  (104) 
 
To a solution of triboc-6-(trimethylstannyl)-ʟ-DOPA ethyl ester 84 (0.50 g, 0.73 mmol) 
in dry acetonitrile (12 mL) under argon was added 4-dimethylaminopyridine (DMAP) 
(35.7 mg, 0.29 mmol) in dry acetonitrile (5 mL) and di-tert-butyl dicarbonate (0.32 g, 
1.46 mmol, 0.34 mL) in dry acetonitrile (5 mL). The reaction was stirred at room 
temperature overnight before being concentrated under vacuum and purified by column 
chromatography (hexane/ethyl acetate, 21:5) to give the product 104 as a colourless 
solid (0.54 g, 94%, m.p. 117-119 °C). 
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IR νmax (cm
-1
; neat) 2984, 2972, 1773, 1767, 1757, 1736, 1697, 1478, 1458, 1367, 1248, 
1134, 1020, 758; 
1
H NMR (250 MHz, CDCl3) δ  ppm: 7.24 (s, with tin satellites J
3
Sn-H = 
49.3 Hz, 1H), 7.03 (s, with tin satellites J
4
Sn-H = 16.2 Hz, 1H), 5.03 (bdd, J = 10.1, 4.7 
Hz, 1H), 4.34-4.09 (m, 2H), 3.45-3.27 (ABX system, bm, 2H), 1.54 (s, 9H), 1.52 (s, 
9H), 1.39 (s, 18H), 1.28 (t, J = 7.1 Hz, 3H), 0.33 (s, with tin satellites J
2
Sn-H = 54.9 Hz, 
9H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 169.9, 151.9, 150.7, 150.5, 143.0, 142.4, 
141.1, 140.5, 129.9 (s, with tin satellites J
2
Sn-C = 40.5 Hz, 1C), 123.7 (s, with tin 
satellites J
2
Sn-C = 42.3 Hz , 1C), 83.3, 83.2, 83.0, 61.3, 59.3, 37.8, 27.8, 27.6, 14.1, -8.2 
(s, with tin satellites J
1
Sn-C = 354.0 Hz, 3C); HRMS (ESI) [M+NH4]
+
found 799.3122 
calc. 799.3111 [C34H55NO12Sn+NH4]
+
. 
[N-di-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester]-
6-(4-anisyl)iodonium tosylate  (106(TsO)) 
 
Using GP1 the product was obtained as a colourless solid (78 mg, 28%, m.p. 75-77 °C). 
IR νmax (cm
-1
; neat) 1771, 1734, 1572, 1491, 1368, 1250, 1142, 1119, 1007, 777, 679; 
1
H NMR (400 MHz; CDCl3) δ ppm: 7.92 (d, J = 9.2 Hz, 2H), 7.63 (s, 1H), 7.59 (d, J = 
8.2 Hz, 2H), 7.36 (s, 1H), 7.04 (d, J = 7.9 Hz, 2H), 6.83 (d, J = 9.2 Hz, 2H), 5.12 (dd, J 
= 8.2, 6.72Hz, 1H), 4.21 (q, J = 7.2 Hz, 2H), 3.80 (s, 3H), 3.67 – 3.30 (ABX system, 
bm, 2H), 2.30 (s, 3H), 1.52 (s, 9H), 1.51 (s, 9H), 1.47 (s, 18H), 1.28 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 169.6, 162.4, 151.8, 149.7, 149.5, 145.2, 142.9, 
142.6, 139.0, 138.7, 137.0, 130.6, 128.3, 126.1, 126.0, 117.6, 115.4, 105.3, 84.9, 84.8, 
84.3, 62.2, 58.1, 55.5, 38.8, 27.9, 27.4, 21.2, 14.0; HRMS (ESI) [M-TsO]
+
 found 
858.2542 calc. 858.2556 [C38H53INO13]
+
. 
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[N-di-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine ethyl ester]-6-
(4-anisyl)iodonium bromide  (106(Br)) 
 
Iodonium tosylate 106(TsO) (65 mg, 0.063 mmol) was dissolved in CH2Cl2 (50 mL) 
and washed with aqueous KBr (0.2 M, 3 × 50 mL) and the organic layer was passed 
through a phase separator. The solvent was removed before the product was triturated 
with hexane from a minimum amount of CH2Cl2 and diethyl ether (1:1). Removal of the 
solvent under reduced pressure gave the product as a white solid (59 mg, 100%, m.p. 
85-88 °C). 
IR νmax (cm
-1
; neat) 1766, 1737, 1573, 1487, 1368, 1250, 1152, 1138, 1120, 820, 736; 
1
H NMR (400 MHz, CDCl3) δ ppm: 7.95 (d, J = 9.2 Hz, 2H), 7.56 (s, 1H), 7.31 (s, 1H), 
6.87 (d, J = 9.2 Hz, 2H), 5.18 (t, J = 7.7 Hz, 1H), 4.27 – 4.17 (m, 2H), 3.81 (s, 3H), 
3.73-3.26 (ABX system, 2m, 2H), 1.52 (s, 9H), 1.51 (s, 9H), 1.46 (s, 18H), 1.29 (t, J = 
7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 169.5, 161.9, 151.9, 149.8, 149.6, 
144.7, 142.5, 138.1, 136.4, 129.9, 126.1, 122.2, 117.5, 109.5, 84.7, 84.5, 84.1, 62.1, 
58.1, 55.6, 38.4, 27.9 (, 27.5 (, 14.1; HRMS (ESI) [M-Br]
+
 found 858.2546 calc. 
858.2556 [C38H53INO13]
+
. 
N-Phthalimide-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine methyl ester  109 
 
N-Phthalimide-3,4-dihydroxy-ʟ-phenylalanine methyl ester 107 was synthesised 
according to the literature.
[25]
To a round bottom flask was added borax (1.0 g, 5.0 
mmol), water (25 mL) and a stirrer bar. The mixture was degassed with argon for 30 
min. The L-DOPA (1.97 g, 10 mmol) was added followed by Na2CO3 (1.06 g, 10 
mmol) and N-carbethoxyphthalimide (2.66 g, 12.1 mmol) in THF (10 mL). The mixture 
was stirred overnight at room temperature and then acidified to pH 1-2 with 1 M HCl 
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solution. The THF was removed by rotary evaporation and the mixture was extracted 
with EtOAc before being washed with water and dried over MgSO4. The solvent was 
removed to give the crude N-phthalimide-3,4-dihydroxy-ʟ-phenylalanine 107 as a grey 
gum (3.7 g). 
Without further purification the crude N-phthalimide-3,4-dihydroxy-ʟ-phenylalanine 
(3.7 g, 10 mmol) was dissolved in methanol (25 mL) and cooled to -41 °C in an 
acetonitrile/ dry ice bath. Thionyl chloride (2.39 g, 20 mmol, 1.46 mL) was added drop 
wise over 5 min. The reaction mixture was allowed to warm to room temperature before 
being stirred overnight. Volatile reagents were removed by rotary evaporation and the 
residue was dissolved in chloroform before being triturated with hexane. The mixture 
was left in a refrigerator overnight and the liquid was decanted. Remaining solvent was 
removed under vacuum to give the crude product 108 as a pink/brown solid (2.5 g, 73% 
(impure)). 
1
H NMR (250 MHz, CDCl3) δ ppm: 7.87-7.63 (m, 4H), 6.72-6.52 (m, 3H), 5.10 (dd, J 
= 10.9, 5.7 Hz, 1H), 3.77 (s, 3H), 3.54-3.36 (ABX system, bm, 2H); 
13
C NMR (100 
MHz, CDCl3) δ ppm: 169.5, 167.7, 143.6, 142.7, 134.2, 131.4, 129.0, 123.5, 121.2, 
115.7, 115.3, 53.4, 53.0, 33.9. 
 
Without further purification the crude phthalimide-ʟ-DOPA methyl ester (1.0 g, 2.9 
mmol) was dissolved in anhydrous DMF (10 mL) and cooled to 0 °C. Triethylamine 
(0.68 g, 6.7 mmol, 0.94 mL) was added followed by di-tert-butyldicarbonate (1.59 g, 
7.3 mmol, 1.68 mL) in DMF (3 mL). The reaction was stirred at 0 °C for 2 h followed 
by 48 h at room temperature. The solution was diluted with ethyl acetate and washed 
with water and brine before being dried over MgSO4. Removal of the solvents gave the 
crude diboc-phthalimide-ʟ-DOPA methyl ester, which was purified by column 
chromatography (hexane/ethyl acetate, 3:1) to give the pure product 109 as a colourless 
solid (1.2 g, 77%, m.p. 55-61 °C). 
IR νmax (cm
-1
; neat) 2980, 2365, 1763, 1713, 1508, 1385, 1246, 1148, 1111, 720; 
1
H 
NMR (250 MHz, CDCl3) δ ppm: 7.96-7.59 (m, 4H), 7.16-7.01 (m, 3H), 5.14 (dd, J = 
10.3, 6.2 Hz, 1H), 3.77 (s, 3H), 3.66-3.42 (ABX system, bm, 2H), 1.49 (s, 9H), 1.48 (s, 
9H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 169.0, 167.4, 150.5, 150.4, 142.2, 141.3, 
135.2, 134.0, 131.5, 126.5, 123.5, 123.5, 123.0, 83.5, 83.5, 52.9, 52.8, 34.0, 27.5 (6C); 
HRMS (ESI) [M+NH4]
+
 found 559.2276 calc. 559.2286 [C28H31NO10+NH4]
+
. 
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N-Phthalimide-3,4-di(tert-butoxycarbonyloxy)-6-iodo-ʟ-phenylalanine methyl ester  (110) 
 
To a round bottom flask containing I2 (0.56 g, 2.20 mmol) and PhI(CF3CO2)2 (1.24 g, 
2.70 mmol) under argon was added freshly distilled CH2Cl2 (10 mL). The mixture was 
stirred at 0 °C for 15 min before addition of diboc-Phth-ʟ-DOPA methyl ester 109 (1.2 
g, 2.2 mmol) in CH2Cl2 (10 mL). The reaction was kept at 0 °C for 15 min before being 
stirred at room temperature overnight. Following dilution with CH2Cl2 the reaction was 
washed with 1 M Na2S2O3 (2 x 10 mL), water and brine before being dried over 
MgSO4. The solvent was removed under vacuum and the product was purified by 
column chromatography (hexane/ethyl acetate, 3:1) to give the pure product as a 
colourless foam (0.64 g, 43%, m.p. 61-64 °C). 
IR νmax (cm
-1
; neat) 1769, 1713, 1483, 1385, 1244, 1150, 1121, 718; 
1
H NMR (250 
MHz, CDCl3) δ ppm: 7.81-7.70 (bm, 5H), 6.98 (s, 1H), 5.33 (dd, J = 10.9, 5.3 Hz, 1H), 
3.79 (s, 3H), 3.75-3.55 (ABX system, bm, 2H), 1.48 (s, 9H), 1.41 (s, 9H); 
13
C NMR 
(100 MHz, CDCl3) δ ppm: 168.8, 167.4, 150.0, 149.8, 142.3, 141.5, 137.7, 134.0, 133.5, 
131.6, 124.7, 123.6, 94.6, 84.1, 83.9, 53.0, 50.9, 38.9, 27.5, 27.4; HRMS (ESI) 
[M+NH4]
+
 found 685.1243 calc. 685.1253 [C28H30INO10+NH4]
+
. 
N-Phthalimide-3,4-di(tert-butoxycarbonyloxy)-6- trimethylstannyl-ʟ-phenylalanine methyl 
ester  (111) 
 
To a solution of diboc-phthalimide-6-iodo-ʟ-DOPA methyl ester 110 (1.29 g, 1.93 
mmol) in anhydrous dioxane (30 mL) under argon and protected from light was added 
tetrakis triphenylphosphine palladium (0.112 g, 0.097 mmol) and hexamethylditin (1.17 
g, 3.57 mmol, 0.74 mL). The mixture was stirred at reflux for 6 h before being cooled to 
room temperature and filtered. The filtrate was diluted with EtOAc, washed with water 
and brine, dried over MgSO4 and concentrated to dryness. The residue was purified by 
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flash chromatography (hexane/ethyl acetate, 3:1) to give the product 111 as a colourless 
foam (0.68 g, 50%, m.p. 58-61 °C). 
IR νmax (cm
-1
; neat) 1765, 1715, 1385, 1370, 1246, 1152, 1121, 772, 718; 
1
H NMR (400 
MHz, CDCl3) δ ppm: 7.83-7.65 (m, 4H), 7.23 (s, with tin satellites J
3
Sn-H = 48.8 Hz, 
1H), 6.94 (s, with tin satellites J
4
Sn-H = 16.1 Hz, 1H), 5.07 (dd, J = 11.1, 5.1 Hz, 1H), 
3.77 (s, 3H), 3.71-3.52 (ABX system, bm, 2H), 1.49 (s, 9H), 1.40 (s, 9H), 0.40 (s, with 
tin satellites J
2
Sn-H = 54.9 Hz, 9H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 169.1, 167.6, 
150.7, 150.4, 142.4, 141.8, 141.2, 140.6, 134.0, 131.8, 130.3 (s, with tin satellites J
2
Sn-C 
= 39.1 Hz, 1C), 123.6, 123.0 (s, with tin satellites J
2
Sn-C = 41.3 Hz, 1C), 83.5, 83.3, 53.0, 
52.8, 36.4, 27.6, 27.5, -8.00 (s, with tin satellites J
1
Sn-C = 347.0 Hz, 3C); HRMS (ESI) 
[M+NH4]
+
 found 715.1971 calc. 715.1960 [C31H39NO10Sn+NH4]
+
. 
[N-Phthalimide-3,4-di(tert-butoxycarbonyloxy)-ʟ-phenylalanine methyl ester]-6-(4-
anisyl)iodonium  tosylate  (113(TsO)) 
 
Using GP1 (on a 0.213 mmol scale) the product was obtained as a colourless solid (59 
mg, 29%, m.p. 105-108 °C). 
IR νmax (cm
-1
; neat) 1767, 1750, 1718, 1489, 1385, 1250, 1150, 1123, 1007, 820, 679; 
1
H NMR (400 MHz; CDCl3) δ ppm: 7.94 (d, J = 9.2 Hz, 2H), 7.85-7.70 (m, 5H), 7.63 
(d, J = 8.2 Hz, 2H), 7.25 (s, 1H), 7.08 (d, J = 7.9 Hz, 2H), 6.88 (d, J = 9.2 Hz, 2H), 
5.04 (dd, J = 8.7, 6.7 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.70-3.44 (m, 2H), 2.32 (s, 
3H), 1.49 (s, 9H), 1.45 (s, 9H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 168.4, 167.3, 
162.3, 149.4, 149.4, 145.2, 142.6, 142.4, 139.1, 137.8, 136.9, 134.2, 131.7, 131.5, 
128.3, 125.9, 125.0, 123.7, 117.5, 115.1, 104.9, 84.6, 84.5, 55.5, 53.3, 51.5, 37.1, 27.4, 
27.3, 21.1; HRMS (ESI) [M-TsO]
+
 found 774.1394 calc. 774.1406 [C35H37INO11]
+
. 
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[N-Phthalimide-3,4-di(tert-butoxycarbonyloxy)- L-phenylalanine methyl ester]-6-(4-
anisyl)iodonium  bromide  (113(Br)) 
 
Iodonium tosylate 113(TsO) (50 mg, 0.053 mmol) was dissolved in CH2Cl2 (50 mL) 
and washed with aqueous KBr (0.2 M, 3 × 50 mL) and the organic layer was passed 
through a phase separator. The solvent was removed before the product was triturated 
with hexane from a minimum amount of CH2Cl2 and diethyl ether (1:1). Removal of the 
solvent under reduced pressure gave the product as a colourless solid (45 mg, 100%, 
m.p. 107-110 °C). 
IR νmax (cm
-1
; neat) 1771, 1717, 1489, 1389, 1372, 1150, 1256, 1153, 1127, 1087, 720; 
1
H NMR (400 MHz, CDCl3) δ ppm: 7.98 (d, J = 9.2 Hz, 2H), 7.85 – 7.77 (m, 2H), 7.76 
(s, 1H), 7.75 – 7.67 (m, 2H), 7.17 (s, 1H), 6.88 (d, J = 9.2 Hz, 2H), 5.04 (dd, J = 9.9, 
5.9 Hz, 1H), 3.81 (s, 3H), 3.80 (s, 3H), 3.91-3.56 (ABX system, bm, 2H), 1.48 (s, 9H), 
1.42 (s, 9H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 168.4, 167.3, 161.8, 149.6, 149.5, 
144.8, 142.4, 137.2, 136.2, 134.1, 131.6, 131.2, 125.0, 123.7, 121.0, 117.4, 110.2, 84.5, 
84.3, 55.5, 53.3, 51.7, 36.8, 27.5, 27.4; HRMS (ESI) [M-Br]
+
 found 774.1401 calc. 
774.1406 [C35H37INO11]
+
. 
N-Phthalimide-3,4-di(trifluoroacetoxy)-ʟ-phenylalanine methyl ester  (115) 
 
Under inert conditions trifluoroacetic anhydride (1.66 mL, 2.47 g, 11.8 mmol) was 
added to a flask containing 108 (0.5 g, 1.5 mmol) equipped with a stirrer bar and a 
condenser. The reaction was refluxed for 1 h before being stirred at room temperature 
for 18 h. The volatiles were removed under a flow of nitrogen to yield the product as a 
pale orange oil (0.69 g, 88%).  
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1
H NMR (250 MHz, CDCl3) δ ppm: 7.85 – 7.70 (m, 4H), 7.30 – 7.14 (m, 3H), 5.15 (dd, 
J = 10.7, 6.0 Hz, 1H), 3.79 (s, 3H), 3.72 – 3.53 (ABX system, bm, 2H); 19F NMR (300 
MHz, CDCl3) δ ppm: -74.4. 
(4-(O-Boc)phenyl)(thienyl)iodonium tosylate (117(TsO)) 
 
To a stirred suspension of O-Boc 4-(diacetoxy)iodophenol 120 (0.85 g, 1.94 mmol) in 
acetonitrile (15 mL) at 0 °C was added p-TsOH∙H2O (369 mg, 1.94 mmol) before 
immediate dilution with chloroform (70 mL). 2-(Tributylstannyl)thiophene (0.616 mL, 
0.724 g, 1.94 mmol) was added dropwise. The reaction mixture was stirred for 18 h at 
room temperature before the solvents were removed under reduced pressure. The 
residue was dissolved in CH2Cl2 (40 mL) and washed with water. The organic layer was 
passed through a phase separator and concentrated under reduced pressure to give the 
crude product as a yellow oil. Trituration with Et2O gave the product as a colourless 
solid (1.10 g, 98%, m.p. 144-145 °C). 
1
H NMR (250 MHz, CDCl3) δ ppm: 7.95 (d, J = 9.0 Hz, 2H), 7.75 (dd, J = 3.8, 1.2 Hz, 
1H), 7.59 (dd, J = 5.3, 1.2 Hz, 1H), 7.52 (d, J = 8.2 Hz, 2H), 7.17 (d, J = 9.1 Hz, 2H), 
7.11 – 7.00 (m, 3H), 2.32 (s, 3H), 1.54 (s, 9H); 13C NMR (125 MHz, CDCl3) δ ppm: 
153.6, 150.9, 142.2, 140.7, 139.8, 136.1, 135.9, 129.7, 128.7, 126.1, 124.5, 114.1, 99.7, 
84.7, 27.8, 21.4; HRMS (ESI) [M-TsO]
+
 found 402.9852 calc. 402.9859 [C15H16ISO3]
+
. 
(4-(O-Boc)phenyl)(thienyl)iodonium bromide (117(Br)) 
 
Iodonium tosylate 117(TsO) (676 mg, 1.18 mmol) was dissolved in CH2Cl2 (50 mL) 
and washed with aqueous KBr (0.2 M, 3 × 50 mL) and the organic layer was passed 
through a phase separator. The solvent was removed before the product was triturated 
with diethyl ether from a minimum amount of CH2Cl2. Filtration gave the product as a 
colourless solid (528 mg, 93%, m.p. 154-156 °C). 
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1
H NMR (250 MHz, CDCl3) δ ppm: 8.03 (d, J = 9.0 Hz, 2H), 7.70 (dd, J = 3.7, 1.2 Hz, 
1H), 7.54 (dd, J = 5.3, 1.2 Hz, 1H), 7.19 (d, J = 9.0 Hz, 2H), 7.01 (dd, J = 5.3, 3.7 Hz, 
1H), 1.54 (s, 9H); 
13
C NMR (125 MHz, (CD3)2SO) δ ppm:  152.4, 150.5, 138.8, 136.1, 
135.8, 129.1, 124.4, 118.1, 106.6, 84.0, 27.1; HRMS (ESI) [M-Br]
+
 found 402.9850 
calc. 402.9859 [C15H16ISO3]
+
. 
O-Boc 4-iodophenol (119) 
 
To a solution of 4-iodophenol (10.0 g, 45.5 mmol) in acetonitrile (17 mL), cooled to 0 
°C, was added triethylamine (6.98 mL, 5.06 g, 49.9 mmol) followed by di-tert-
butyldicarbonate (10.5 mL, 9.93 g, 45.5 mmol) in acetonitrile (17 mL). The reaction 
was stirred at 0 °C for 2 h followed by 48 h at room temperature. The solution was 
diluted with ethyl acetate and washed with water and brine before being dried over 
MgSO4. Removal of the solvents gave the crude O-Boc 4-iodophenol which was 
purified by column chromatography (hexane:ethyl acetate, 10:1) to give the pure 
product as a colourless solid (13.5 g, 93%, m.p. 39-42 °C (lit. 116-118 °C).
[26]
 
1
H NMR (250 MHz, CDCl3) δ ppm: 7.69 (d, J = 8.9 Hz, 2H), 6.94 (d, J = 8.9 Hz, 2H), 
1.55 (s, 9H); 
13
C NMR (100 MHz, CDCl3) δ ppm:  151.5, 151.0, 138.5, 123.4, 89.8, 
84.1, 27.7. In accordance with literature data.
[26]
 
O-Boc 4-(Diacetoxy)iodophenol (120) 
 
O-Boc 4-iodophenol (217 mg, 0.625 mmol) in CH2Cl2 (3 mL) at 0 °C, was treated with 
peracetic acid (1 mL, 39%). The reaction was stirred at 0 °C for 8 h. The reaction was 
then partitioned between CH2Cl2 (40 mL) and water (2 × 40 mL). The CH2Cl2 layer was 
separated, dried over MgSO4 and concentrated under vacuum to give a pale yellow oil. 
The crude was triturated with hexane to give a white solid (162 mg, 59%, m.p. 138-141 
°C). 
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1
H NMR (250 MHz, CDCl3) δ ppm: 8.08 (d, J = 9.0 Hz, 2H), 7.31 (d, J = 9.0 Hz, 2H), 
2.01 (s, 6H), 1.57 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ ppm: 176.6, 153.6, 151.1, 
136.7, 124.1, 117.4, 84.8, 27.8, 20.5 (2C); HRMS (APCI) [M-OAc]
+
 found 379.0035 
calc. 379.0037 [C13H16IO5]
+
. 
O-Boc 4-fluorophenol (121) 
 
To a solution of 4-fluorophenol (2.0 g, 17.8 mmol) in acetonitrile (3 mL), cooled to 0 
°C, was added triethylamine (2.73 mL, 1.98 g, 19.58 mmol) followed by di-tert-
butyldicarbonate (4.91 mL, 4.66 g, 21.36 mmol) in acetonitrile (3 mL). The reaction 
was stirred at 0 °C for 2 h followed by 48 h at room temperature. The solution was 
diluted with ethyl acetate and washed with water and brine before being dried over 
MgSO4. Removal of the solvents gave the crude O-Boc 4-iodophenol which was 
purified by column chromatography (hexane:ethyl acetate, 10:1) to give the pure 
product as a colourless solid (3.75 g, 99%, m.p. 43-45 °C (lit. 38-39 °C)).  
1
H NMR (250 MHz, CDCl3) δ ppm: 7.20 – 6.92 (m, 4H), 1.56 (s, 9H); 
13
C NMR (63 
MHz, CDCl3) δ ppm: 160.3 (d, J = 244.1 Hz), 152.0, 147.1 (d, J = 2.9 Hz), 122.8 (d, J = 
8.5 Hz, 2C), 116.1 (d, J = 23.5 Hz, 2C), 83.9, 27.8;
 19
F NMR (300 MHz, CDCl3) δ ppm: 
-117.0. In accordance with previous literature data.
[1]
 
[
18
F]O-Boc 4-fluorophenol ([
18
F]121) 
 
Radiofluorination was achieved using GP7. The reaction was analysed using radio 
HPLC and radio TLC. 
 
 
 
 Experimental Ch4 
196 
 
Radio HPLC of the crude reaction mixture 
 
Analytical HPLC Conditions 
Column:  Analytical Phenomenex Synergi 4 μm Hydro‐RP 80 C‐18 4.6 × 250 mm 
column 
Gradient: 80% MeCN in H2O (0.01% TFA)  
Flow Rate: 1 mL/min 
4-iodophenyl 2,2,2-trifluoroacetate (122) 
 
Under inert conditions trifluoroacetic anhydride (11.3 mL, 16.8 g, 80 mmol) was added 
to a flask containing 4-iodophenol (2.2 g, 10 mmol) equipped with a stirrer bar and a 
condenser. The reaction was refluxed for 1 h before being stirred at room temperature 
for 18 h. The volatiles were removed under a flow of nitrogen to yield the product as a 
pale orange oil (2.65 g, 84%).  
1
H NMR (250 MHz, CDCl3) δ ppm: 7.77 (d, J = 8.9 Hz, 2H), 7.00 (d, J = 8.9 Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 149.3, 139.2, 122.7, 114.6 (q, J = 285.7 Hz,1C), 
91.8;
 19
F NMR (300 MHz, CDCl3) δ ppm: -74.6. 
[
18
F]121 
121 
Radioactivity  
(Counts) 
 
UV (mAU) 
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 (4-hydroxyphenyl)(thiophen-2-yl)iodonium Tosylate (125) 
 
To a stirred solution of 122 (0.5 g, 1.58 mmol) in CH2Cl2/TFE (1:1) (16 mL) was added 
mCPBA (77 wt.%, 354 mg, 1.58 mmol) followed by p-TsOH·H2O (301 mg, 1.58 
mmol). The resulting solution was stirred for 30 min before being concentrated under 
nitrogen. Signs of decomposition were observed. Therefore, CH2Cl2/TFE (1:1) (16 mL) 
was added to give a stable suspension.  Addition of 2-(tributylstannyl)thiophene 
resulted in a dark orange solution. The solution was stirred for 1.5 h before being 
concentrated under a flow of nitrogen to give an orange gum. Resolubilisation in a 
minimum amount of methanol resulted in a green solution. Trituration with Et2O gave 
the 4-hydroxy phenyl product as a brown green powder (194 mg, 26%, m.p. 159-165 
°C). 
1
H NMR (250 MHz, MeOD) δ ppm: 8.05 – 7.91 (m, 3H), 7.86 (dd, J = 5.4, 1.2 Hz, 1H), 
7.70 (d, J = 8.2 Hz, 2H), 7.23 (d, J = 7.9 Hz, 2H), 7.15 (dd, J = 5.4, 3.8 Hz, 1H), 6.95 – 
6.80 (d, J = 9.1 Hz, 2H), 5.50 (s, 1H), 2.37 (s, 3H); HRMS (ESI) [M-TsO]
+
 found 
302.9338 calc. 302.9346 [C10H8ISO]
+
. 
Production of dimethyldioxirane (DMDO) 
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DMDO was produced according to a literature procedure.
[27]
 A round bottom flask 
containing a mixture of water (40 mL), acetone (25 mL, 0.34 mol), and sodium 
bicarbonate (48 g, 0.57 mol), was equipped with a magnetic stir bar and a pressure 
equalizing addition funnel containing water (30 mL) and acetone (30 mL, 0.41 mol). A 
round bottom flask containing Oxone (90 g, 0.15 mol) was attached to the reaction 
vessel via a rubber tube and glass adaptors. A condenser was attached to the reaction 
vessel. The outlet of the condenser was connected to a dry ice cooled condenser, 
connected to a round bottom flask cooled in a dry ice-acetone bath. A stream of nitrogen 
gas was bubbled through the reaction mixture as the Oxone
®
 was added in portions. The 
acetone-water mixture was simultaneously added dropwise. The reaction mixture was 
stirred vigorously throughout the addition of reagents (30 min). A pale yellow solution 
of dimethyldioxirane in acetone collected in the receiving flask. Vigorous stirring was 
continued for an additional 15 min while a slight vacuum was applied to the cold trap. 
The dioxirane solution was dried over Na2SO4 before being filtered and stored in a 
freezer (−25 °C) over Na2SO4 (≈50 mL, 60 mM).  
The concentration of dimethyldioxirane in acetone was assessed by oxidation of 
thioanisole to the corresponding sulfoxide and determined by 
1
H NMR integration of 
the different phenyl protons according to the literature.
[28]
 A solution of DMDO (0.50 
mL) was reacted with thioanisole (0.10 mL, 0.7 M in acetone-d6) at 10 °C for 10 min. 
The reaction mixture was directly transferred to an NMR tube for 
1
H NMR. The 
concentration of DMDO in acetone was established by integration of the thioanisole 
protons and the sulphoxide phenyl protons. 
N-Phthalimide-3,4-di(tert-butoxycarbonyloxy)-6-iodyl-ʟ-phenylalanine methyl ester (131) 
 
131 was synthesised adapting a literature procedure.
[29]
 IodoDOPA compound 110 (67 
mg, 0.1 mmol) was dissolved in anhydrous acetone (3 mL) and cooled to 0 °C in an ice 
bath. DMDO (17 mL, 60 mM, 1.0 mmol) was added dropwise and the reaction was 
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stirred for 1 h. The solvent was then removed under reduced pressure. The residue was 
dissolved in chloroform and washed with water. The organic layer was dried over 
MgSO4 and filtered before removal of the solvent under reduced pressure to give the 
product as a white solid (69 mg, 99%, m.p. 112-113 °C).  
1
H NMR (400 MHz, CDCl3) δ ppm: 8.07 (s, 1H), 7.93 – 7.67 (m, 4H), 7.27 (s, 1H), 
5.03 (dd, J = 9.8, 4.3 Hz, 1H), 4.10 (dd, J = 14.8, 9.9 Hz, 1H), 3.71 (s, 1H), 3.34 (dd, J 
= 14.8, 4.3 Hz, 1H), 1.52 (s, 2H), 1.48 (s, 2H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 
170.3, 167.1, 149.9, 149.6, 145.9, 142.5, 137.8, 134.3, 131.7, 125.5, 124.0, 121.5, 
184.3, 53.6, 52.5, 39.0, 27.6, 27.5; HRMS (ESI) [M+NH4]
+
 found 717.1155 calc. 
717.1151 [C28H30INO12NH4]
+
. 
N-di-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-fluoro-ʟ-phenylalanine ethyl 
ester  (134) 
 
 
 
N-di-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-fluoro-ʟ-phenylalanine 
ethyl ester 134 was synthesised adapting a literature procedure.
[20]
 To tetraboc-6-
(trimethylstannyl)-ʟ-DOPA ethyl ester 104 (305 mg, 0.39 mmol) in acetone (7 mL) at 
room temperature was added Ag2O (4.4 mg, 0.019 mmol), NaHCO3 (65 mg, 0.77 
mmol), KOTf (73 mg, 0.39 mmol) and selectfluor
®
 (205 mg, 0.58 mmol). The reaction 
mixture was stirred for 5 h at 65 °C in a sealed vial. After cooling to room temperature 
the reaction mixture was filtered through a pad of celite, eluted with CH2Cl2 and the 
filtrate was concentrated in vacuo. The residue was purified by chromatography 
(hexane:EtOAc, 6:1), to give the product as a colourless solid (149 mg, 60%). 
IR νmax (cm
-1
; neat) 2982, 2936, 2361, 2342, 1767, 1740, 1697, 1368, 1250, 1142, 1109, 
841; 
1
H NMR (250 MHz, CDCl3) δ ppm: 7.08 (d, J
4
F-H = 7.2 Hz, 1H), 6.99 (d, J
3
F-H = 
9.6 Hz, 1H), 5.18 (dd, J = 10.3, 5.1 Hz, 1H), 4.20 (q, J = 7.2 Hz, 2H), 3.51-3.19 (ABX 
system, bm, 2H), 1.53 (s, 18H), 1.41 (s, 18H), 1.27 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 
MHz, CDCl3) δ ppm: 169.9, 158.1 (d, JF-C = 246.1 Hz, 1C), 151.6, 150.5, 150.1, 141.7 
(d, JF-C = 11.5 Hz, 1C), 138.4 (d, JF-C = 3.4 Hz, 1C), 125.3 (d, JF-C = 6.0 Hz, 1C), 122.8 
(d, JF-C = 17.6 Hz, 1C), 110.4 (d, JF-C = 27.1 Hz, 1C), 84.0, 83.7, 83.1, 61.4, 57.8, 29.3, 
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27.8 (, 27.5, 27.5, 14.1; 
19
F NMR (300 MHz, CDCl3) δ ppm: –117.6; HRMS (ESI) 
[M+NH4]
+
 found 661.3343 calc. 661.3342 [C31H46FNO12+NH4]
+
. 
[
18
F]N-di-(tert-Butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-fluoro-ʟ-phenylalanine 
ethyl ester  ([
18
F]134) 
 
Radiofluorination was achieved using GP7 at 90 °C using 0.03 mmol precursor 
106(Br). The reaction was analysed using radio HPLC and radio TLC. 
 
 
Analytical HPLC Conditions 
Column:  Analytical Phenomenex Synergi 4 μm Hydro‐RP 80 C‐18 4.6 × 250 mm 
column 
Gradient: 90% MeCN in H2O (0.01% TFA) 
Flow Rate: 1 mL/min 
[
18
F]134 
134 
Radioactivity  
(Counts) 
 
UV (mAU) 
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N-Phthalimide-3,4-di(tert-butoxycarbonyloxy)-6-fluoro-ʟ-phenylalanine methyl ester  
(136) 
 
N-Phthalimide-3,4-di(tert-butoxycarbonyloxy)-6-fluoro-ʟ-phenylalanine methyl ester 
136 was synthesised adapting a literature procedure.
[20]
 To N-phthalimide diboc-6-
(trimethylstannyl)-ʟ-DOPA methyl ester 111 (258 mg, 0.37 mmol) in acetone (7 mL) at 
room temperature was added Ag2O (4.2 mg, 0.018 mmol), NaHCO3 (62 mg, 0.73 
mmol), KOTf (69 mg, 0.37 mmol) and selectfluor
®
 (195 mg, 0.55 mmol).The reaction 
mixture was stirred for 5 h at 65 °C in a sealed vial. After cooling to room temperature 
the reaction mixture was filtered through a pad of celite, eluted with CH2Cl2 and the 
filtrate was concentrated in vacuo. The residue purified by chromatography 
(hexane:EtOAc, 4:1), to give the product 136 as a colourless oil (69 mg, 34%). 
IR νmax (cm
-1
; neat) 2982, 2934, 2361, 2342, 1765, 1751, 1715, 1508, 1387, 1372, 1273, 
1248, 1140, 1109, 719; 
1
H NMR (250 MHz, CDCl3) δ ppm: 7.81-7.68 (bm, 4H), 7.00 
(d, J
4
F-H = 7.0 Hz, 1H), 6.97 (d, J
3
F-H = 9.7 Hz, 1H), 5.18 (dd, J = 11.1, 5.0 Hz, 1H), 
3.77 (s, 3H), 3.76-3.34 (ABX system, bm, 2H), 1.49 (s, 9H), 1.45 (s, 9H); 
13
C NMR 
(126 MHz, CDCl3) δ ppm: 168.9, 167.4, 158.1 (d, JF-C = 246.5 Hz, 1C), 150.4, 150.0, 
142.1 (d, JF-C = 11.6 Hz, 1C), 138.5 (d, JF-C = 3.4 Hz, 1C), 134.1, 131.7, 125.0 (d, JF-C 
= 5.9 Hz, 1C), 123.6, 121.8 (d, JF-C = 17.4 Hz, 1C), 110.7 (d, JF-C = 26.9 Hz, 1C), 84.1, 
83.8, 53.0, 51.5, 28.6, 27.6, 27.5; 
19
F NMR (300 MHz, CDCl3) δ ppm: –117.7; HRMS 
(ESI) [M+NH4]
+
 found 577.2187 calc. 577.2192 [C28H30FNO10+NH4]
+
. 
[N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-ʟ-phenylalanine ethyl ester]-6-(4-
anisyl)iodonium tosylate  137(TsO) 
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Using GP1 (on a 0.41 mmol scale) the product was obtained as a colourless solid (244 
mg, 79%, m.p. 102-103 °C). 
1
H NMR (400 MHz; CDCl3) δ ppm: 7.81 (d, J = 9.0 Hz, 2H), 7.50 (d, J = 8.2 Hz, 2H), 
7.39 (s, 1H), 7.03 (d, J = 7.9 Hz, 2H), 6.87 (s, 1H), 6.85 (d, J = 9.2 Hz, 2H), 5.95 (s, 
1H), 4.60 (s, 1H), 4.26-4.14 (m, 2H), 3.87 (s, 3H), 3.79 (s, 3H), 3.78 (s, 3H), 3.36 (d, J 
= 7.2 Hz, 2H), 2.31 (s, 3H), 1.35 (s, 9H), 1.26 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, 
CDCl3) δ ppm: 171.6, 161.9, 152.0, 149.1, 142.6, 139.1, 136.4, 133.5, 128.2, 125.8, 
119.8 , 117.1, 112.6 , 109.3, 104.1, 79.4, 61.5, 56.4, 55.9, 55.4, 53.5, 39.1, 28.2, 21.1, 
14.0; HRMS (ESI) [M-TsO]
+
 found 586.1302 calc. 586.1296 [C25H33INO7]
+
. 
[N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-L-phenylalanine ethyl ester]-6-(4-
anisyl)iodonium bromide  137(Br) 
 
Iodonium tosylate 137(TsO) (140 mg, 0.184 mmol) was dissolved in CH2Cl2 (50 mL) 
and washed with aqueous KBr (0.2 M, 3 × 50 mL) and the organic layer was passed 
through a phase separator. The solvent was removed before the product was triturated 
with hexane from a minimum amount of CH2Cl2 and diethyl ether (1:1). Removal of the 
solvent under reduced pressure gave the product as a colourless solid (120 mg, 98%, 
m.p. 111-112 °C). 
1
H NMR (400 MHz; CDCl3) δ ppm: 7.88 (d, J = 7.3 Hz, 2H), 7.60 (s, 1H), 6.78 (s, 1H), 
6.66 (d, J = 7.8 Hz, 2H), 5.45 (s, 1H), 4.68 (s, 1H), 4.28-4.08 (m, 2H), 3.77 (s, 3H), 
3.69 (s, 3H), 3.55 (s, 3H), 3.47-3.30 (m, 2H), 1.29 (s, 9H), 1.22 (t, J = 7.1 Hz, 3H); 
13
C 
NMR (126 MHz, CDCl3) δ ppm: 171.8, 161.3, 155.7, 151.2, 148.9, 138.2, 136.4, 131.7, 
119.4, 166.4, 115.6, 111.4, 79.6, 61.4, 57.2, 55.9, 55.2, 53.2, 39.0, 28.3, 14.2; HRMS 
(ESI) [M-Br]
+
 found 586.1302 calc. 586.1296 [C25H33INO7]
+
. 
 Experimental Ch4 
203 
 
N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-ʟ-phenylalanine ethyl ester  (139) 
 
N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-ʟ-phenylalanine ethyl ester was synthesised 
according to the literature.
[21]
 To a suspension of 3,4-dihydroxy-ʟ-phenylalanine (4.9 g, 
25.0 mmol) in dry ethanol (125 mL), under argon, cooled to 0 °C, was added SOCl2 (5.1 
g, 3.1 mL, 42.0 mmol) dropwise over 30 min. The reaction was heated at reflux for 20 h 
before being cooled to room temperature and concentrated under reduced pressure. 
Toluene was added and the mixture was concentrated under reduced pressure to give the 
crude 3,4-dihydroxy-ʟ-phenylalanine ethyl ester (hydrochloride salt) as an off white 
gum (6.05 g).  
Without further purification the crude 3,4-dihydroxy-ʟ-phenylalanine ethyl ester 
(hydrochloride salt) (3.30 g, 12.6 mmol) was dissolved in ethanol (55 mL) and treated 
with triethylamine (1.31 g, 12.9 mmol, 1.8 mL) followed by di-tert-butyldicarbonate 
(2.90 g, 13.3 mmol). The reaction was stirred at room temperature for 2 h before the 
solvent was removed under reduced pressure. The mixture was acidified with 1M HCl 
at 0 °C and extracted with ethyl acetate (3 × 20 mL). The extracts were dried over 
MgSO4 and concentrated under reduced pressure to give the crude N-(tert-
butoxycarbonyl)-3,4-(dihydroxy)-ʟ-phenylalanine ethyl ester, which was purified by 
column chromatography (15 – 50% ethyl acetate/hexane) to give the pure product as a 
colourless oil (3.17 g, 77%). 
1
H NMR (250 MHz, CDCl3) δ ppm: 6.76 - 6.51 (m, 3H), 6.08 (bs, 2H), 5.06 (d, J = 8.3 
Hz, 1H), 4.48 (dd, J = 14.5, 6.4 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.07-2.83 (ABX 
system, bm, 2H), 1.42 (s, 9H), 1.24 (t, J = 7.1 Hz, 3H); 
13
C NMR (63 MHz, CDCl3) δ 
ppm: 172.4, 155.6, 144.0, 143.1, 128.1, 121.4, 116.1, 115.2, 80.5, 61.6, 54.7, 37.8, 28.3, 
14.1. 
N-(tert-butoxycarbonyl)-3,4-(dihydroxy)-ʟ-phenylalanine ethyl ester (3.13 g, 9.62 
mmol) was dissolved in anhydrous DMF (20 mL) followed by addition of K2CO3 
(11.97 g, 86.6 mmol). MeI (6.15 g, 2.7 mL, 43.3 mmol) was added and the reaction was 
stirred at room temperature in the dark for 24 h. The reaction was diluted with water and 
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the pH was adjusted to 1-2 using 1 M HCl before extraction with diethyl ether. The 
combined extracts were washed with brine and dried over MgSO4. Removal of the 
solvent under reduced pressure gave the crude N-(tert-butoxycarbonyl)-3,4-
(dimethoxy)-ʟ-phenylalanine ethyl ester. The crude was purified by column 
chromatography (5 – 30% ethyl acetate/hexane) to give the pure N-(tert-
butoxycarbonyl)-3,4-(dimethoxy)-ʟ-phenylalanine ethyl ester as a white solid (3.09 g, 
91%, m.p. 75-76 °C (lit. 62-63 °C)).
[30]
 
1
H NMR (400 MHz, CDCl3) δ ppm: 6.79 (d, J = 8.1 Hz, 1H), 6.71-6.61 (m, 2H), 4.97 
(d, J = 7.6 Hz, 1H), 4.53 (dd, J = 14.0, 6.0 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.86 (s, 
6H), 3.10-2.96 (ABX system, bm, 2H), 1.42 (s, 9H), 1.25 (t, J = 7.1 Hz, 3H); 
13
C NMR 
(100 MHz, CDCl3) δ ppm: 171.9, 155.1, 148.9, 148.2, 128.6, 121.5, 112.6, 111.3, 79.9, 
61.3, 55.9, 55.8, 54.6, 37.9, 28.3, 14.2. In accordance with literature data.
[21]
 
N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-6-iodo-ʟ-phenylalanine ethyl ester  (140) 
 
N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-6-iodo-ʟ-phenylalanine ethyl ester was 
synthesised according to the literature.
[21]
 To a round bottom flask containing I2 (1.45 g, 
5.70 mmol) and PhI(CF3CO2)2 (2.94 g, 6.84 mmol) under argon was added freshly 
distilled CH2Cl2 (30 mL). The mixture was stirred at 0 °C for 15 min before addition of 
N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-ʟ-phenylalanine ethyl ester (2.0 g, 5.70 mmol) 
in CH2Cl2 (10 mL). The reaction was kept at 0 °C for 15 min before being stirred at 
room temperature for 3 h. Following dilution with CH2Cl2 the reaction was washed with 
1 M Na2S2O3 (2 x 40 mL), water and brine before being dried over MgSO4. The solvent 
was removed under vacuum and the product was purified by column chromatography 
(15% - 30% EtOAc in hexane) to give the pure product as a colourless solid (1.01 g, 
37%, m.p. 108-111 °C). 
1
H NMR (250 MHz, CDCl3) δ ppm: 7.21 (s, 1H), 6.72 (s, 1H), 5.06 (d, J = 9.1 Hz, 1H), 
4.58 (dd, J = 14.4, 8.3 Hz, 1H), 4.28-4.11 (m, 2H), 3.84 (s, 6H), 3.25-2.98 (ABX 
system, bm, 2H), 1.39 (s, 9H), 1.23 (t, J = 7.1 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
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ppm: 171.8, 154.9, 149.1, 148.3, 131.7, 121.5, 112.7, 88.9, 79.8, 61.4, 56.0, 55.8, 53.7, 
42.6, 28.2, 14.0. In accordance with literature data.
[21]
 
N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-6- trimethylstannyl-ʟ-phenylalanine methyl ester 
(141) 
 
N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-6-(trimethylstannyl)-ʟ-phenylalanine methyl 
ester was synthesised adapting a literature procedure.
[15]
 To a solution of N-(tert-
butoxycarbonyl)-3,4-(dimethoxy)-6-iodo-ʟ-phenylalanine ethyl ester (0.79 g, 1.65 
mmol) in anhydrous dioxane (25 mL) under argon and protected from light was added 
tetrakis triphenylphosphine palladium (0.095 mg, 0.082 mmol) and hexamethylditin 
(1.00 g, 3.05 mmol, 0.63 mL). The mixture was stirred at reflux for 6 h before being 
cooled to room temperature and filtered. The filtrate was diluted with EtOAc, washed 
with water and brine, dried over MgSO4 and concentrated to dryness. The residue was 
purified by flash chromatography (10% - 25% EtOAc in hexane) to give the product as 
a colourless oil (0.483 g, 57%).  
1
H NMR (400 MHz, CDCl3) δ ppm: 6.89 (s, with tin satellites J
3
Sn-H = 49.4 Hz, 1H), 
6.71 (s, with tin satellites J
4
Sn-H = 17.4 Hz, 1H), 4.86 (d, J = 8.5 Hz, 1H), 4.56 – 4.44 
(m, 1H), 4.18 (q, J = 7.2 Hz, 2H), 3.87 (s, 3H), 3.85 (s, 3H), 3.16 – 2.83 (ABX system, 
bm, 2H), 1.38 (s, 9H), 1.24 (t, J = 7.2 Hz, 3H), 0.34 (s, with tin satellites J
2
Sn-H = 53.2 
Hz, 9H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 172.3, 155.1, 149.4, 147.5 (s, with tin 
satellites J
2
Sn-C = 47.3 Hz, 1C), 135.9, 133.2, 118.9, 112.6 (s, with tin satellites J
2
Sn-C = 
51.4 Hz, 1C), 79.6, 61.1, 55.9, 55.6, 54.7, 40.6, 28.2, 14.0, -7.9 (s, with tin satellites 
J
1
Sn-C = 349.7 Hz, 1C); HRMS (APCI) [M+H]
+
 found 518.1557 calc. 518.1563 
[C21H35NO6SnH]
+
. 
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N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-6-fluoro-ʟ-phenylalanine ethyl ester (143) 
 
N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-6-fluoro-ʟ-phenylalanine ethyl ester 143 was 
synthesised adapting a literature procedure.
[20]
 To N-(tert-Butoxycarbonyl)-3,4-
(dimethoxy)-6-(trimethylstannyl)-ʟ-phenylalanine ethyl ester 141 (85 mg, 0.17 mmol) in 
acetone (3.5 mL) at room temperature was added Ag2O (1.9 mg, 0.008 mmol), NaHCO3 
(28 mg, 0.33 mmol), KOTf (31 mg, 0.17 mmol) and selectfluor
®
 (88 mg, 0.25 
mmol).The reaction mixture was stirred for 5 h at 65 °C in a sealed vial. After cooling 
to room temperature the reaction mixture was filtered through a pad of celite, eluted 
with CH2Cl2 and the filtrate was concentrated in vacuo. The residue was partially 
purified by chromatography (hexane:EtOAc, 4:1), to give the impure product as a 
colourless gum (32 mg, 71% purity, 34%, 72-79 °C (lit. 89-90 °C)).
[1]
 
1
H NMR (400 MHz, CDCl3) δ ppm: 6.68 – 6.51 (m, 2H), 5.07 (d, J = 8.2 Hz, 1H), 4.60 
– 4.43 (m, 1H), 4.24 – 4.08 (m, 2H), 3.84 (s, 3H), 3.83 (s, 3H), 3.14 – 2.87 (ABX 
system, bm, 2H), 1.41 (s, 9H), 1.25 (t, J = 7.2 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ 
ppm: 171.9, 155.6 (d, JF-C = 238.4 Hz, 1C), 155.2, 149.0 (d, JF-C = 9.9 Hz, 1C), 145.7, 
113.8 (d, JF-C = 6.0 Hz, 1C), 113.6 (d, JF-C = 17.5 Hz, 1C), 100.1 (d, JF-C = 28.5 Hz, 
1C), 79.9, 61.6, 56.6, 56.2, 53.9, 31.6, 28.4, 14.2; 
19
F NMR (300 MHz, CDCl3) δ ppm: 
–124.7. In accordance with literature data.[1] 
[
18
F]N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-6-fluoro-ʟ-phenylalanine ethyl ester (143) 
 
Radiofluorination was achieved using GP7 at 90 °C using 0.03 mmol precursor 
137(Br). The reaction was analysed using radio HPLC and radio TLC. 
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Production of protected [
18
F]4-fluorobenzaldehyde [
18
F]143 was confirmed by 
comparison with a cold standard. 
 
Analytical HPLC Conditions 
Column: Analytical Phenomenex Synergi 4µ Hydro-RP80 C-18 4.6 × 250 mm column 
Gradient: 60% MeCN in aqueous ammonium formate (50mM) (Isocratic) 
Flow Rate: 1 mL/min 
Synthesis of [
18
F]N-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-6-fluoro-ʟ-phenylalanine ethyl 
ester (143) using Boronic Ester Precursor (32) 
 
[
18
F]143 was produced according to literature procedure.
[1]
  [
18
F]Fluoride delivered 
from the cyclotron as an aqueous solution was trapped on a pre-treated QMA cartridge 
to remove the 
18
O enriched water. The [
18
F]fluoride was eluted with a Kryptofix 2.2.2 
carbonate solution (0.6 mL) (0.3 mL MeCN, 0.3 mL H2O, 22.8 mg Kr-2.2.2, 8.4 mg 
K2CO3) into a 5 mL V-shaped vial. The mixture was dried under a flow of nitrogen and 
reduced pressure at 120 °C for 440 seconds. The residue was azeotropically dried twice 
[
18
F]143 
143 
Radioactivity  
(Counts) 
 
UV (mAU) 
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with the addition of acetonitrile (2 × 1 mL). Distillation was achieved by heating at 120 
°C under a flow of nitrogen for 440 seconds. The dried [
18F]KF • Kryptofix 222 • 
K2CO3 salt was redissolved in anhydrous acetonitrile (0.5 mL). The reaction vial was 
then purged with air, followed by addition of 32 (35 mg, 0.06 mmol) and 
tetrakis(pyridine)copper(II) triflate (15 mg, 0.022 mmol) in DMF (300 µL). The 
reaction was heated at 110 °C for 20 min and then eluted into a product vial. The 
radioactivity recovered was measured in a well counter before a sample was taken for 
radio TLC analysis. Radio TLC showed a radiochemical conversion of 34%. 
Radio TLC of reaction mixture (100% MeCN) 
 
(4-formylphenyl)(phenyl)iodonium bromide (146) 
 
BF3·Et2O  (0.8 mL, 0.98 g, 6.3 mmol) was added dropwise to an ice-cold solution of 4-
formylphenylboronic acid (480 mg, 3.2 mmol) in anhydrous CH2Cl2 (15 mL) under 
argon and the resulting mixture was stirred for 10 min. Diacetoxy iodobenzene (1.03 g, 
3.2 mmol) was added and the cooling bath was removed. The mixture was stirred at 
room temperature for 1 h. The solvent was removed under reduced pressure before 
resolvation in CH2Cl2 (25 mL) and vigorous stirring with aqueous saturated NaBr (25 
Radioactivity  
(Counts) 
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mL). The product was filtered and washed with water and diethyl ether to give the 
product as an off white solid (1.16 g, 93%). 
1
H NMR (400 MHz, (CD3)2SO) δ ppm: 10.07 (s, 1H), 8.48 (d, J = 8.3 Hz, 2H), 8.31 
(dd, J = 8.3, 1.0 Hz, 2H), 8.02 (d, J = 8.4 Hz, 2H), 7.70 (t, J = 7.4 Hz, 1H), 7.57 (t, J = 
7.9, 2H); 
13
C NMR (100 MHz, (CD3)2SO) δ ppm: 192.6, 137.5, 135.6, 135.1, 131.7, 
131.6, 125.7, 119.7. In accordance with literature data.
[31]
 
N-di-(tert-Butoxycarbonyl)-3,4-(dimethoxy)-6-iodo-ʟ-phenylalanine ethyl ester (147) 
 
To a solution of 140 (250 mg, 0.52 mmol) in dry acetonitrile (5 mL) under argon was 
added 4-dimethylaminopyridine (DMAP) (26 mg, 0.21 mmol) in dry acetonitrile (5 mL) 
and di-tert-butyl dicarbonate (228 mg, 1.04 mmol) in dry acetonitrile (5 mL). The 
reaction was stirred at room temperature overnight before being concentrated under 
vacuum and purified by column chromatography (10% - 25% EtOAc in hexane) to give 
the product 147 as a colourless solid (227 mg, 75%). 
1
H NMR (250 MHz, CDCl3) δ ppm: 7.19 (s, 1H), 6.63 (s, 1H), 5.17 (dd, J = 11.1, 4.2 
Hz, 1H), 4.23 (q, J = 7.1 Hz, 2H), 3.82 (s, 6H), 3.75-3.24 (ABX system, bm, 2H), 1.38 
(s, 18H), 1.30 (t, J = 7.1 Hz, 3H); 
13
C NMR (63 MHz, CDCl3) δ ppm: 170.2, 151.9, 
149.2, 148.4, 132.9, 121.5, 113.7, 89.0, 83.0, 61.6, 58.0, 56.3, 55.9, 40.2, 28.0 (, 14.3. 
6-(4-Iodophenoxy)hexanoic acid (150) 
 
150 was synthesised according to a literature procedure.
[32]
 Ethyl 6-(4-
iodophenoxy)hexanoate (2.17 g, 6.0 mmol) in ethanol (20 mL), and water (20 mL) was 
treated with sodium hydroxide (0.6 g, 15 mmol), and the reaction was stirred under 
reflux for 3 h. The reaction was then allowed to cool and concentrated to a white solid 
under vacuum before being treated with ethyl acetate (2 × 35 mL) and 1 M hydrochloric 
acid (2 × 35 mL). The ethyl acetate layer was separated, dried over sodium sulphate and 
concentrated under vacuum to give a white solid (1.98 g, 99%, m.p. 95-97 °C). 
 Experimental Ch4 
210 
 
IR νmax (cm
-1
; KBr) 2943, 1708, 1581, 1488, 1471, 1243, 1174, 826; 
1
H NMR (500 
MHz, CDCl3) δ ppm: 7.45 (d, J = 9.0 Hz, 2H), 6.57 (d, J = 9.0 Hz, 2H), 3.83 (t, J = 6.4 
Hz, 2H), 2.31 (t, J = 7.4 Hz, 2H), 1.71-1.43 (m, 6H); 
13
C NMR (126 MHz, CDCl3) δ 
ppm: 179.9, 158.9, 138.1, 116.9, 82.5, 67.7, 33.9, 28.8, 25.5, 24.3. In accordance with 
data provided in patent literature.
[32]
 
Ethyl-6-(4-iodophenoxy)hexanoate (152) 
 
152 was synthesised according to a literature procedure.
[32]
 Ethyl 6-bromohexanoate 
(1.39 g, 6.25 mmol) in acetone (25 mL) was treated with 4-iodophenol (1.38 g, 6.25 
mmol) and potassium carbonate (1.73 g, 12.5 mmol) in a round bottom flask. The 
reaction mixture was stirred and heated under reflux for 60 h. The reaction was then 
allowed to cool to room temperature before being concentrated under vacuum to a beige 
gum and oil. The reaction was then partitioned in ethyl acetate (25 mL) and water (5 × 
25 mL). The ethyl acetate layer was separated, and dried over MgSO4 before being 
concentrated under vacuum to give the crude as a yellow oil. The crude was purified by 
chromatography (Petroleum Ether:EtOAc, 30:1) to give the product as a colourless oil 
(2.15 g, 95%). 
IR νmax (cm
-1
; KBr) 2939, 2868, 1732, 1586, 1572, 1486, 1470, 1243, 1175, 820; 
1
H 
NMR (500 MHz, CDCl3) δ ppm: 7.52 (d, J = 8.9 Hz, 2H), 6.65 (d, J = 8.9 Hz, 2H), 
4.13 (q, J = 7.1 Hz, 2H), 3.91 (t, J = 6.4 Hz, 2H), 2.32 (t, J = 7.4 Hz, 2H), 1.81-1.46 
(m, 6H) 1.25 (t, J = 7.1 Hz, 3H); 
13
C NMR (126 MHz, CDCl3) δ ppm: 173.3, 158.8, 
138.0, 116.8, 82.4, 67.7, 60.1, 34.1, 28.7, 25.5, 24.6, 14.2. In accordance with data 
provided in patent literature.
[32]
 
Ethyl-6-(4-diacetoxyiodophenoxy)hexanoate (156) 
 
156 was synthesised according to a literature procedure.
[32]
 Ethyl 6-(4-
iodophenoxy)hexanoate 152 (1 g, 2.76 mmol), was treated with peracetic acid (5 mL, 39 
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wt.%) and CH2Cl2 (15 mL) in an ice bath with stirring to give a pink coloured reaction 
mixture. The reaction was allowed to warm to room temperature over 2 h to give a 
yellow solution. The reaction was then partitioned between CH2Cl2 (40 mL) and water 
(2 × 40 mL). The CH2Cl2 layer was separated, dried over MgSO4 and concentrated 
under vacuum to give a yellow oil. The crude was triturated with hexane to give a pale 
yellow oil (82% product 18% starting material) (0.65 g, 40%). 
1
H NMR (500 MHz, CDCl3) δ ppm: 7.99 (d, J = 9.1 Hz, 2H), 6.93 (d, J = 9.1 Hz, 2H), 
4.13 (q, J = 7.1 Hz, 2H), 4.00 (t, J = 6.3 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 1.99 (s, 6H), 
1.93-1.42 (m, 6H), 1.26 (t, J = 7.1 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 176.4, 
173.6, 159.1, 138.3, 117.2, 117.1, 68.0, 60.4, 34.3, 28.9, 25.7, 24.8, 20.5, 14.4. In 
accordance with data provided in patent literature.
[32]
 
6-(4-Iodophenoxy)-N-phenylhexanamide (158) 
 
To a solution of 6-(4-iodophenoxy)hexanoic acid 150 (0.4 g, 1.2 mmol) in ethylacetate 
(7 mL), T3P (50% in EtOAc, 1.44 mmol, 0.85 mL), diisopropylethylamine (0.31 g, 2.4 
mmol, 0.45 mL) and aniline (0.11 g, 1.2 mmol, 0.11 mL) were added at 0 °C. After 
being stirred for 20 min at 0 °C, the reaction was allowed to warm to room temperature 
and stirred overnight. The reaction was then quenched with water and neutralised with 
HCl (1 N). The ethyl acetate layer was washed with water and dried over MgSO4. The 
solvent was evapourated under vacuum to give the product as an off white powder 
(0.448 g, 91%, m.p. 107 – 108 °C). 
IR νmax (cm
-1
; neat) 3287, 2940, 1655, 1599, 1519, 1484, 1251, 1174, 974, 814, 758, 
1
H 
NMR (400 MHz; CDCl3) δ ppm: 7.58 – 7.46 (m, 4H), 7.32 (t, J = 7.9 Hz, 2H), 7.11 (t, J 
= 7.4 Hz, 1H), 6.66 (d, J = 8.9 Hz, 2H), 3.98 – 3.99 (m, 2H), 2.39 (t, J = 7.4 Hz, 2H), 
1.86-1.46 (m, 6H);
13
C NMR (126 MHz, CDCl3) δ ppm: 171.0, 158.91, 138.2, 137.8, 
129.0, 124.3, 119.8, 117.0, 82.5, 67.8, 37.6, 28.82, 25.6, 25.2.  
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6-(4-Iodophenoxy)hexanoic acid – tris(2-aminoethyl)amine polystyrene resin amide (159) 
 
Under argon tris(2-aminoethyl)amine-polymer resin (0.25 g, 0.88 mmol) in freshly 
distilled CH2Cl2 (7 mL) was treated with 6-(4-iodophenoxy)hexanoic acid (0.39 g, 1.17 
mmol), diisopropylethylamine (0.34 g, 2.63 mmol) and diphenylphosphorylchloride 
(0.31 g, 1.17 mmol). The reaction was kept under agitation for 43 h. The reaction was 
then filtered and washed thoroughly with CH2Cl2 (100 mL) and 20% water in methanol 
(100 mL). The resin was then dried under vacuum to give a beige sand like product 
(0.47 g, 1.73 mmolg
-1
, 85%). Found C 68.12%, H 6.34%, N 3.57%, I 13.6%. 
6-(4-Diacetoxyiodophenoxy)hexanoic acid – tris(2-aminoethyl)amine polystyrene resin 
amide (160) 
 
6-(4-iodophenoxy)hexanoic acid - tris(2-aminoethyl)amine-polymer resin amide (0.25 
g, 0.52 mmol) in CH2Cl2 (7 mL) was treated with peracetic acid (2 mL, 39 wt.%). The 
reaction was agitated at room temperature for 18 h before the reaction was filtered and 
washed with CH2Cl2. The resin was then dried under vacuum to give a sand like solid 
(0.284 g, 1.16 mmolg
-1
, 55%). Found C 66.34%, H 6.62%, N 3.67%, I 9.53%. 
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6-(4-Phenyliodoniumphenoxy)hexanoic acid – tris(2-aminoethyl)amine polystyrene amide 
trifluoroacetate salt (161(TFA)) 
 
161(TFA) was produced adapting a literature procedure.
[32]
 6-(4-iodophenoxy)hexanoic 
acid - aminomethyl polystyrene resin amide (0.15 g, 0.174 mmol) in CH2Cl2 (5 mL) 
was cooled in a acetonitrile and dry ice bath to – 41 °C and treated with tri-n-
butylphenyl tin (128 mg, 0.348 mmol). The reaction was agitated and treated with 
trifluoroacetic acid (79 mg, 0.696 mmol) and allowed to warm to room temperature 
over 2 h. The resin was then washed with CH2Cl2 to give a beige sand like solid (0.244 
g, 1.16 mmolg
-1
, 100%). Found C 62.55%, H 6.16%, N 3.29%, I 9.97%, F 5.99%. 
6-(4-(4-Phenoxyphenyl)iodoniumphenoxy)hexanoic acid – tris(2-aminoethyl)amine 
polystyrene amide tosylate salt (164(TsO/Cl)) 
 
Under argon tris(2-aminoethyl)amine-polymer resin (224 mg, 0.75 mmol) in freshly 
distilled CH2Cl2 (7 mL) was treated with 176 (516 mg, 0.75 mmol), 
diisopropylethylamine (218 mg, 1.69 mmol) and diphenylphosphorylchloride (201 mg, 
0.75 mmol). The reaction was kept under agitation for 26 h. The reaction was then 
filtered and washed thoroughly with CH2Cl2 (100 mL) and 20% water in methanol (100 
mL). The resin was then dried under vacuum to give a beige sand like product (375 mg, 
0.60 mmolg
-1
, 40%).  
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6-(4-(4-Phenoxyphenyl)iodoniumphenoxy)hexanoic acid – tris(2-aminoethyl)amine 
polystyrene amide bromide salt (164(Br)) 
 
6-(4-(4-phenoxyphenyl)iodoniumphenoxy)hexanoic acid – tris(2-aminoethyl)amine 
polystyrene amide tosylate salt 164(TsO/Cl) (250 mg, 0.6 mmolg
-1
, 0.15 mmol) was 
agitated in a mixture of CH2Cl2 (3 mL) and aqueous saturated KBr (3 mL) overnight. 
The reaction was then filtered and washed thoroughly with CH2Cl2 (100 mL) and 20% 
water in methanol (100 mL). The resin was then dried under vacuum to give a beige 
sand like product (238 mg, 0.60 mmolg
-1
, 100%). Found C 68.48%, H 6.24%, N 3.27%, 
Br 10.83%, I 8.45%, S <0.3% (none detectable). 
1-(Benzyloxy)-4-fluorobenzene (165) 
 
To a solution of 4-fluorophenol (112 mg, 1.0 mmol) in acetone (5 mL) was added 
K2CO3 (166 mg, 1.2 mmol) and benzylbromide (180 mg, 0.13 mL, 1.05 mmol) at room 
temperature. The reaction mixture was refluxed for 6 h. After cooling the reaction 
mixture was filtered and the insoluble material was rinsed with acetone. The filtrate was 
concentrated under reduced pressure and the residue was purified by chromatography 
(Hexane, EtOAc, 20:1) to give the product as a white solid (190 mg, 94%, m.p. 55-56 
°C (lit. 56 °C)).
[33]
  
1
H NMR (400 MHz, CDCl3) δ ppm: 7.45 - 7.37 (m, 4H), 7.36 - 7.31 (m, 1H), 
7.02 - 6.94 (m, 2H), 6.94 - 6.88 (m, 2H), 5.03 (s, 2H); 
13
C NMR (100 MHz, CDCl3) δ 
ppm: 157.4 (d, JF-C = 238.3 Hz, 1C), 155.0 (d, JF-C  = 2.2 Hz, CAr), 136.9, 128.7, 128.2, 
127.6, 116.0 (d, JF-C  = 7.0 Hz, 2C), 115.9 (d, JF-C  = 8.0 Hz, 2C), 70.7; 
19
F NMR (300 
MHz, CDCl3) δ ppm: -123.6 (d, J = 15.0). In accordance with previous literature.
[33]
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(4-Formylphenyl)(4-methoxyphenyl)iodonium bromide (166(Br)) 
 
BF3·Et2O (170 mg, 148 µl, 1.2 mmol) was added dropwise to a solution of 4-
formylphenylboronic acid (90 mg, 0.6 mmol) in anhydrous CH2Cl2 (3 mL) under argon 
at 0 °C and the mixture was stirred for 10 min. (Diacetoxy)iodoanisole (211 mg, 0.6 
mmol) was added and the cooling bath was removed. The mixture was stirred for 15 
min before addition of aqueous KBr (sat.) (3 mL). The aqueous layer was extracted with 
chloroform (3 × 3 mL) and the solvents were removed in vacuo to give a brown residue. 
Trituration with Et2O followed by recrystallisation from CH2Cl2 /Et2O gave the product 
as a brown solid (45 mg, 18%). 
1
H NMR (400 MHz, CDCl3) δ ppm: 9.95 (s, 1H) 8.18 (d, J = 8.2 Hz, 2H), 7.94 (d, J = 
8.8 Hz, 2H), 7.74 (d, J = 8.2 Hz, 2H), 6.82 (d, J = 8.8 Hz, 2H) 3.78 (s, 3H); HRMS 
(ESI) [M-Br]
+
 found 338.9876 calc. 338.9876 [C13H11IO2]
+
. 
4-(Trimethylstannyl)benzaldehyde (168) 
 
To a solution of 4-bromobenzaldehyde (434 mg, 2.34 mmol) in dry toluene under argon 
was added Pd(PPh3)4 (135 mg, 0.117 mmol) and hexamethylditin (1 g, 3.05 mmol). The 
reaction was heated overnight at 100 °C. The reaction mixture was allowed to cool and 
then passed through a pad of celite before removal of the volatiles under reduced 
pressure. The crude was purified by chromatography (Hexane:EtOAc, 19:1) to give the 
product as a colorless oil (519 mg, 83%). 
1
H NMR (400 MHz, CDCl3) δ ppm: 10.00 (s, 1 H) 7.81 (d, J = 7.92 Hz, 2H), 7.68 (d, J 
= 8.2 Hz, 2H), 3.78 (s, with tin satellites J
2
Sn-H = 54.7 Hz, 9H). In accordance with 
previous literature.
[34]
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(4-(Benzyloxy)phenyl)(4-methoxyphenyl)iodonium tosylate (169(TsO)) 
 
Koser reagent 174 (200 mg, 0.401 mmol) was dissolved in dichloromethane (3 mL) and 
cooled to 0 °C before addition of anisole (43.8 mg, 0.405 mmol). TFE (0.3 mL) was 
added to the solution and the reaction was allowed to warm to room temperature over 2 
h. The solvents were removed in vacuo and the product was triturated with Et2O. 
Filtration gives the iodonium salt which may be recrystallized from dichloromethane 
and Et2O if necessary (59 mg, 87%, m.p. 140-141 °C).  
1
H NMR (400 MHz, CDCl3) δ ppm: 7.85 (d, J = 8.9 Hz, 4H), 7.50 (d, J = 8.1 Hz, 2H), 
7.41 - 7.30 (m, 5H), 7.00 (d, J = 7.9 Hz, 2H), 6.86 (d, J = 8.9 Hz, 2H), 6.78 (d, J = 9.0 
Hz, 2H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 162.4, 161.5, 139.4, 137.0 (3C), 135.9, 
128.9, 128.6, 128.5, 127.6, 126.2, 118.3, 117.5, 104.8, 104.4, 70.5, 55.7, 21.4; HRMS 
(ESI) [M-TsO]
+
 found 417.0350 calc. 417.0346 [C20H18IO2]
+
. 
(4-(Benzyloxy)phenyl)(4-methoxyphenyl)iodonium bromide (169(Br)) 
 
To a solution of iodonium tosylate 169(TsO) (80 mg, 0.136 mmol) in CH2Cl2 (1.5 mL) 
was added an aqueous solution of KBr (sat.) (1.5 mL). The mixture was stirred for 1 h 
at room temperature. The precipitated iodonium bromide was filtered off and washed 
with CH2Cl2. The aqueous layer was extracted with ethyl acetate and the combined 
organic extracts were evaporated to yield more iodonium bromide as a white solid. The 
combined iodonium bromides were isolated as a white solid (59 mg, 87%, m.p. 204-205 
°C). 
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1
H NMR (400 MHz, MeOD) δ ppm: 8.08 – 8.01 (m, 4H), 7.44 - 7.28 (m, 5H), 7.11 (d, J 
= 9.0 Hz, 2H), 7.04 (d, J = 9.0 Hz, 2H), 5.15 (s, 2H), 3.84 (s, 3H); 
13
C NMR (126 MHz, 
MeOD) δ ppm: 164.4, 163.4, 138.1, 138.0, 137.5, 129.6, 129.2, 128.7, 19.7, 118.7, 
105.7, 105.5, 71.5, 56.4. 
(4-(Benzyloxy)phenyl)(4-((6-ethoxy-6-oxohexyl)oxy)phenyl)iodonium tosylate (170(TsO)) 
 
Koser reagent 174 (150 mg, 0.30 mmol) was dissolved in dichloromethane (2 mL) and 
cooled to 0 °C before addition of 175 (716mg, 0.303 mmol). TFE (0.2 mL) was added 
to the solution and the reaction was allowed to warm to room temperature over 2 h. The 
solvents were removed in vacuo and the product was triturated with Et2O. Filtration 
gives the iodonium salt which may be recrystallized from dichloromethane and Et2O if 
necessary to give the product as an off white solid (193 mg, 90%, m.p. 138-139 °C). 
1
H NMR (400 MHz, CDCl3) δ ppm: 7.87 - 7.77 (m, 4H), 7.56 (d, J = 8.1 Hz, 2H), 7.42 
– 7.29 (m, 5H), 7.04 (d, J = 7.9 Hz, 2H), 6.90 (d, J = 9.1 Hz, 2H), 6.80 (d, J = 9.1 Hz, 
2H, 5.04 (s, 2H), 4.12 (q, J = 7.3 Hz, 2H), 3.93 (t, J = 6.3 Hz, 2H), 2.39 - 2.26 (m, 5H), 
1.90 - 1.57 (m, 4H), 1.54 - 1.29 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ ppm: 173.7, 161.8, 161.4, 142.9, 139.4, 137.0, 136.8, 135.8, 128.9, 128.6, 
128.5, 127.6, 126.1, 118.2, 117.9, 104.7, 104.0, 70.44, 68.2, 60.4, 34.3, 28.8, 25.7, 24.7, 
21.5, 14.2; HRMS (ESI) [M-TSO]
+
 found 545.1183 calc. 545.1183 [C27H30IO4]
+
. 
(4-(Benzyloxy)phenyl)(4-((6-ethoxy-6-oxohexyl)oxy)phenyl)iodonium bromide (170(Br)) 
 
To a solution of iodonium tosylate 170(TsO) (200 mg, 0.419 mmol) in CH2Cl2 (3.0 mL) 
was added an aqueous solution of KBr (sat.) (3.0 mL). The mixture was stirred for 1 h 
at room temperature. The precipitated iodonium bromide was filtered off and washed 
with CH2Cl2. The aqueous layer was extracted with ethyl acetate and the combined 
organic extracts were evaporated to yield more iodonium bromide as a white solid. The 
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combined iodonium bromides were isolated as a white solid (174 mg, 67%, m.p. 130-
132 °C). 
1
H NMR (400 MHz, MeOD): δ ppm: 8.06 - 7.97 (m, 4H), 7.44 - 7.28 (m, 5H), 7.12 (d, J 
= 9.1 Hz, 2H), 7.03 (d, J = 9.1 Hz, 2H), 5.15 (s, 2H), 4.10 (q, J = 7.1 Hz, 2H), 4.03 (t, J 
= 6.3 Hz, 2H), 2.34 (t, J = 7.3 Hz, 2H), 1.87 – 1.73 (m, 2H), 1.71 – 1.60 (m, 2H), 1.55 – 
1.42 (m, 2H), 1.22 (t, J = 7.1 Hz, 3H).  
1-(Benzyloxy)-4-iodobenzene (171) 
 
To a solution of 4-iodophenol (7.70 g, 35 mmol) in acetone (80 mL) was added K2CO3 
(5.81 g, 42 mmol) and benzylbromide (5.99 g, 4.16 mL, 35 mmol) at room temperature. 
The reaction mixture was refluxed for 6 h. After cooling the reaction mixture was 
filtered and the insoluble material was rinsed with acetone. The filtrate was 
concentrated under reduced pressure and the residue was purified by chromatography 
(Hexane, EtOAc, 95:5) to give the product as a white solid (8.58 g, 79%, m.p. 61 °C (lit. 
62-63 °C)).
[35]
 
1
H NMR (400 MHz, CDCl3) δ ppm: 7.56 (d, J = 9.0 Hz, 2H), 7.44 - 7.29 (m, 5H), 6.75 
(d, J = 9.0 Hz, 2H), 5.03 (s, 2H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 158.7, 138.4, 
136.6, 128.8, 128.3, 127.6, 117.4, 83.2, 70.2. In accordance with previous literature.
[35]
 
2-(4-(Benzyloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (172) 
 
Bis(pinocolato)diboron (838 mg, 3.3 mmol), Pd(dppf)Cl2· CH2Cl2 (123 mg, 0.15 mmol) 
and KOAc (1.24 g, 9.0 mmol) were added to a round bottom flask under nitrogen 
atmosphere. Anhydrous DMF (15 mL) was added and the mixture was stirred for 15 
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min to give a dark red solution. 1-(benzyloxy)-4-iodobenzene (935 mg, 3.0 mmol) was 
added and the mixture was heated to 80 °C and stirred for 21 h. The reaction was 
allowed to cool to room temperature before addition of brine (15 mL) was added 
followed by extraction with Et2O (3×30 mL). The combined organic extracts were dried 
over Mg2SO4 and concentrated in vacuo. The crude product was purified using 
chromatography to give the product as a white solid (598 mg, 64%). 
1
H NMR (400 MHz, CDCl3) δ ppm: 7.75 (d, J = 8.7 Hz, 2H), 7.45 - 7.29 (m, 5H), 6.98 
(d, J = 8.7 Hz, 2H), 5.09 (s, 2H), 1.33 (s, 12H); 
13
C NMR (100 MHz, CDCl3) δ ppm: 
161.4, 136.9, 136.6, 128.7, 128.1, 127.6, 114.3, 83.7, 69.8, 25.0 ppm. In accordance 
with previous literature.
[36]
 
1-(Benzyloxy)-4-(diacetoxy)iodobenzene (173) 
 
A solution of O-benzyl 4-iodophenol 171 (1.55 g, 5.0 mmol) and selectfluor
®
 (8.86 g, 
25.0 mmol) in MeCN/AcOH (3:1) (200 mL) was stirred for 5 h at room temperature. 
The acetonitrile was evaporated in vacuo and water was added to the residue before 
extraction with dichloromethane. The combined organic layers were washed with water 
and dried over MgSO4. Removal of the solvent gave the crude product as a yellow solid. 
Trituration with hexane gave the pure product as a white solid (2.13 g, 95%, m.p. 61-62 
°C). 
1
H NMR (400 MHz, CDCl3) δ ppm: 8.01 (d, J = 8.9 Hz, 2H), 7.45 - 7.32 (m, 5H), 7.04 
(d, J = 9.0 Hz, 2H), 5.11 (s, 2H), 2.00 (s, 6H); 
13
C NMR (100 MHz, CDCl3) δ 
ppm: 176.5, 161.4, 137.3, 135.8, 128.9, 128.6, 127.6, 117.5, 111.8, 70.5, 20.6. In 
accordance with previous literature.
[37]
 
Hydroxy(p-tosyloxy)iodo-4-benzyloxybenzene (174) 
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Diacetate 173 (1.9 g, 4.44 mmol) was dissolved in MeCN (50 mL) and cooled to 0 °C 
before the addition of p-TsOH·H2O (843 mg, 44 mmol). The product began to 
precipitate immediately. After 10 min Et2O was added to the slurry and the product was 
filtered off and washed with Et2O. The pure product was dried under a flow of nitrogen 
to give the product as a pale yellow solid (2.09 g, 95%). The compound was stored 
under nitrogen at -20 °C. If the compound was submitted to high vacuum it decomposed 
to a brown solid. 
1
H NMR (400 MHz, MeOD) δ ppm: 8.30 (d, J = 8.9 Hz, 2H), 7.69 (d, J = 8.1 Hz, 2H), 
7.49 - 7.31 (m, 5H), 7.27 (d, J = 8.9 Hz, 2H), 7.23 (d, J = 8.0 Hz, 2H), 5.25 (s, 2H), 2.37 
(s, 4H); 
13
C NMR (100 MHz, MeOD) δ ppm: 164.7, 143.3, 141.8, 140.3, 137.4, 129.8, 
129.7, 129.4, 128.8, 126.9, 119.3, 71.6, 21.3. 
Ethyl 6-phenoxyhexanoate (175) 
 
Ethyl 6-bromohexanoate (3.50 g, 2.79 mL, 15 mmol) in acetone (60 mL) was treated 
with phenol (1.41 g, 15 mmol) and potassium carbonate (4.15 g, 30 mmol) in a round 
bottom flask. The reaction mixture was stirred and heated under reflux for 60 h. The 
reaction was then allowed to cool to room temperature before being concentrated under 
vacuum to a beige gum and oil. The reaction was then partitioned in ethyl acetate (60 
mL) and water (5 × 60 mL). The ethyl acetate layer was separated, and dried over 
MgSO4 before being concentrated under vacuum to give the crude as a yellow oil. The 
crude was purified by chromatography (Petroleum Ether:EtOAc, 15:1) to give the 
product as a colourless oil (3.39 g, 96%). 
1
H NMR (400 MHz, CDCl3) δ ppm: 7.27 (t, J = 7.2 Hz, 2H), 6.98 - 6.84 (m, 3H), 4.13 
(q, J = 7.1 Hz, 2H) 3.96 (t, J = 6.4 Hz, 2H), 2.34 (t, J = 7.5 Hz, 2H), 1.94 - 1.77 (m, 
2H), 1.76 - 1.59 (m, 2H), 1.57 - 1.43 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H); 
13
C 
NMR (100 MHz, CDCl3) δ ppm: 173.7, 159.1, 129.4, 120.6, 114.5, 67.5, 60.3,  34.3, 
29.0, 25.8, 24.9, 14.4; HRMS (ESI) [M+H]
+
 found 237.1483 calc. 237.1485 
[C14H21O3]
+
. 
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(4-(Benzyloxy)phenyl)(4-((5-carboxypentyl)oxy)phenyl)iodonium tosylate (176(TsO)) 
 
Iodonium tosylate 170(TsO) (1.47 g, 1.6 mmol) in trifluoroacetic acid and water (1:1) 
(1 mL) was stirred for 19 h at 40 °C. Subsequently the solvent was removed and the 
yellow oil was triturated with Et2O to give a grey gum. Recrystalisation from CH2Cl2 
/Et2O gave the product as a white solid (1.01 g, 92%, m.p.124-125 °C) 
1
H NMR (400 MHz, CDCl3) δ ppm: 8.08 – 7.94 (m, 1H), 7.70 (d, J = 8.1 Hz, 2H), 7.47 
– 7.27 (m, 2H), 7.23 (d, J = 8.0 Hz, 2H), 7.11 (d, J = 9.0 Hz, 2H), 7.03 (d, J = 9.0 Hz, 
2H), 5.14 (s, 2H), 4.03 (t, J = 6.3 Hz, 2H), 2.37 (s, 3H), 2.31 (t, J = 7.3 Hz, 2H), 1.88 – 
1.74 (m, 2H), 1.71 – 1.59 (m, 2H), 1.56 – 1.43 (m, 2H); 13C NMR (100 MHz, MeOD) δ 
ppm: 177.4, 163.8, 163.3, 143.5, 141.6, 138.1 (2C), 137.5, 129.8, 129.6, 129.3, 128.7, 
126.9, 119.6, 119.1, 105.4, 104.9, 71.4, 69.5, 34.8, 29.8, 26.6, 25.7, 21.3; HRMS  (ESI) 
[M-TsO]
+
 found 517.0858 calc. 517.0870 [C25H26IO4]
+
. 
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